AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 56_CD Preparation_NNP of_IN the_DT Financial_NNP Statements_NNP and_CC Directors_NNS Responsibilities_NNS The_DT Directors_NNS are_VBP required_VBN by_IN UK_NNP company_NN law_NN to_TO prepare_VB for_IN each_DT accounting_NN period_NN financial_JJ statements_NNS which_WDT give_VBP a_DT true_JJ and_CC fair_JJ view_NN of_IN the_DT state_NN of_IN affairs_NNS of_IN the_DT Group_NNP and_CC the_DT Company_NN as_IN at_IN the_DT end_NN of_IN the_DT accounting_NN period_NN and_CC of_IN the_DT profit_NN or_CC loss_NN for_IN that_DT period_NN ._.
In_IN preparing_VBG the_DT financial_JJ statements_NNS ,_, the_DT Directors_NNS are_VBP required_VBN to_TO select_VB and_CC apply_VB consistently_RB suitable_JJ accounting_NN policies_NNS and_CC make_VB reasonable_JJ and_CC prudent_JJ judgements_NNS and_CC estimates_NNS ._.
Applicable_JJ accounting_NN standards_NNS also_RB have_VBP to_TO be_VB followed_VBN and_CC a_DT statement_NN made_VBD to_TO that_DT effect_NN in_IN the_DT financial_JJ statements_NNS ,_, subject_JJ to_TO any_DT material_NN departures_NNS being_VBG disclosed_VBN and_CC explained_VBN in_IN the_DT notes_NNS to_TO the_DT financial_JJ statements_NNS ._.
The_DT Directors_NNS are_VBP required_VBN to_TO prepare_VB the_DT financial_JJ statements_NNS on_IN a_DT going_VBG concern_NN basis_NN unless_IN it_PRP is_VBZ inappropriate_JJ to_TO presume_VB that_IN the_DT Group_NNP will_MD continue_VB in_IN business_NN ._.
The_DT Directors_NNS are_VBP responsible_JJ for_IN ensuring_VBG proper_JJ accounting_NN records_NNS are_VBP kept_VBN which_WDT disclose_VBP with_IN reasonable_JJ accuracy_NN at_IN any_DT time_NN the_DT financial_JJ position_NN of_IN the_DT Company_NN and_CC enable_VB them_PRP to_TO ensure_VB that_IN the_DT financial_JJ statements_NNS comply_VBP with_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
They_PRP are_VBP also_RB responsible_JJ for_IN taking_VBG reasonable_JJ steps_NNS to_TO safeguard_VB the_DT assets_NNS of_IN the_DT Company_NN and_CC prevent_VB and_CC detect_VB fraud_NN and_CC other_JJ irregularities_NNS ._.
com_NN 57_CD Independent_NNP Auditors_NNS Report_NNP to_TO the_DT Members_NNS of_IN AstraZeneca_NNP PLC_NNP We_PRP have_VBP audited_VBN the_DT Financial_NNP Statements_NNP on_IN We_PRP review_VBP whether_IN the_DT statement_NN on_IN page_NN 46_CD Opinion_NN pages_NNS 58_CD to_TO 122_CD ._.
We_PRP have_VBP also_RB audited_VBN the_DT reflects_VBZ the_DT Companys_NNP compliance_NN with_IN the_DT In_NNP our_PRP$ opinion_NN information_NN in_IN the_DT Directors_NNS Remuneration_NNP seven_CD provisions_NNS of_IN the_DT Combined_NNP Code_NNP Report_NNP that_WDT is_VBZ described_VBN as_IN having_VBG been_VBN specified_VBN for_IN our_PRP$ review_NN by_IN the_DT Listing_NNP Rules_NNP ,_, the_DT Financial_NNP Statements_NNP give_VB a_DT true_JJ and_CC audited_JJ ._.
and_CC we_PRP report_VBP if_IN it_PRP does_VBZ not_RB ._.
We_PRP are_VBP not_RB fair_JJ view_NN of_IN the_DT state_NN of_IN affairs_NNS of_IN the_DT required_VBN to_TO consider_VB whether_IN the_DT Boards_NNP Company_NN and_CC the_DT Group_NNP as_IN at_IN This_DT report_NN is_VBZ made_VBN solely_RB to_TO the_DT Companys_NNPS statements_NNS on_IN internal_JJ control_NN cover_VB all_DT risks_NNS 31_CD December_NNP 2002_CD and_CC of_IN the_DT profit_NN of_IN members_NNS ,_, as_IN a_DT body_NN ,_, in_IN accordance_NN with_IN and_CC controls_NNS ,_, or_CC form_VB an_DT opinion_NN on_IN the_DT the_DT Group_NNP for_IN the_DT year_NN then_RB ended_VBD :_: and_CC section_NN 235_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
Our_PRP$ effectiveness_NN of_IN the_DT Groups_NNS corporate_JJ governance_NN procedures_NNS or_CC its_PRP$ risk_NN and_CC control_VB the_DT Financial_NNP Statements_NNP and_CC the_DT part_NN of_IN audit_NN work_NN has_VBZ been_VBN undertaken_VBN so_RB that_IN we_PRP procedures_NNS ._.
the_DT Directors_NNS Remuneration_NNP Report_NNP to_TO be_VB might_MD state_VB to_TO the_DT Companys_NNPS members_NNS audited_VBN have_VBP been_VBN properly_RB prepared_VBN in_IN those_DT matters_NNS we_PRP are_VBP required_VBN to_TO state_NN to_TO We_PRP read_VBP the_DT other_JJ information_NN contained_VBN in_IN accordance_NN with_IN the_DT Companies_NNS Act_NNP them_PRP in_IN an_DT auditors_NNS report_NN and_CC for_IN no_DT other_JJ the_DT Annual_JJ Report_NNP and_CC Form_NN 20-F_NN ,_, including_VBG 1985_CD ._.
purpose_NN ._.
To_TO the_DT fullest_JJS extent_NN permitted_VBN by_IN the_DT corporate_JJ governance_NN statement_NN and_CC law_NN ,_, we_PRP do_VBP not_RB accept_VB or_CC assume_VB consider_VB whether_IN it_PRP is_VBZ consistent_JJ with_IN the_DT responsibility_NN to_TO anyone_NN other_JJ than_IN the_DT audited_JJ Financial_NNP Statements_NNP ._.
We_PRP consider_VBP 30_CD January_NNP 2003_CD Company_NN and_CC the_DT Companys_NNPS members_NNS as_IN a_DT the_DT implications_NNS for_IN our_PRP$ report_NN if_IN we_PRP become_VBP body_NN ,_, for_IN our_PRP$ audit_NN work_NN ,_, for_IN this_DT report_NN ,_, or_CC for_IN aware_JJ of_IN any_DT apparent_JJ misstatements_NNS or_CC KPMG_NNP Audit_NNP Plc_NNP the_DT opinions_NNS we_PRP have_VBP formed_VBN ._.
material_NN inconsistencies_NNS with_IN the_DT Financial_NNP Chartered_NNP Accountants_NNPS Statements_NNP ._.
Registered_NNP Auditor_NNP Respective_NNP responsibilities_NNS of_IN Directors_NNS 8_CD Salisbury_NNP Square_NNP and_CC Auditor_NNP Basis_NNP of_IN audit_NN opinion_NN London_NNP EC4Y_NNP 8BB_NNP The_NNP Directors_NNS are_VBP responsible_JJ for_IN preparing_VBG We_PRP conducted_VBD our_PRP$ audit_NN in_IN accordance_NN with_IN the_DT Annual_JJ Report_NNP and_CC Form_NN 20-F_NN and_CC the_DT Auditing_NNP Standards_NNPS issued_VBN by_IN the_DT Auditing_NNP Directors_NNS Remuneration_NNP Report_NNP ._.
An_DT audit_NN includes_VBZ The_DT above_JJ opinion_NN is_VBZ provided_VBN in_IN compliance_NN described_VBN on_IN page_NN 56_CD this_DT includes_VBZ examination_NN ,_, on_IN a_DT test_NN basis_NN ,_, of_IN evidence_NN with_IN UK_NNP requirements_NNS ._.
An_DT opinion_NN complying_VBG responsibility_NN for_IN preparing_VBG the_DT Financial_NNP relevant_JJ to_TO the_DT amounts_NNS and_CC disclosures_NNS in_IN the_DT with_IN auditing_NN standards_NNS generally_RB accepted_VBN in_IN Statements_NNP in_IN accordance_NN with_IN applicable_JJ UK_NNP law_NN and_CC accounting_NN standards_NNS :_: the_DT Directors_NNS Financial_NNP Statements_NNP and_CC the_DT part_NN of_IN the_DT the_DT US_NNP will_MD be_VB included_VBN in_IN the_DT Annual_JJ Report_NNP have_VBP also_RB presented_VBN additional_JJ information_NN Directors_NNS Remuneration_NNP Report_NNP to_TO be_VB on_IN Form_NN 20-F_NN filed_VBN with_IN the_DT US_NNP Securities_NNPS and_CC under_IN US_NNP requirements_NNS ._.
It_PRP also_RB includes_VBZ an_DT assessment_NN of_IN the_DT Exchange_NNP Commission_NNP ._.
as_IN independent_JJ auditor_NN ,_, are_VBP established_VBN in_IN the_DT significant_JJ estimates_NNS and_CC judgements_NNS made_VBD UK_NNP by_IN statute_NN ,_, the_DT Auditing_NNP Practices_NNPS Board_NNP ,_, by_IN the_DT Directors_NNS in_IN the_DT preparation_NN of_IN the_DT Generally_RB accepted_VBN accounting_NN principles_NNS in_IN the_DT Listing_NNP Rules_NNP of_IN the_DT Financial_NNP Services_NNP Financial_NNP Statements_NNP and_CC of_IN whether_IN the_DT the_DT UK_NNP vary_VBP in_IN certain_JJ significant_JJ respects_NNS Authority_NNP ,_, and_CC by_IN our_PRP$ professions_NNS ethical_JJ accounting_NN policies_NNS are_VBP appropriate_JJ to_TO the_DT from_IN generally_RB accepted_VBN accounting_NN guidance_NN ._.
Groups_NNS circumstances_NNS ,_, consistently_RB applied_VBN principles_NNS in_IN the_DT US_NNP ._.
Application_NN of_IN generally_RB and_CC adequately_RB disclosed_VBN ._.
accepted_VBN accounting_NN principles_NNS in_IN the_DT US_NNP We_PRP report_VBP to_TO you_PRP our_PRP$ opinion_NN as_IN to_TO whether_IN would_MD have_VB affected_VBN results_NNS of_IN operations_NNS for_IN the_DT Financial_NNP Statements_NNP give_VB a_DT true_JJ and_CC fair_JJ We_PRP planned_VBD and_CC performed_VBD our_PRP$ audit_NN so_RB as_IN to_TO each_DT of_IN the_DT years_NNS in_IN the_DT three-year_JJ period_NN view_NN and_CC whether_IN the_DT Financial_NNP Statements_NNP obtain_VB all_PDT the_DT information_NN and_CC explanations_NNS ended_VBD 31_CD December_NNP 2002_CD and_CC consolidated_JJ and_CC the_DT part_NN of_IN the_DT Directors_NNS Remuneration_NNP which_WDT we_PRP considered_VBD necessary_JJ in_IN order_NN to_TO shareholders_NNS equity_NN at_IN 31_CD December_NNP 2002_CD Report_NNP to_TO be_VB audited_VBN have_VBP been_VBN properly_RB provide_VB us_PRP with_IN sufficient_JJ evidence_NN to_TO give_VB and_CC 2001_CD ,_, to_TO the_DT extent_NN summarised_VBN on_IN prepared_JJ in_IN accordance_NN with_IN the_DT Companies_NNS reasonable_JJ assurance_NN that_IN the_DT Financial_NNP pages_NNS 113_CD to_TO 122_CD ._.
We_PRP also_RB report_VBP to_TO you_PRP if_IN ,_, in_IN our_PRP$ Statements_NNS and_CC the_DT part_NN of_IN the_DT Directors_NNS opinion_NN ,_, the_DT Directors_NNS Report_NNP is_VBZ not_RB Remuneration_NNP Report_NNP to_TO be_VB audited_VBN are_VBP free_JJ consistent_JJ with_IN the_DT Financial_NNP Statements_NNP ,_, if_IN from_IN material_NN misstatement_NN ,_, whether_IN caused_VBN the_DT Company_NN has_VBZ not_RB kept_VBN proper_JJ accounting_NN by_IN fraud_NN or_CC other_JJ irregularity_NN or_CC error_NN ._.
In_IN records_NNS ,_, if_IN we_PRP have_VBP not_RB received_VBN all_PDT the_DT forming_VBG our_PRP$ opinion_NN we_PRP also_RB evaluated_VBD the_DT information_NN and_CC explanations_NNS we_PRP require_VBP for_IN overall_JJ adequacy_NN of_IN the_DT presentation_NN of_IN our_PRP$ audit_NN ,_, or_CC if_IN information_NN specified_VBN by_IN law_NN information_NN in_IN the_DT Financial_NNP Statements_NNP and_CC regarding_VBG Directors_NNS remuneration_NN and_CC the_DT part_NN of_IN the_DT Directors_NNS Remuneration_NNP transactions_NNS with_IN the_DT Group_NNP is_VBZ not_RB disclosed_VBN ._.
com_NN 58_CD Group_NNP Profit_NN and_CC Loss_NN Account_NNP for_IN the_DT year_NN ended_VBD 31_CD December_NNP Continuing_NNP Exceptional_NNP 2002_CD operations_NNS items_NNS Total_JJ Notes_NNP $_$ m_CD $_$ m_CD $_$ m_CD Turnover_NN :_: Group_NNP and_CC share_NN of_IN joint_JJ ventures_NNS 18,032_CD 18,032_CD Less_RBR :_: Share_NN of_IN joint_JJ venture_NN turnover_NN 191_CD 191_CD Group_NNP turnover_NN 3_CD 17,841_CD 17,841_CD Operating_NN costs_NNS 3_CD 13,728_CD 350_CD 14,078_CD Other_JJ operating_NN income_NN 3_CD 243_CD 243_CD Group_NNP operating_NN profit_NN 3_CD 4,356_CD 350_CD 4,006_CD Share_NN of_IN operating_VBG loss_NN of_IN joint_JJ ventures_NNS and_CC associates_NNS 4_CD Profits_NNS less_RBR losses_NNS on_IN sale_NN ,_, closure_NN ,_, or_CC demerger_NN of_IN operations_NNS 5_CD Profits_NNS on_IN sale_NN of_IN fixed_JJ assets_NNS 5_CD Dividend_NN income_NN 1_CD 1_CD Profit_NN on_IN ordinary_JJ activities_NNS before_IN interest_NN 4,357_CD 350_CD 4,007_CD Net_JJ interest_NN 630_CD 30_CD Profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 4,387_CD 350_CD 4,037_CD Taxation_NNP 7_CD 1,177_CD 1,177_CD Profit_NN on_IN ordinary_JJ activities_NNS after_IN taxation_NN 3,210_CD 350_CD 2,860_CD Attributable_JJ to_TO minorities_NNS 24_CD 24_CD Net_JJ profit_NN for_IN the_DT financial_JJ year_NN 3,186_CD 350_CD 2,836_CD Dividends_NNS to_TO shareholders_NNS Cash_NN 8_CD 1,206_CD Dividend_NN in_IN specie_NN demerger_NN of_IN Zeneca_NNP Agrochemicals_NNPS 8_CD Profit_NN loss_NN retained_VBN for_IN the_DT financial_JJ year_NN 1,630_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NN before_IN exceptional_JJ items_NNS 9_CD $_$ 1.84_CD $_$ 1.84_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP basic_JJ 9_CD $_$ 1.84_CD $_$ 0.20_CD $_$ 1.64_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP diluted_VBD 9_CD $_$ 1.84_CD $_$ 0.20_CD $_$ 1.64_CD Weighted_VBN average_JJ number_NN of_IN Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS 9_CD 1,733_CD Group_NNP Statement_NNP of_IN Total_NNP Recognised_NNP Gains_NNS and_CC Losses_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD Notes_NNP $_$ m_CD Net_JJ profit_NN for_IN the_DT financial_JJ year_NN 2,836_CD Exchange_NNP adjustments_NNS on_IN net_JJ assets_NNS 22_CD 1,106_CD Translation_NN differences_NNS on_IN foreign_JJ currency_NN borrowings_NNS 22_CD 6_CD Tax_NNP on_IN translation_NN differences_NNS on_IN foreign_JJ currency_NN borrowings_NNS 22_CD 2_CD Total_JJ recognized_VBN gains_NNS and_CC losses_NNS relating_VBG to_TO the_DT financial_JJ year_NN 3,946_CD Prior_RB year_NN adjustment_NN page_NN 62_CD 200_CD Total_JJ recognized_VBN gains_NNS and_CC losses_NNS since_IN the_DT last_JJ annual_JJ report_NN 3,746_CD $_$ m_JJ means_NNS millions_NNS of_IN US_NNP dollars_NNS AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 60_CD Group_NNP Balance_NNP Sheet_NNP at_IN 31_CD December_NNP 2002_CD 2001_CD restated_VBN Notes_NNP $_$ m_CD $_$ m_CD Fixed_VBN assets_NNS Tangible_JJ fixed_VBN assets_NNS 11_CD 6,597_CD 5,409_CD Goodwill_NNP and_CC intangible_JJ assets_NNS 12_CD 2,807_CD 2,700_CD Fixed_VBN asset_NN investments_NNS 13_CD 46_CD 23_CD 9,450_CD 8,132_CD Current_JJ assets_NNS Stocks_NNS 14_CD 2,593_CD 2,402_CD Debtors_NNS 15_CD 4,845_CD 4,139_CD Short_JJ term_NN investments_NNS 16_CD 3,962_CD 3,118_CD Cash_NN 30 726 705_CD 12,126_CD 10,364_CD Total_JJ assets_NNS 21,576_CD 18,496_CD Creditors_NNS due_JJ within_IN one_CD year_NN Short_JJ term_NN borrowings_NNS 17 202 214_CD Current_JJ instalments_NNS of_IN loans_NNS 19 314 107_CD Other_JJ creditors_NNS 18_CD 7,699_CD 6,159_CD 8,215_CD 6,480_CD Net_JJ current_JJ assets_NNS 3,911_CD 3,884_CD Total_JJ assets_NNS less_RBR current_JJ liabilities_NNS 13,361_CD 12,016_CD Creditors_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN Loans_NNPS 19 328 635_CD Other_JJ creditors_NNS 18 34 152 362_CD 787_CD Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS 21_CD 1,773_CD 1,600_CD Net_JJ assets_NNS 11,226_CD 9,629_CD Capital_NN and_CC reserves_NNS Called-up_JJ share_NN capital_NN 38 429 436_CD Share_NN premium_NN account_NN 23 403 334_CD Capital_NNP redemption_NN reserve_NN 23_CD 16_CD 9_CD Merger_NN reserve_NN 23 433 433_CD Other_JJ reserves_NNS 23_CD 1,440_CD 1,470_CD Profit_NN and_CC loss_NN account_NN 23_CD 8,451_CD 6,904_CD Shareholders_NNS funds_NNS equity_NN interests_NNS 22_CD 11,172_CD 9,586_CD Minority_NNP equity_NN interests_NNS 54_CD 43_CD Shareholders_NNS funds_NNS and_CC minority_NN interests_NNS 11,226_CD 9,629_CD The_DT Financial_NNP Statements_NNP on_IN pages_NNS 58_CD to_TO 122_CD were_VBD approved_VBN by_IN the_DT Board_NNP of_IN Directors_NNS on_IN 30_CD January_NNP 2003_CD and_CC were_VBD signed_VBN on_IN its_PRP$ behalf_NN by_IN :_: Sir_NNP Tom_NNP McKillop_NNP Jonathan_NNP Symonds_NNP Director_NNP Director_NNP AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 61_CD Statement_NN of_IN Group_NNP Cash_NNP Flow_NNP for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002 2001 2000_CD Notes_NNP $_$ m_CD $_$ m_CD $_$ m_CD Cash_NN flow_NN from_IN operating_VBG activities_NNS Net_JJ cash_NN inflow_NN from_IN trading_NN operations_NNS 24_CD 5,686_CD 4,130_CD 4,992_CD Outflow_NNP related_VBN to_TO exceptional_JJ items_NNS 25 93 368 809_CD Net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS 5,593_CD 3,762_CD 4,183_CD Dividends_NNS received_VBN from_IN joint_JJ ventures_NNS Returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN Interest_NN received_VBD 142 232 180_CD Interest_NN paid_VBN 96_CD 84_CD 145_CD Dividends_NNS received_VBD 8_CD Dividends_NNS paid_VBN by_IN subsidiaries_NNS to_TO minority_NN interests_NNS 11_CD 16_CD 35_CD 156_CD 19_CD Tax_NNP paid_VBD 795 792 648_CD Capital_NNP expenditure_NN and_CC financial_JJ investment_NN Cash_NN expenditure_NN on_IN tangible_JJ fixed_JJ assets_NNS 11_CD 1,340_CD 1,385_CD 1,347_CD Cash_NN expenditure_NN on_IN intangible_JJ assets_NNS and_CC goodwill_NN 268 197 113_CD Cash_NN expenditure_NN on_IN fixed_JJ asset_NN investments_NNS 1_CD 5_CD 3_CD Disposals_NNS of_IN fixed_JJ assets_NNS 66_CD 44_CD 37_CD 1,543_CD 1,543_CD 1,426_CD Acquisitions_NNS and_CC disposals_NNS Acquisitions_NNS of_IN subsidiaries_NNS and_CC purchases_NNS of_IN minority_NN interests_NNS 26_CD 44_CD 167_CD Net_JJ repayment_NN of_IN debt_NN by_IN Zeneca_NNP Agrochemicals_NNPS 27_CD 909_CD Disposals_NNS of_IN business_NN operations_NNS 28_CD Disposals_NNS of_IN investments_NNS in_IN joint_JJ ventures_NNS and_CC associates_NNS 2_CD 44_CD 740_CD Equity_NNP dividends_NNS paid_VBD to_TO Shareholders_NNS 1,234_CD 1,236_CD 1,220_CD Net_JJ cash_NN inflow_NN before_IN management_NN of_IN liquid_JJ resources_NNS and_CC financing_NN 30_CD 2,056_CD 303_CD 1,648_CD Management_NN of_IN liquid_JJ resources_NNS and_CC financing_NN Movement_NNP in_IN short_JJ term_NN investments_NNS and_CC fixed_VBN deposits_NNS net_JJ 806 260 608_CD Financing_NN 31_CD 118_CD 35_CD 66_CD Net_JJ share_NN re-purchases_VBZ 1,154_CD 994_CD 334_CD Decrease_NN increase_NN in_IN cash_NN in_IN the_DT year_NN 29 22 396 640_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 62_CD Basis_NN of_IN Consolidation_NN and_CC Presentation_NN of_IN Financial_NNP Information_NNP The_NNP preparation_NN of_IN the_DT Financial_NNP Statements_NNP in_IN have_VBP fallen_VBN from_IN $_$ 1.77_CD to_TO $_$ 1.73_CD 2000_CD $_$ 1.76_CD conformity_NN with_IN generally_RB accepted_VBN to_TO $_$ 1.62_CD ._.
Comparative_JJ periods_NNS have_VBP been_VBN accounting_VBG principles_NNS requires_VBZ management_NN restated_VBN ._.
to_TO make_VB estimates_NNS and_CC assumptions_NNS that_WDT affect_VBP the_DT reported_VBN amounts_NNS of_IN assets_NNS and_CC In_IN addition_NN ,_, the_DT following_VBG new_JJ accounting_NN liabilities_NNS and_CC disclosure_NN of_IN contingent_JJ assets_NNS standard_NN had_VBD been_VBN issued_VBN but_CC has_VBZ not_RB yet_RB and_CC liabilities_NNS at_IN the_DT date_NN of_IN the_DT Financial_NNP been_VBN fully_RB adopted_VBN :_: Statements_NNS and_CC the_DT reported_VBN amounts_NNS of_IN revenues_NNS and_CC expenses_NNS during_IN the_DT reporting_NN UK_NNP Financial_NNP Reporting_NNP Standard_NNP 17_CD FRS_NNP 17_CD period_NN ._.
Actual_JJ results_NNS could_MD differ_VB from_IN those_DT Retirement_NNP Benefits_NNPS becomes_VBZ fully_RB estimates_NNS ._.
effective_JJ for_IN accounting_NN periods_NNS beginning_VBG on_IN or_CC after_IN 1_CD January_NNP 2005_CD ,_, with_IN increasing_VBG levels_NNS As_IN part_NN of_IN AstraZenecas_NNP objective_NN to_TO align_VB of_IN disclosure_NN required_VBN for_IN each_DT accounting_NN with_IN accounting_NN best_JJS practice_NN ,_, cash_NN period_NN ending_VBG on_IN or_CC after_IN 22_CD June_NNP 2001_CD ._.
It_PRP discounts_VBZ arising_VBG from_IN prompt_JJ payment_NN of_IN sets_NNS out_IN the_DT requirements_NNS for_IN accounting_NN for_IN invoices_NNS have_VBP been_VBN reclassified_VBN from_IN cost_NN of_IN retirement_NN benefits_NNS ,_, including_VBG the_DT fair_JJ value_NN of_IN sales_NNS to_TO sales_NNS ._.
Comparatives_NNS have_VBP also_RB been_VBN assets_NNS and_CC liabilities_NNS arising_VBG from_IN employers_NNS reclassified_VBN for_IN consistency_NN of_IN presentation_NN ._.
obligations_NNS ,_, the_DT treatment_NN of_IN related_JJ costs_NNS and_CC Both_DT sales_NNS and_CC cost_NN of_IN sales_NNS have_VBP been_VBN level_NN of_IN disclosure_NN ._.
AstraZeneca_NNP has_VBZ adopted_VBN reduced_VBN by_IN $_$ 287m_CD in_IN the_DT current_JJ year_NN 2001_CD FRS_NNP 17_CD to_TO the_DT extent_NN of_IN the_DT mandated_VBN disclosure_NN requirements_NNS for_IN the_DT year_NN ended_VBD $_$ 258m_CD ,_, 2000_CD $_$ 221m_CD ._.
The_DT change_NN has_VBZ 31_CD December_NNP 2002_CD and_CC these_DT are_VBP included_VBN in_IN minimal_JJ impact_NN on_IN previously_RB stated_VBN sales_NNS Note_VBP 32_CD to_TO the_DT Financial_NNP Statements_NNP ._.
Furthermore_RB ,_, neither_DT profits_NNS nor_CC net_JJ assets_NNS have_VBP been_VBN affected_VBN ._.
Discontinued_VBN operations_NNS Following_VBG the_DT demerger_NN of_IN the_DT Zeneca_NNP Agrochemicals_NNPS business_NN on_IN 13_CD November_NNP 2000_CD and_CC its_PRP$ subsequent_JJ merger_NN with_IN Novartis_NNP agribusiness_NN to_TO form_VB Syngenta_NNP AG_NNP ,_, Zeneca_NNP Agrochemicals_NNPS results_NNS have_VBP been_VBN reported_VBN as_IN discontinued_VBN operations_NNS ._.
New_NNP accounting_NN standards_NNS The_DT following_JJ new_JJ accounting_NN standard_NN was_VBD adopted_VBN during_IN the_DT year_NN :_: UK_NNP Financial_NNP Reporting_NNP Standard_NNP 19_CD FRS_NNP 19_CD Deferred_NNP Tax_NNP is_VBZ applicable_JJ for_IN accounting_NN periods_NNS ending_VBG on_IN or_CC after_IN 23_CD January_NNP 2002_CD ._.
It_PRP requires_VBZ full_JJ provision_NN to_TO be_VB made_VBN for_IN deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS arising_VBG from_IN timing_VBG differences_NNS between_IN the_DT recognition_NN of_IN gains_NNS and_CC losses_NNS in_IN the_DT Financial_NNP Statements_NNP and_CC their_PRP$ recognition_NN in_IN a_DT tax_NN computation_NN except_IN for_IN certain_JJ exemptions_NNS set_VBN out_RP in_IN the_DT standard_NN ._.
The_DT impact_NN of_IN adoption_NN in_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD has_VBZ been_VBN to_TO reduce_VB net_JJ profit_NN by_IN $_$ 19m_CD ._.
Compliance_NN with_IN FRS_NNP 19_CD at_IN 31_CD December_NNP 2001_CD reduced_VBD net_JJ assets_NNS by_IN $_$ 193m_CD ,_, being_VBG an_DT increase_NN in_IN assets_NNS of_IN $_$ 511m_CD and_CC an_DT increase_NN in_IN liabilities_NNS of_IN $_$ 704m_CD ._.
The_DT net_JJ profit_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2001_CD decreased_VBN by_IN $_$ 61m_CD 2000_CD $_$ 261m_CD ,_, resulting_VBG in_IN an_DT effective_JJ tax_NN rate_NN of_IN 28.5_CD %_NN 2000_CD 40.6_CD %_NN compared_VBN with_IN the_DT previously_RB reported_VBN 27_CD %_NN 2000_CD 33.8_CD %_NN ._.
The_DT adjustments_NNS did_VBD not_RB change_VB the_DT tax_NN effects_NNS on_IN exceptional_JJ items_NNS ._.
Basic_JJ earnings_NNS per_IN share_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2001_CD have_VBP been_VBN restated_VBN from_IN $_$ 1.69_CD to_TO $_$ 1.65_CD 2000_CD $_$ 1.44_CD to_TO $_$ 1.30_CD whilst_NN earnings_NNS per_IN share_NN before_IN exceptional_JJ items_NNS AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 63_CD Accounting_NNP Policies_NNS Basis_NN of_IN accounting_VBG up_RP to_TO and_CC including_VBG 1997_CD was_VBD to_TO eliminate_VB ventures_NNS and_CC associates_NNS together_RB with_IN those_DT The_DT Financial_NNP Statements_NNP are_VBP prepared_VBN under_IN goodwill_NN arising_VBG upon_IN acquisitions_NNS against_IN on_IN relevant_JJ foreign_JJ currency_NN loans_NNS are_VBP taken_VBN the_DT historical_JJ cost_NN convention_NN ,_, modified_VBN to_TO reserves_NNS ._.
Such_JJ goodwill_NN will_MD remain_VB eliminated_VBN directly_RB to_TO reserves_NNS via_IN the_DT statement_NN of_IN total_JJ include_VBP the_DT revaluation_NN to_TO market_NN value_NN of_IN against_IN reserves_NNS until_IN disposal_NN or_CC termination_NN recognized_VBN gains_NNS and_CC losses_NNS ._.
certain_JJ current_JJ asset_NN investments_NNS held_VBN by_IN of_IN the_DT previously_RB acquired_VBN business_NN including_VBG Group_NNP subsidiaries_NNS as_IN described_VBN below_IN ,_, in_IN the_DT planned_VBN disposal_NN or_CC termination_NN when_WRB Taxation_NNP accordance_NN with_IN the_DT Companies_NNS Act_NNP 1985_CD there_EX are_VBP indications_NNS that_IN the_DT value_NN of_IN the_DT The_DT charge_NN for_IN taxation_NN is_VBZ based_VBN on_IN the_DT profits_NNS and_CC UK_NNP generally_RB accepted_VBD accounting_NN goodwill_NN has_VBZ been_VBN permanently_RB impaired_VBN ,_, for_IN the_DT year_NN and_CC takes_VBZ into_IN account_NN taxation_NN principles_NNS UK_NNP GAAP_NNP ._.
Where_WRB there_EX are_VBP when_WRB the_DT profit_NN or_CC loss_NN on_IN disposal_NN or_CC deferred_VBN because_IN of_IN timing_NN differences_NNS significant_JJ differences_NNS to_TO US_NNP GAAP_NNP these_DT termination_NN will_MD be_VB calculated_VBN after_IN charging_VBG between_IN the_DT treatment_NN of_IN certain_JJ items_NNS for_IN have_VBP been_VBN described_VBN in_IN the_DT US_NNP GAAP_NNP section_NN the_DT gross_JJ amount_NN ,_, at_IN current_JJ exchange_NN rates_NNS ,_, taxation_NN and_CC for_IN accounting_NN purposes_NNS ._.
The_DT following_NN of_IN any_DT such_JJ goodwill_NN ._.
provision_NN is_VBZ made_VBN for_IN the_DT tax_NN effects_NNS of_IN these_DT paragraphs_NNS describe_VBP the_DT main_JJ accounting_NN differences_NNS ._.
No_DT provision_NN is_VBZ made_VBN for_IN policies_NNS under_IN UK_NNP GAAP_NNP ._.
The_DT accounting_NN Post-retirement_NN benefits_NNS unremitted_JJ earnings_NNS of_IN foreign_JJ subsidiaries_NNS policies_NNS of_IN some_DT overseas_JJ subsidiaries_NNS and_CC The_DT pension_NN costs_NNS relating_VBG to_TO UK_NNP retirement_NN where_WRB there_EX is_VBZ no_DT commitment_NN to_TO remit_VB such_JJ associated_VBN undertakings_NNS do_VBP not_RB conform_VB with_IN plans_NNS are_VBP assessed_VBN in_IN accordance_NN with_IN the_DT earnings_NNS ,_, nor_CC is_VBZ provision_NN made_VBN for_IN rolled_VBN over_IN UK_NNP GAAP_NNP and_CC ,_, where_WRB appropriate_JJ ,_, advice_NN of_IN independent_JJ qualified_JJ actuaries_NNS ._.
The_DT deferred_JJ tax_NN balances_NNS are_VBP adjustments_NNS are_VBP made_VBN on_IN consolidation_NN in_IN amounts_NNS so_IN determined_JJ include_VBP the_DT regular_JJ not_RB discounted_VBN ._.
order_NN to_TO present_VB the_DT Group_NNP Financial_NNP cost_NN of_IN providing_VBG the_DT benefits_NNS under_IN the_DT plans_NNS Statements_NNS on_IN a_DT consistent_JJ basis_NN ._.
which_WDT it_PRP is_VBZ intended_VBN should_MD remain_VB as_IN a_DT level_NN Fixed_VBN assets_NNS ,_, depreciation_NN and_CC percentage_NN of_IN current_JJ and_CC expected_JJ future_JJ amortisation_NN On_IN 13_CD November_NNP 2000_CD ,_, AstraZeneca_NNP earnings_NNS of_IN the_DT employees_NNS covered_VBN under_IN the_DT AstraZenecas_NNPS policy_NN is_VBZ to_TO write_VB off_RP the_DT demerged_JJ Zeneca_NNP Agrochemicals_NNPS ,_, which_WDT plans_VBZ ._.
Variations_NNS from_IN the_DT regular_JJ pension_NN difference_NN between_IN the_DT cost_NN of_IN each_DT tangible_JJ was_VBD merged_VBN with_IN the_DT Novartis_NNP agribusiness_NN to_TO cost_NN are_VBP spread_VBN on_IN a_DT systematic_JJ basis_NN over_IN fixed_JJ asset_NN and_CC its_PRP$ residual_JJ value_NN evenly_RB over_IN form_NN Syngenta_NNP AG_NNP ._.
The_DT impact_NN of_IN the_DT the_DT estimated_VBN average_JJ remaining_VBG service_NN lives_VBZ its_PRP$ estimated_VBN remaining_VBG life_NN ._.
Reviews_NNS are_VBP demerger_NN on_IN the_DT AstraZeneca_NNP Financial_NNP of_IN current_JJ employees_NNS in_IN the_DT plans_NNS ._.
Retirement_NNP made_VBD periodically_RB of_IN the_DT estimated_VBN remaining_VBG Statements_NNP for_IN the_DT year_NN ended_VBD 31_CD December_NNP plans_NNS of_IN non-UK_JJ subsidiaries_NNS are_VBP accounted_VBN lives_NNS of_IN individual_JJ productive_JJ assets_NNS ,_, taking_VBG 2000_CD is_VBZ shown_VBN in_IN Note_NN 27_CD ._.
for_IN in_IN accordance_NN with_IN local_JJ conditions_NNS and_CC account_NN of_IN commercial_JJ and_CC technological_JJ practice_NN ._.
With_IN minor_JJ exceptions_NNS ,_, these_DT obsolescence_NN as_RB well_RB as_IN normal_JJ wear_NN and_CC Critical_JJ accounting_NN policies_NNS subsidiaries_NNS recognize_VBP the_DT expected_VBN cost_NN of_IN tear_VB ._.
Under_IN this_DT policy_NN it_PRP becomes_VBZ AstraZenecas_NNP management_NN considers_VBZ the_DT providing_VBG pensions_NNS on_IN a_DT systematic_JJ basis_NN impracticable_JJ to_TO calculate_VB average_JJ asset_NN lives_VBZ following_VBG to_TO be_VB the_DT most_RBS important_JJ over_IN the_DT average_JJ remaining_VBG service_NN lives_NNS of_IN exactly_RB ._.
However_RB ,_, the_DT total_JJ lives_NNS range_VBP from_IN accounting_VBG policies_NNS in_IN the_DT context_NN of_IN the_DT employees_NNS in_IN accordance_NN with_IN the_DT advice_NN of_IN approximately_RB 13_CD to_TO 50_CD years_NNS for_IN buildings_NNS ,_, Groups_NNS operations_NNS ._.
The_DT impact_NN of_IN these_DT independent_JJ qualified_JJ actuaries_NNS ._.
The_DT costs_NNS of_IN and_CC 3_CD to_TO 15_CD years_NNS for_IN plant_NN and_CC equipment_NN ._.
policies_NNS and_CC management_NN judgements_NNS made_VBD providing_VBG post-retirement_JJ benefits_NNS other_JJ than_IN Intangible_JJ assets_NNS ,_, including_VBG patents_NNS acquired_VBN ,_, when_WRB applying_VBG them_PRP are_VBP discussed_VBN in_IN the_DT pensions_NNS ,_, principally_RB healthcare_NN ,_, are_VBP charged_VBN are_VBP capitalized_VBN and_CC amortised_VBN over_IN their_PRP$ Financial_JJ Review_NNP ._.
to_TO the_DT profit_NN and_CC loss_NN account_NN on_IN a_DT consistent_JJ estimated_VBN useful_JJ lives_NNS generally_RB not_RB basis_NN over_IN the_DT average_JJ service_NN lives_NNS of_IN exceeding_VBG 20_CD years_NNS ,_, in_IN line_NN with_IN the_DT benefits_NNS Turnover_NN employees_NNS ._.
Such_JJ costs_NNS are_VBP assessed_VBN in_IN accruing_VBG ._.
If_IN related_JJ products_NNS fail_VBP ,_, the_DT Turnover_NN excludes_VBZ intercompany_NN turnover_NN accordance_NN with_IN the_DT advice_NN of_IN independent_JJ remaining_VBG unamortised_JJ amounts_NNS are_VBP and_CC value_VBP added_VBN taxes_NNS and_CC represents_VBZ net_JJ qualified_VBN actuaries_NNS ._.
AstraZeneca_NNP has_VBZ adopted_VBN immediately_RB written_VBN off_RP to_TO revenue_NN expense_NN ._.
invoice_NN value_NN less_RBR estimated_JJ rebates_NNS ,_, returns_VBZ the_DT disclosure_NN requirements_NNS of_IN FRS_NNP 17_CD ._.
Finance_NNP costs_NNS and_CC internally_RB developed_VBN and_CC settlement_NN discounts_NNS ._.
Revenue_NN is_VBZ intangible_JJ assets_NNS are_VBP not_RB capitalized_VBN ._.
All_DT fixed_VBN recognized_VBN at_IN the_DT point_NN at_IN which_WDT title_NN passes_VBZ ._.
Other_JJ accounting_NN policies_NNS assets_NNS are_VBP reviewed_VBN for_IN impairment_NN when_WRB there_EX are_VBP indications_NNS that_IN the_DT carrying_VBG value_NN Research_NN and_CC development_NN Foreign_JJ currencies_NNS may_MD not_RB be_VB recoverable_JJ ._.
Research_NNP and_CC development_NN expenditure_NN is_VBZ Profit_NN and_CC loss_NN accounts_NNS in_IN foreign_JJ currencies_NNS charged_VBN to_TO profit_VB in_IN the_DT year_NN in_IN which_WDT it_PRP is_VBZ are_VBP translated_VBN into_IN US_NNP dollars_NNS at_IN average_JJ rates_NNS Leases_VBZ incurred_VBN ._.
for_IN the_DT relevant_JJ accounting_NN periods_NNS ._.
Assets_NNS Assets_NNS held_VBN under_IN finance_NN leases_NNS are_VBP and_CC liabilities_NNS are_VBP translated_VBN at_IN exchange_NN rates_NNS capitalized_VBN and_CC included_VBN in_IN tangible_JJ fixed_VBN Goodwill_NNP prevailing_VBG at_IN the_DT date_NN of_IN the_DT Group_NNP balance_NN assets_NNS at_IN fair_JJ value_NN ._.
Each_DT asset_NN is_VBZ depreciated_VBN On_IN the_DT acquisition_NN of_IN a_DT business_NN ,_, fair_JJ values_NNS sheet_NN ._.
over_IN the_DT shorter_JJR of_IN the_DT lease_NN term_NN or_CC its_PRP$ useful_JJ are_VBP attributed_VBN to_TO the_DT net_JJ assets_NNS acquired_VBN ._.
The_DT obligations_NNS related_VBN to_TO finance_VB leases_NNS ,_, Goodwill_NNP arises_VBZ where_WRB the_DT fair_JJ value_NN of_IN the_DT Exchange_NNP gains_NNS and_CC losses_NNS on_IN short_JJ term_NN net_NN of_IN finance_NN charges_NNS in_IN respect_NN of_IN future_JJ consideration_NN given_VBN for_IN a_DT business_NN exceeds_VBZ foreign_JJ currency_NN borrowings_NNS and_CC deposits_NNS are_VBP periods_NNS ,_, are_VBP included_VBN ,_, as_IN appropriate_JJ ,_, the_DT fair_JJ value_NN of_IN such_JJ net_JJ assets_NNS ._.
Goodwill_NN included_VBD within_IN net_JJ interest_NN payable_JJ ._.
under_IN creditors_NNS due_JJ within_IN ,_, or_CC creditors_NNS due_RB arising_VBG on_IN acquisitions_NNS since_IN 1998_CD is_VBZ Exchange_NNP differences_NNS on_IN all_DT other_JJ after_IN ,_, one_CD year_NN ._.
The_DT interest_NN element_NN of_IN the_DT capitalized_JJ and_CC amortised_JJ over_IN its_PRP$ estimated_JJ transactions_NNS ,_, except_IN relevant_JJ foreign_JJ currency_NN rental_JJ obligation_NN is_VBZ allocated_VBN to_TO accounting_VBG useful_JJ life_NN generally_RB not_RB exceeding_VBG 20_CD years_NNS ._.
loans_NNS ,_, are_VBP taken_VBN to_TO operating_VBG profit_NN ._.
In_IN the_DT periods_NNS during_IN the_DT lease_NN term_NN to_TO reflect_VB a_DT Goodwill_NNP is_VBZ reviewed_VBN for_IN impairment_NN when_WRB consolidated_JJ Financial_NNP Statements_NNP exchange_NN constant_JJ rate_NN of_IN interest_NN on_IN the_DT remaining_VBG there_EX are_VBP indications_NNS that_IN the_DT carrying_VBG value_NN differences_NNS arising_VBG on_IN consolidation_NN of_IN the_DT net_JJ balance_NN of_IN the_DT obligation_NN for_IN each_DT accounting_NN may_MD not_RB be_VB recoverable_JJ ._.
The_DT Groups_NNS policy_NN investments_NNS in_IN overseas_JJ subsidiaries_NNS ,_, joint_JJ period_NN ._.
Rentals_NNS under_IN operating_VBG leases_NNS are_VBP AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 64_CD Accounting_NNP Policies_NNS continued_VBD charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN as_IN AstraZeneca_NNP is_VBZ exposed_VBN to_TO environmental_JJ incurred_VBN ._.
liabilities_NNS relating_VBG to_TO its_PRP$ past_JJ operations_NNS ,_, principally_RB in_IN respect_NN of_IN soil_NN and_CC groundwater_NN Investments_NNP remediation_NN costs_NNS ._.
Provisions_NNS for_IN these_DT costs_NNS An_DT associate_NN is_VBZ an_DT undertaking_NN ,_, not_RB being_VBG a_DT are_VBP made_VBN when_WRB there_EX is_VBZ a_DT present_JJ obligation_NN ,_, it_PRP subsidiary_NN or_CC joint_JJ venture_NN ,_, in_IN which_WDT is_VBZ probable_JJ that_IN expenditure_NN on_IN remedial_JJ work_NN AstraZeneca_NNP has_VBZ a_DT participating_VBG interest_NN and_CC will_MD be_VB required_VBN and_CC a_DT reliable_JJ estimate_NN can_MD be_VB over_IN whose_WP$ commercial_JJ and_CC financial_JJ policy_NN made_VBN of_IN the_DT cost_NN ._.
decisions_NNS AstraZeneca_NNP exercises_VBZ significant_JJ influence_NN ._.
Stock_NNP valuation_NN Finished_VBN goods_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN A_DT joint_JJ venture_NN is_VBZ an_DT entity_NN in_IN which_WDT or_CC net_JJ realisable_JJ value_NN and_CC raw_JJ materials_NNS and_CC AstraZeneca_NNP holds_VBZ an_DT interest_NN on_IN a_DT long_JJ term_NN other_JJ stocks_NNS at_IN the_DT lower_JJR of_IN cost_NN or_CC basis_NN and_CC which_WDT is_VBZ jointly_RB controlled_VBN by_IN replacement_NN price_NN ._.
The_DT first_JJ in_IN ,_, first_RB out_IN or_CC an_DT AstraZeneca_NNP and_CC one_CD or_CC more_JJR other_JJ venturers_NNS average_JJ method_NN of_IN valuation_NN is_VBZ used_VBN ._.
determining_VBG cost_NN ,_, depreciation_NN is_VBZ included_VBN but_CC selling_VBG expenses_NNS and_CC certain_JJ overhead_JJ AstraZenecas_NNP share_NN of_IN the_DT profits_NNS less_RBR losses_NNS expenses_NNS principally_RB central_JJ administration_NN of_IN all_DT significant_JJ joint_JJ ventures_NNS and_CC associates_NNS costs_NNS are_VBP excluded_VBN ._.
Net_JJ realisable_JJ value_NN is_VBZ is_VBZ included_VBN in_IN the_DT Group_NNP profit_NN and_CC loss_NN determined_VBN as_IN estimated_VBN selling_NN price_NN less_JJR account_NN on_IN the_DT equity_NN accounting_NN basis_NN or_CC ,_, in_IN costs_NNS of_IN disposal_NN ._.
the_DT case_NN of_IN joint_JJ ventures_NNS ,_, the_DT gross_JJ equity_NN accounting_NN basis_NN ._.
The_DT holding_NN value_NN of_IN Principal_NN financial_JJ instruments_NNS significant_JJ associates_NNS and_CC joint_JJ ventures_NNS in_IN the_DT Forward_NNP foreign_JJ exchange_NN contracts_NNS for_IN Group_NNP balance_NN sheet_NN is_VBZ calculated_VBN by_IN existing_VBG transactions_NNS are_VBP revalued_VBN to_TO year_NN end_NN reference_NN to_TO AstraZenecas_NNP equity_NN in_IN the_DT net_JJ spot_NN rates_NNS and_CC the_DT gains_NNS losses_NNS arising_VBG are_VBP assets_NNS of_IN such_JJ associates_NNS and_CC joint_JJ ventures_NNS ,_, recognized_VBN in_IN the_DT Group_NNP profit_NN and_CC loss_NN as_IN shown_VBN by_IN the_DT most_RBS recent_JJ accounts_NNS account_VBP ._.
Interest_NN differentials_NNS are_VBP amortised_VBN available_JJ ,_, adjusted_VBN where_WRB appropriate_JJ and_CC on_IN a_DT straight_JJ line_NN basis_NN over_IN the_DT life_NN of_IN the_DT including_VBG goodwill_NN on_IN acquisitions_NNS made_VBN since_IN contract_NN ._.
The_DT gains_NNS losses_NNS on_IN forward_RB foreign_JJ Fixed_JJ asset_NN investments_NNS are_VBP stated_VBN at_IN cost_NN exchange_NN contracts_NNS and_CC currency_NN option_NN and_CC reviewed_VBN for_IN impairment_NN if_IN there_EX are_VBP contracts_NNS hedging_VBG anticipated_JJ exposures_NNS are_VBP indications_NNS that_IN the_DT carrying_VBG value_NN may_MD not_RB be_VB deferred_VBN until_IN the_DT date_NN the_DT underlying_VBG recoverable_JJ ._.
transaction_NN being_VBG hedged_VBN is_VBZ completed_VBN ._.
Current_JJ asset_NN investments_NNS held_VBN by_IN the_DT Interest_NN rate_NN swaps_NNS are_VBP accounted_VBN for_IN on_IN an_DT Groups_NNS insurance_NN company_NN subsidiaries_NNS ,_, to_TO accruals_NNS basis_NN ._.
Cross-currency_NN swaps_NNS are_VBP the_DT extent_NN that_IN they_PRP are_VBP actively_RB matched_VBN translated_VBN at_IN year_NN end_NN exchange_NN rates_NNS :_: against_IN insurance_NN liabilities_NNS ,_, are_VBP valued_VBN at_IN gains_NNS losses_NNS arising_VBG are_VBP included_VBN in_IN the_DT market_NN value_NN and_CC unrealised_JJ gains_NNS and_CC losses_NNS measurement_NN of_IN the_DT related_JJ liabilities_NNS and_CC are_VBP taken_VBN directly_RB to_TO reserves_NNS via_IN the_DT dealt_VBN with_IN in_IN the_DT Group_NNP profit_NN and_CC loss_NN account_NN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC or_CC reserves_NNS as_IN appropriate_JJ ._.
Realised_VBN gains_NNS and_CC losses_NNS are_VBP taken_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
Contingent_JJ liabilities_NNS Through_IN the_DT normal_JJ course_NN of_IN business_NN ,_, AstraZeneca_NNP is_VBZ involved_VBN in_IN legal_JJ disputes_NNS the_DT settlement_NN of_IN which_WDT may_MD involve_VB cost_NN to_TO the_DT Group_NNP ._.
Provision_NNP is_VBZ made_VBN where_WRB the_DT outcome_NN and_CC associated_VBN costs_NNS can_MD be_VB estimated_VBN reliably_RB ._.
com_NN 65_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP 1_CD Composition_NN of_IN the_DT Group_NNP The_NNP Group_NNP Financial_NNP Statements_NNP consolidate_VB the_DT financial_JJ statements_NNS of_IN AstraZeneca_NNP PLC_NNP and_CC its_PRP$ subsidiaries_NNS ,_, of_IN which_WDT there_EX were_VBD 235_CD ,_, at_IN 31_CD December_NNP 2002_CD ._.
Owing_VBG to_TO local_JJ conditions_NNS and_CC to_TO avoid_VB undue_JJ delay_NN in_IN the_DT presentation_NN of_IN the_DT Group_NNP Financial_NNP Statements_NNP ,_, Salick_NNP Health_NNP Care_NNP prepares_VBZ its_PRP$ financial_JJ statements_NNS to_TO 30_CD November_NNP ._.
2_CD Note_NN of_IN historical_JJ cost_NN profits_NNS and_CC losses_NNS There_EX were_VBD no_DT material_NN differences_NNS between_IN reported_VBN profits_NNS and_CC losses_NNS and_CC historical_JJ cost_NN profits_NNS and_CC losses_NNS on_IN ordinary_JJ activities_NNS before_IN taxation_NN ._.
com_NN 66_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 3_CD Group_NNP operating_NN profit_NN Continuing_VBG operations_NNS Pre_NNP exceptional_JJ Exceptional_JJ 2002_CD items_NNS items_NNS Total_JJ $_$ m_CD $_$ m_CD $_$ m_CD Group_NNP turnover_NN 17,841_CD 17,841_CD Operating_NN costs_NNS Cost_NN of_IN sales_NNS 4,520_CD 4,520_CD Distribution_NN costs_NNS 141_CD 141_CD Research_NNP and_CC development_NN 3,069_CD 3,069_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ expenses_NNS 5,998_CD 350_CD 6,348_CD 13,728_CD 350_CD 14,078_CD Other_JJ operating_NN income_NN Royalties_NNS 113_CD 113_CD Other_JJ income_NN 130 130 243 243_CD Other_JJ income_NN includes_VBZ gains_NNS arising_VBG from_IN disposals_NNS under_IN ongoing_JJ product_NN rationalisation_NN programs_NNS ._.
Group_NNP operating_NN profit_NN 4,356_CD 350_CD 4,006_CD Charges_NNS included_VBD above_IN for_IN depreciation_NN 705_CD 705_CD for_IN amortisation_NN 255_CD 255_CD for_IN impairment_NN Gross_NNP profit_NN ,_, as_IN defined_VBN by_IN the_DT Companies_NNS Act_NNP 1985_CD 13,321_CD 13,321_CD 4_CD Share_NN of_IN operating_VBG profits_NNS losses_NNS of_IN joint_JJ ventures_NNS and_CC associates_NNS Continuing_VBG operations_NNS Pre_NNP exceptional_JJ Exceptional_JJ 2002_CD items_NNS items_NNS Total_JJ $_$ m_CD $_$ m_CD $_$ m_CD Share_NN of_IN operating_VBG loss_NN profit_NN of_IN joint_JJ ventures_NNS Share_NN of_IN operating_NN profit_NN of_IN associates_NNS AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 68_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 5_CD Exceptional_JJ items_NNS 2002 2001 2000_CD $_$ m_CD $_$ m_CD $_$ m_CD Accrual_NNP related_VBN to_TO Zoladex_NNP investigation_NN 350_CD Integration_NNP and_CC synergy_NN costs_NNS 202_CD 322_CD Exceptional_JJ items_NNS included_VBN in_IN operating_VBG profits_NNS 350 202 322_CD Continuing_VBG operations_NNS Provision_NNP of_IN impairment_NN of_IN investment_NN in_IN Advanta_NNP BV_NNP after_IN charging_VBG $_$ 49m_CD of_IN goodwill_NN previously_RB written_VBN off_RP to_TO reserves_NNS 137_CD Share_NN of_IN operating_NN losses_NNS of_IN joint_JJ ventures_NNS and_CC associates_NNS 137_CD Discontinued_VBN operations_NNS Costs_NNS related_VBN to_TO the_DT demerger_NN of_IN Zeneca_NNP Agrochemicals_NNPS and_CC formation_NN of_IN Syngenta_NNP AG_NNP 150_CD Profits_NNS less_RBR losses_NNS on_IN sale_NN ,_, closure_NN ,_, or_CC demerger_NN of_IN operations_NNS 150_CD Profit_NN on_IN sale_NN of_IN fixed_JJ assets_NNS 10_CD Total_JJ exceptional_JJ items_NNS before_IN taxation_NN 350 192 609_CD Net_JJ taxation_NN credit_NN 54_CD 28_CD Total_JJ exceptional_JJ items_NNS after_IN taxation_NN 350 138 581_CD The_DT US_NNP Department_NNP of_IN Justice_NNP has_VBZ been_VBN conducting_VBG an_DT investigation_NN into_IN the_DT sale_NN and_CC marketing_NN of_IN Zoladex_NNP goserelin_NN acetate_NN implant_VBP ._.
This_DT investigation_NN was_VBD prompted_VBN by_IN the_DT filing_NN of_IN a_DT qui_FW tam_FW complaint_NN by_IN a_DT private_JJ party_NN in_IN 1997_CD and_CC involves_VBZ allegations_NNS of_IN improper_JJ submissions_NNS of_IN claims_NNS to_TO the_DT Medicare_NNP and_CC Medicaid_NNP programs_NNS ._.
The_DT Company_NN and_CC federal_JJ and_CC state_NN authorities_NNS are_VBP in_IN the_DT process_NN of_IN negotiating_VBG a_DT potential_JJ settlement_NN of_IN the_DT civil_JJ and_CC criminal_JJ claims_NNS at_IN issue_NN in_IN the_DT investigation_NN ._.
As_IN a_DT result_NN ,_, although_IN no_DT final_JJ agreement_NN has_VBZ been_VBN concluded_VBN ,_, the_DT Company_NN believes_VBZ it_PRP appropriate_JJ to_TO accrue_VB $_$ 350m_CD to_TO cover_VB estimated_VBN settlement_NN costs_NNS ._.
The_DT integration_NN and_CC synergy_NN program_NN initiated_VBN in_IN 1999_CD was_VBD completed_VBN during_IN 2001_CD ,_, with_IN further_JJ exceptional_JJ charges_NNS of_IN $_$ 202m_CD 2000_CD $_$ 322m_CD ,_, principally_RB for_IN manpower_NN related_VBN costs_NNS ,_, IT_PRP costs_VBZ ,_, and_CC contractors_NNS ._.
The_DT Group_NNP took_VBD an_DT exceptional_JJ charge_NN of_IN $_$ 137m_CD in_IN 2000_CD to_TO provide_VB for_IN impairment_NN of_IN its_PRP$ 50_CD %_NN interest_NN in_IN the_DT seeds_NNS company_NN Advanta_NNP BV_NNP ,_, including_VBG a_DT write_VB off_IN of_IN $_$ 49m_CD of_IN related_JJ goodwill_NN previously_RB taken_VBN to_TO reserves_NNS ._.
The_DT costs_NNS related_VBN to_TO the_DT demerger_NN of_IN Zeneca_NNP Agrochemicals_NNPS and_CC formation_NN of_IN Syngenta_NNP AG_NNP included_VBD advisors_NNS fees_NNS ,_, the_DT costs_NNS of_IN separating_VBG computer_NN systems_NNS ,_, employee_NN related_VBN costs_NNS and_CC environmental_JJ and_CC occupational_JJ health_NN provisions_NNS ._.
The_DT exceptional_JJ charge_NN was_VBD reduced_VBN by_IN the_DT gain_NN on_IN disposal_NN of_IN products_NNS whose_WP$ sale_NN was_VBD required_VBN by_IN the_DT competition_NN authorities_NNS as_IN a_DT condition_NN of_IN the_DT creation_NN of_IN Syngenta_NNP AG_NNP ._.
Tax_NNP relief_NN on_IN the_DT net_JJ exceptional_JJ costs_NNS was_VBD more_JJR than_IN offset_VBN by_IN the_DT provision_NN for_IN capital_NN taxes_NNS arising_VBG out_IN of_IN the_DT restructuring_NN of_IN the_DT business_NN in_IN preparation_NN for_IN demerger_NN ,_, resulting_VBG in_IN a_DT net_JJ tax_NN cost_NN of_IN $_$ 50m_CD ._.
com_NN 69_CD 6_CD Net_JJ interest_NN 2002 2001 2000_CD $_$ m_CD $_$ m_CD $_$ m_CD Interest_NN receivable_NN and_CC similar_JJ income_NN from_IN investments_NNS Securities_NNPS 21_CD 19_CD 30_CD Short_JJ term_NN deposits_NNS 90 179 192_CD Exchange_NNP gain_NN 6_CD 146_CD Joint_NNP ventures_NNS 1_CD 117 199 269_CD Interest_NN payable_JJ and_CC similar_JJ charges_NNS Loan_NN interest_NN 10_CD 32_CD 50_CD Interest_NN on_IN short_JJ term_NN borrowings_NNS and_CC other_JJ financing_NN costs_NNS 51_CD 35_CD 62_CD Discount_NNP on_IN liability_NN 10_CD 15_CD 19_CD Exchange_NNP losses_NNS 16_CD 12_CD Joint_NNP ventures_NNS 3_CD 87_CD 94_CD 134_CD Net_JJ interest_NN receivable_NN 30 105 135_CD The_DT discounting_NN charge_NN above_IN relates_VBZ to_TO amounts_NNS owed_VBN in_IN respect_NN of_IN the_DT re-acquisition_NN of_IN certain_JJ distribution_NN rights_NNS ,_, the_DT final_JJ instalment_NN of_IN which_WDT is_VBZ payable_JJ in_IN 2003_CD ._.
In_IN prior_JJ years_NNS ,_, all_DT interest_NN has_VBZ been_VBN classified_VBN within_IN continuing_VBG operations_NNS as_IN the_DT management_NN of_IN the_DT Groups_NNS liquidity_NN and_CC funding_NN is_VBZ carried_VBN out_RP by_IN the_DT central_JJ treasury_NN function_NN and_CC it_PRP is_VBZ not_RB practicable_JJ to_TO allocate_VB interest_NN to_TO the_DT different_JJ reporting_NN segments_NNS ._.
com_NN 70_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 7_CD Taxation_NNP Profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN ,_, as_IN shown_VBN in_IN the_DT Group_NNP profit_NN and_CC loss_NN account_NN ,_, was_VBD as_IN follows_VBZ :_: 2002 2001 2000_CD restated_VBN restated_VBN $_$ m_CD $_$ m_CD $_$ m_CD UK_NNP 741 618 808_NNP Overseas_NNP 3,296_CD 3,459_CD 3,039_CD 4,037_CD 4,077_CD 3,847_CD Taxes_NNS on_IN profit_NN on_IN ordinary_JJ activities_NNS were_VBD as_IN follows_VBZ :_: UK_NNP taxation_NN Corporation_NNP tax_NN 165 147 130_CD Double_RB taxation_NN relief_NN 29_CD 37_CD 42_CD Deferred_JJ taxation_NN 24_CD 53_CD 3_CD 160_CD 163_CD 85_CD Overseas_JJ taxation_NN Overseas_JJ taxes_NNS 929_CD 739_CD 1,066_CD Adjustments_NNS in_IN respect_NN of_IN prior_JJ periods_NNS 51_CD 17_CD 4_CD Deferred_VBN taxation_NN 139 275 402_CD 1,017_CD 997_CD 1,472_CD Share_NN of_IN taxation_NN of_IN joint_JJ ventures_NNS and_CC associates_NNS 3_CD Tax_NN on_IN profit_NN on_IN ordinary_JJ activities_NNS 1,177_CD 1,160_CD 1,560_CD In_IN prior_JJ years_NNS ,_, the_DT charge_NN for_IN taxation_NN has_VBZ been_VBN allocated_VBN between_IN continuing_VBG operations_NNS and_CC discontinued_VBN operations_NNS based_VBN on_IN the_DT effective_JJ tax_NN rates_NNS for_IN the_DT Group_NNP in_IN the_DT territories_NNS in_IN which_WDT these_DT operations_NNS are_VBP based_VBN ._.
UK_NNP and_CC overseas_JJ taxation_NN has_VBZ been_VBN provided_VBN at_IN current_JJ rates_NNS on_IN the_DT profits_NNS earned_VBN for_IN the_DT periods_NNS covered_VBN by_IN the_DT Group_NNP financial_JJ statements_NNS ._.
To_TO the_DT extent_NN that_IN dividends_NNS remitted_VBN from_IN overseas_JJ subsidiaries_NNS ,_, joint_JJ ventures_NNS and_CC associates_NNS are_VBP expected_VBN to_TO result_VB in_IN additional_JJ taxes_NNS ,_, appropriate_JJ amounts_NNS have_VBP been_VBN provided_VBN ._.
No_DT deferred_JJ tax_NN has_VBZ been_VBN provided_VBN for_IN unremitted_JJ earnings_NNS of_IN Group_NNP companies_NNS overseas_RB as_IN these_DT are_VBP ,_, in_IN the_DT main_JJ ,_, considered_VBN permanently_RB employed_VBN in_IN the_DT businesses_NNS of_IN these_DT companies_NNS and_CC ,_, in_IN the_DT case_NN of_IN joint_JJ ventures_NNS and_CC associates_NNS ,_, the_DT taxes_NNS would_MD not_RB be_VB material_NN ._.
Cumulative_JJ unremitted_JJ earnings_NNS of_IN overseas_JJ subsidiaries_NNS and_CC related_VBN undertakings_NNS totalled_VBD approximately_RB $_$ 9,141_CD m_NN at_IN 31_CD December_NNP 2002_CD ._.
Unremitted_JJ earnings_NNS may_MD be_VB liable_JJ to_TO overseas_JJ taxes_NNS and_CC or_CC UK_NNP taxation_NN after_IN allowing_VBG for_IN double_JJ taxation_NN relief_NN if_IN they_PRP were_VBD to_TO be_VB distributed_VBN as_IN dividends_NNS ._.
Exceptional_JJ items_NNS included_VBN in_IN tax_NN on_IN ordinary_JJ activities_NNS 2002 2001 2000_CD $_$ m_CD $_$ m_CD $_$ m_CD Tax_NNP credit_NN on_IN exceptional_JJ items_NNS 54_CD 28_CD Includes_VBZ deferred_JJ tax_NN relief_NN of_IN $_$ nil_JJ 2001_CD $_$ 23m_CD ,_, 2000_CD $_$ 66m_CD ._.
Statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS In_IN certain_JJ circumstances_NNS ,_, tax_NN charges_NNS or_CC credits_NNS on_IN currency_NN differences_NNS on_IN borrowings_NNS are_VBP taken_VBN to_TO reserves_NNS via_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ._.
The_DT tax_NN charge_NN on_IN such_JJ currency_NN translation_NN differences_NNS amounted_VBD to_TO $_$ 2m_CD in_IN 2002_CD 2001_CD $_$ 6m_CD ,_, 2000_CD $_$ 42m_CD ,_, and_CC has_VBZ been_VBN reported_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ._.
Factors_NNS affecting_VBG future_JJ tax_NN charges_NNS As_IN a_DT group_NN involved_VBN in_IN worldwide_JJ operations_NNS ,_, AstraZeneca_NNP is_VBZ subject_JJ to_TO several_JJ factors_NNS that_WDT may_MD affect_VB future_JJ tax_NN charges_NNS ,_, principally_RB the_DT levels_NNS and_CC mix_NN of_IN profitability_NN in_IN different_JJ jurisdictions_NNS ,_, transfer_NN pricing_NN policies_NNS and_CC tax_NN levels_NNS imposed_VBN ._.
com_NN 71_CD 7_CD Taxation_NNP continued_VBD Tax_NNP reconciliation_NN to_TO UK_NNP statutory_JJ rate_NN The_DT table_NN shown_VBN below_IN reconciles_NNS the_DT UK_NNP statutory_JJ tax_NN charge_NN to_TO the_DT Groups_NNS current_JJ tax_NN charge_NN on_IN profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN ._.
2002 2001 2000_CD restated_VBN restated_VBN $_$ m_CD $_$ m_CD $_$ m_CD Profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 4,037_CD 4,077_CD 3,847_CD Notional_NNP taxation_NN charge_NN at_IN UK_NNP corporation_NN tax_NN rate_NN of_IN 30_CD %_NN 30_CD %_NN for_IN 2001_CD ,_, 30_CD %_NN for_IN 2000_CD 1,211_CD 1,223_CD 1,154_CD Differences_NNS in_IN effective_JJ overseas_JJ tax_NN rates_NNS 141 108 215_CD Capital_NNP allowances_NNS tax_NN reliefs_NNS in_IN excess_NN of_IN depreciation_NN 291 401 235_CD Other_JJ timing_NN differences_NNS 40_CD 99_CD 134_CD Items_NNS not_RB deductible_JJ for_IN tax_NN purposes_NNS 49_CD 48_CD 37_CD Items_NNS not_RB chargeable_JJ for_IN tax_NN purposes_NNS 110_CD 58_CD 54_CD Adjustments_NNS in_IN respect_NN of_IN prior_JJ periods_NNS 51_CD 17_CD 4_CD Exceptional_JJ items_NNS 105_CD 28_CD 171_CD Current_JJ ordinary_JJ tax_NN charge_NN for_IN the_DT year_NN 1,014_CD 832_CD 1,158_CD Balance_NN sheet_NN 2002 2001 2000_CD $_$ m_CD $_$ m_CD $_$ m_CD Deferred_VBN taxation_NN liability_NN asset_NN movement_NN At_IN beginning_NN of_IN year_NN 212_CD 96_CD 369_CD Prior_RB year_NN adjustment_NN page_NN 62_CD 33_CD 212_CD 96_CD 336_CD Profit_NN and_CC loss_NN account_NN 163 328 399_CD Statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS 155_CD 19_CD 83_CD Exchange_NNP 139_CD 39_CD 76_CD At_IN end_NN of_IN year_NN 359_CD 212_CD 96_CD Debtors_NNS amount_NN due_JJ within_IN one_CD year_NN Note_NN 15 625 550 541_CD Debtors_NNS amount_NN due_JJ after_IN more_JJR than_IN one_CD year_NN Note_NN 15 226 146 189_CD Provisions_NNS Note_VBP 21_CD 1,210_CD 908 634 359 212_CD 96_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 72_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 7_CD Taxation_NNP continued_VBD Deferred_JJ taxation_NN The_DT amounts_NNS of_IN deferred_VBN taxation_NN accounted_VBD for_IN in_IN the_DT Group_NNP balance_NN sheet_NN comprised_VBD the_DT following_JJ deferred_JJ tax_NN liabilities_NNS and_CC assets_NNS :_: 2002_CD 2001_CD restated_VBN $_$ m_CD $_$ m_CD Deferred_VBN tax_NN liabilities_NNS UK_NNP fixed_VBN assets_NNS 429_CD 332_CD Non-UK_JJ fixed_JJ assets_NNS 570_CD 455_CD Interest_NN accruals_VBZ 13_CD 72_CD Untaxed_JJ reserves_NNS 86_CD 11_CD Pension_NN and_CC post-retirement_NN benefits_NNS 46_CD Other_JJ 53_CD 150_CD 1,197_CD 1,020_CD Deferred_JJ tax_NN assets_NNS Intercompany_NNP inventory_NN transfers_NNS 496_CD 413_CD Merger_NNP ,_, integration_NN and_CC restructuring_NN charges_NNS 16_CD 121_CD Accrued_VBN expenses_NNS 243_CD 161_CD Pension_NN and_CC post-retirement_NN benefits_NNS 26_CD 91_CD Other_JJ 57 22 838 808_CD Deferred_JJ tax_NN liability_NN 359_CD 212_CD No_DT provision_NN has_VBZ been_VBN made_VBN ,_, in_IN accordance_NN with_IN FRS19_CD ,_, for_IN rolled_VBN over_IN gains_NNS amounting_VBG to_TO $_$ 126m_CD 2001_CD $_$ 75m_CD ,_, 2000_CD $_$ 79m_CD ._.
com_NN 73_CD 8_CD Dividends_NNPS 2002 2001 2000 2002_CD 2001_CD 2000_CD Per_IN Per_IN Per_IN Share_NN Share_NN Share_NN $_$ m_CD $_$ m_CD $_$ m_CD Interim_NNP ,_, paid_VBN on_IN 7_CD October_NNP 2002_CD $_$ 0.23_CD $_$ 0.23_CD $_$ 0.23_CD 398 405 406_CD Second_JJ interim_NN ,_, to_TO be_VB confirmed_VBN as_IN final_JJ ,_, payable_JJ 7_CD April_NNP 2003_CD $_$ 0.47_CD $_$ 0.47_CD $_$ 0.47_CD 808 820 830_CD $_$ 0.70_CD $_$ 0.70_CD $_$ 0.70_CD 1,206_CD 1,225_CD 1,236_CD Dividend_NN in_IN specie_NN demerger_NN of_IN Zeneca_NNP Agrochemicals_NNPS 1,669_CD The_DT demerger_NN of_IN Zeneca_NNP Agrochemicals_NNPS in_IN 2000_CD was_VBD recorded_VBN in_IN the_DT Group_NNP accounts_NNS at_IN the_DT book_NN value_NN of_IN the_DT net_JJ assets_NNS which_WDT were_VBD deconsolidated_VBN ,_, $_$ 2,059_CD m_NN net_NN of_IN minority_NN interest_NN ,_, together_RB with_IN $_$ 813m_CD of_IN related_JJ goodwill_NN which_WDT had_VBD previously_RB been_VBN written_VBN off_RP to_TO reserves_NNS ,_, less_JJR debt_NN and_CC liabilities_NNS assumed_VBN by_IN Zeneca_NNP Agrochemicals_NNPS ,_, $_$ 1,203_CD m_NN ,_, giving_VBG a_DT dividend_NN in_IN specie_NN of_IN $_$ 1,669_CD m._NN 9_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP 2002 2001 2000_CD restated_VBN restated_VBN $_$ m_CD $_$ m_CD $_$ m_CD Net_JJ profit_NN for_IN the_DT financial_JJ year_NN before_IN exceptional_JJ items_NNS $_$ m_CD 3,186_CD 3,044_CD 2,858_CD Exceptional_JJ items_NNS after_IN tax_NN $_$ m_CD see_VBP Note_NN 5_CD 350 138 581_CD Net_JJ profit_NN for_IN the_DT financial_JJ year_NN $_$ m_CD 2,836_CD 2,906_CD 2,277_CD Earnings_NNS per_IN Ordinary_NNP Share_NN before_IN exceptional_JJ items_NNS $_$ $_$ 1.84_CD $_$ 1.73_CD $_$ 1.62_CD Loss_NN per_IN Ordinary_NNP Share_NN on_IN exceptional_JJ items_NNS $_$ $_$ 0.20_CD $_$ 0.08_CD $_$ 0.32_CD Earnings_NNS per_IN Ordinary_NNP Share_NNP $_$ $_$ 1.64_CD $_$ 1.65_CD $_$ 1.30_CD Diluted_VBN earnings_NNS per_IN Ordinary_NNP Share_NN before_IN exceptional_JJ items_NNS $_$ $_$ 1.84_CD $_$ 1.73_CD $_$ 1.62_CD Diluted_VBN loss_NN per_IN Ordinary_NNP Share_NN on_IN exceptional_JJ items_NNS $_$ $_$ 0.20_CD $_$ 0.08_CD $_$ 0.32_CD Diluted_VBN earnings_NNS per_IN Ordinary_NNP Share_NNP $_$ $_$ 1.64_CD $_$ 1.65_CD $_$ 1.30_CD Weighted_VBN average_JJ number_NN of_IN Ordinary_NNP Shares_NNP in_IN issue_NN for_IN basic_JJ earnings_NNS millions_NNS 1,733_CD 1,758_CD 1,768_CD Dilutive_JJ impact_NN of_IN share_NN options_NNS outstanding_JJ millions_NNS 2_CD 32_CD Diluted_VBN average_JJ number_NN of_IN Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS 1,735_CD 1,761_CD 1,770_CD There_EX are_VBP no_DT options_NNS ,_, warrants_NNS or_CC rights_NNS outstanding_JJ in_IN respect_NN of_IN unissued_JJ shares_NNS except_IN for_IN employee_NN share_NN option_NN schemes_NNS ._.
The_DT number_NN of_IN options_NNS outstanding_JJ and_CC the_DT weighted_JJ average_JJ exercise_NN price_NN of_IN these_DT options_NNS is_VBZ shown_VBN in_IN Note_NN 33_CD ._.
The_DT earnings_NNS figures_NNS used_VBN in_IN the_DT calculations_NNS above_IN are_VBP unchanged_JJ for_IN diluted_JJ earnings_NNS per_IN Ordinary_NNP Share_NNP ._.
Earnings_NNS per_IN Ordinary_NNP Share_NN before_IN exceptional_JJ items_NNS have_VBP been_VBN calculated_VBN to_TO eliminate_VB the_DT impact_NN of_IN exceptional_JJ items_NNS on_IN the_DT results_NNS of_IN the_DT business_NN ._.
com_NN 74_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 10_CD Segment_NN information_NN Classes_NNS of_IN Business_NNP Turnover_NN 2002 2001 2000_CD reclassified_VBD reclassified_VBN $_$ m_CD $_$ m_CD $_$ m_CD Continuing_VBG operations_NNS 17,841_CD 16,222_CD 15,583_CD Discontinued_VBN operations_NNS Agrochemicals_NNPS 2,299_CD Group_NNP turnover_NN 17,841_CD 16,222_CD 17,882_CD Share_NN of_IN joint_JJ venture_NN turnover_NN 191 183 195_CD Group_NNP turnover_NN and_CC share_NN of_IN joint_JJ venture_NN turnover_NN 18,032_CD 16,405_CD 18,077_CD The_DT Groups_NNS policy_NN is_VBZ to_TO transfer_VB products_NNS internally_RB at_IN external_JJ market_NN prices_NNS ._.
Operating_NN profit_NN Profit_NN loss_NN before_IN after_IN exceptionals_NNS interest_NN and_CC taxation_NN 2002 2001 2000 2002_CD 2001_CD 2000_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Profit_NN arising_VBG in_IN Continuing_VBG operations_NNS 4,006_CD 3,954_CD 3,662_CD 4,007_CD 3,972_CD 3,665_CD Discontinued_VBN operations_NNS Agrochemicals_NNPS 346_CD 196_CD 4,006_CD 3,954_CD 4,008_CD 4,007_CD 3,972_CD 3,861_CD Share_NN of_IN operating_VBG loss_NN of_IN joint_JJ ventures_NNS and_CC associates_NNS 149_CD 4,007_CD 3,972_CD 3,712_CD In_IN prior_JJ years_NNS ,_, corporate_JJ overheads_NNS have_VBP been_VBN allocated_VBN to_TO each_DT business_NN segment_NN on_IN a_DT consistent_JJ basis_NN ._.
The_DT effect_NN of_IN these_DT allocations_NNS was_VBD not_RB material_NN ._.
Net_JJ assets_NNS liabilities_NNS Total_JJ assets_NNS 2002 2001 2000 2002_CD 2001_CD 2000_CD restated_VBN restated_VBN restated_VBN restated_VBN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Continuing_VBG operations_NNS 9,868_CD 8,808_CD 7,604_CD 16,212_CD 14,158_CD 13,658_CD Discontinued_VBN operations_NNS Specialties_NNS 126_CD 3_CD 9,868_CD 8,808_CD 7,478_CD 16,212_CD 14,158_CD 13,661_CD Intra-Group_NNP eliminations_NNS 12_CD Non-operating_JJ assets_NNS 1,358_CD 821_CD 1,938_CD 5,364_CD 4,338_CD 5,208_CD Investments_NNP in_IN joint_JJ ventures_NNS and_CC associates_NNS 11,226_CD 9,629_CD 9,416_CD 21,576_CD 18,496_CD 18,857_CD Non-operating_JJ assets_NNS include_VBP short_JJ term_NN investments_NNS and_CC cash_NN ,_, short_JJ term_NN borrowings_NNS ,_, loans_NNS ,_, and_CC non-operating_JJ debtors_NNS and_CC creditors_NNS not_RB attributable_JJ to_TO individual_JJ business_NN segments_NNS ._.
Depreciation_NN ,_, amortisation_NN Capital_NN expenditure_NN and_CC impairment_NN 2002 2001 2000 2002_CD 2001_CD 2000_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Continuing_VBG operations_NNS 1,463_CD 1,501_CD 1,248_CD 960 872 890_CD Discontinued_VBN operations_NNS Agrochemicals_NNPS 153_CD 121_CD 1,463_CD 1,501_CD 1,401_CD 960_CD 872_CD 1,011_CD Capital_NN expenditure_NN includes_VBZ expenditure_NN on_IN goodwill_NN and_CC intangible_JJ assets_NNS ._.
com_NN 75_CD 10_CD Segment_NN information_NN continued_VBD Geographic_JJ areas_NNS The_DT tables_NNS below_IN show_NN information_NN by_IN geographic_JJ area_NN and_CC ,_, for_IN turnover_NN and_CC tangible_JJ fixed_VBN assets_NNS ,_, material_NN countries_NNS ._.
The_DT figures_NNS for_IN each_DT area_NN show_VBP the_DT turnover_NN ,_, operating_VBG profit_NN and_CC profit_NN on_IN ordinary_JJ activities_NNS before_IN interest_NN and_CC taxation_NN made_VBN by_IN companies_NNS located_VBN in_IN that_DT area_NN country_NN ,_, together_RB with_IN net_JJ operating_NN assets_NNS and_CC tangible_JJ fixed_VBN assets_NNS owned_VBN by_IN the_DT same_JJ companies_NNS :_: export_NN sales_NNS and_CC the_DT related_JJ profit_NN are_VBP included_VBN in_IN the_DT areas_NNS from_IN which_WDT those_DT sales_NNS were_VBD made_VBN ._.
com_NN 77_CD 10_CD Segment_NN information_NN continued_VBD 2002 2001 2000_CD reclassified_VBN reclassified_VBD $_$ m_CD $_$ m_CD $_$ m_CD Geographic_JJ markets_NNS Turnover_NN in_IN each_DT geographic_JJ market_NN in_IN which_WDT customers_NNS located_VBN UK_NNP 623 759 787_CD Continental_NNP Europe_NNP 5,072_CD 4,477_CD 4,359_CD The_DT Americas_NNPS 10,287_CD 9,353_CD 8,799_CD Asia_NNP ,_, Africa_NNP &_CC Australasia_NNP 1,859_CD 1,633_CD 1,638_CD Continuing_VBG operations_NNS 17,841_CD 16,222_CD 15,583_CD Discontinued_VBN operations_NNS Agrochemicals_NNPS 2,299_CD 17,841_CD 16,222_CD 17,882_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 78_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 11_CD Tangible_JJ fixed_VBN assets_NNS Capital_NNP expenditure_NN and_CC assets_NNS in_IN Total_JJ Land_NN and_CC Plant_NN and_CC course_NN of_IN tangible_JJ buildings_NNS equipment_NN construction_NN assets_NNS $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Cost_NN At_IN beginning_NN of_IN year_NN 2,490_CD 5,295_CD 1,119_CD 8,904_CD Exchange_NNP adjustments_NNS 292 612 139_CD 1,043_CD Capital_NN expenditure_NN 48_CD 212_CD 1,082_CD 1,342_CD Transfer_NNP of_IN assets_NNS into_IN use_NN 387_CD 631_CD 1,018_CD Disposals_NNS and_CC other_JJ movements_NNS 72_CD 150_CD 24_CD 246_CD At_IN end_NN of_IN year_NN 3,145_CD 6,600_CD 1,298_CD 11,043_CD Depreciation_NN At_IN beginning_NN of_IN year_NN 753_CD 2,742_CD 3,495_CD Exchange_NNP adjustments_NNS 87 354 441_CD Charge_NNP for_IN year_NN 104 601 705_CD Disposals_NNS and_CC other_JJ movements_NNS 49 146 195_CD At_IN end_NN of_IN year_NN 895_CD 3,551_CD 4,446_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2002_CD 2,250_CD 3,049_CD 1,298_CD 6,597_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2001_CD 1,737_CD 2,553_CD 1,119_CD 5,409_CD Capital_NN expenditure_NN in_IN the_DT year_NN of_IN $_$ 1,342_CD m_NN 2001_CD $_$ 1,393_CD m_NN did_VBD not_RB include_VB any_DT capitalized_VBN finance_NN leases_NNS 2001_CD $_$ nil_JJ ._.
Cash_NN expenditure_NN on_IN tangible_JJ fixed_JJ assets_NNS was_VBD $_$ 1,340_CD m_NN 2001_CD $_$ 1,385_CD m_NN ,_, 2000_CD $_$ 1,347_CD m._FW 2002_CD 2001_CD $_$ m_CD $_$ m_CD The_DT net_JJ book_NN value_NN of_IN land_NN and_CC buildings_NNS comprised_VBD Freeholds_NNP 2,220_CD 1,690_CD Long_NNP leases_NNS over_IN 50_CD years_NNS unexpired_JJ 29_CD 45_CD Short_JJ leases_NNS 1_CD 2_CD 2,250_CD 1,737_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 79_CD 12_CD Goodwill_NNP and_CC intangible_JJ assets_NNS Intangible_NNP Goodwill_NNP assets_NNS Total_JJ $_$ m_CD $_$ m_CD $_$ m_CD Cost_NN At_IN beginning_NN of_IN year_NN 1,000_CD 2,727_CD 3,727_CD Exchange_NNP adjustments_NNS 85 311 396_CD Additions_NNS 17 104 121_CD Disposals_NNS and_CC other_JJ movements_NNS 25_CD 25_CD At_IN end_NN of_IN year_NN 1,102_CD 3,117_CD 4,219_CD Amortisation_NNP At_IN beginning_NN of_IN year_NN 166_CD 861_CD 1,027_CD Exchange_NNP adjustments_NNS 28 128 156_CD Charge_NNP for_IN year_NN 55 200 255_CD Disposals_NNS and_CC other_JJ movements_NNS 26_CD 26_CD At_IN end_NN of_IN year_NN 249_CD 1,163_CD 1,412_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2002_CD 853_CD 1,954_CD 2,807_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2001_CD 834_CD 1,866_CD 2,700_CD 13_CD Fixed_VBN asset_NN investments_NNS Joint_NNP Other_JJ ventures_NNS investments_NNS Total_JJ $_$ m_CD $_$ m_CD $_$ m_CD Cost_NN At_IN beginning_NN of_IN year_NN 134_CD 23_CD 157_CD Additions_NNPS 25_CD 25_CD Disposals_NNS and_CC other_JJ movements_NNS ,_, including_VBG exchange_NN 2_CD 2_CD At_IN end_NN of_IN year_NN 134_CD 46_CD 180_CD Share_NN of_IN post-acquisition_JJ reserves_NNS At_IN beginning_NN and_CC end_NN of_IN year_NN 134_CD 134_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2002_CD 46_CD 46_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2001_CD 23_CD 23_CD The_DT fair_JJ values_NNS of_IN other_JJ investments_NNS are_VBP not_RB materially_RB different_JJ from_IN their_PRP$ carrying_VBG values_NNS ._.
At_IN 31_CD December_NNP 2002_CD ,_, the_DT Companys_NNP share_NN ownership_NN trust_NN held_VBD 885,425_CD Ordinary_NNP Shares_NNP ._.
Share_NN of_IN joint_JJ venture_NN assets_NNS and_CC liabilities_NNS 2002_CD 2001_CD $_$ m_CD $_$ m_CD Gross_NNP assets_NNS 107_CD 99_CD Gross_NNP liabilities_NNS 107_CD 99_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 80_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 14_CD Stocks_NNS 2002_CD 2001_CD $_$ m_CD $_$ m_CD Raw_NNP materials_NNS and_CC consumables_NNS 992_CD 796_CD Stocks_NNS in_IN process_NN 1,062_CD 720_CD Finished_VBN goods_NNS and_CC goods_NNS for_IN resale_NN 539_CD 886_CD 2,593_CD 2,402_CD 15_CD Debtors_NNS 2002_CD 2001_CD restated_VBN $_$ m_CD $_$ m_CD Amounts_NNS due_JJ within_IN one_CD year_NN Trade_NNP debtors_NNS 2,701_CD 2,430_CD Less_RBR :_: Amounts_NNS provided_VBN for_IN doubtful_JJ debts_NNS 56_CD 42_CD 2,645_CD 2,388_CD Deferred_JJ taxation_NN Note_NN 7_CD 625_CD 550_CD Other_JJ debtors_NNS 658_CD 641_CD Prepayments_NNS and_CC accrued_VBN income_NN 519_CD 274_CD 4,447_CD 3,853_CD Amounts_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN Deferred_VBN taxation_NN Note_NN 7_CD 226_CD 146_CD Other_JJ debtors_NNS 16_CD 23_CD Prepayments_NNS and_CC accrued_VBN income_NN 156 117 398 286_CD 4,845_CD 4,139_CD Figures_NNS include_VBP prepaid_VBN pension_NN costs_NNS Note_VBP 32_CD ._.
Provisions_NNS for_IN doubtful_JJ debts_NNS 2002 2001 2000_CD $_$ m_CD $_$ m_CD $_$ m_CD Balance_NN at_IN beginning_NN of_IN year_NN 42_CD 39_CD 118_CD Profit_NN and_CC loss_NN account_NN charge_NN 11_CD 434_CD Amounts_NNS utilised_JJ and_CC other_JJ movements_NNS incl_NN ._.
Agrochemicals_NNS demerger_VBP in_IN 2000_CD 3_CD 1_CD 113_CD Balance_NN at_IN end_NN of_IN year_NN 56_CD 42_CD 39_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 81_CD 16_CD Short_JJ term_NN investments_NNS 2002_CD 2001_CD $_$ m_CD $_$ m_CD Listed_VBN debt_NN securities_NNS 144_CD 288_CD Other_JJ listed_VBN investments_NNS 46_CD 45_CD Investment_NN securities_NNS 190_CD 333_CD Fixed_VBN deposits_NNS 3,772_CD 2,785_CD 3,962_CD 3,118_CD The_DT Groups_NNS insurance_NN subsidiaries_NNS hold_VBP cash_NN and_CC short_JJ term_NN investments_NNS totalling_VBG $_$ 173m_CD 2001_CD $_$ 186m_CD ,_, of_IN which_WDT $_$ 120m_CD 2001_CD $_$ 105m_CD is_VBZ required_VBN to_TO meet_VB insurance_NN solvency_NN requirements_NNS and_CC which_WDT ,_, as_IN a_DT result_NN ,_, is_VBZ not_RB readily_RB available_JJ for_IN the_DT general_JJ purposes_NNS of_IN the_DT Group_NNP ._.
In_IN addition_NN ,_, some_DT $_$ 126m_CD 2001_CD $_$ 236m_CD of_IN short_JJ term_NN investments_NNS shown_VBN above_IN are_VBP committed_VBN as_IN security_NN against_IN deferred_VBN payments_NNS due_JJ under_IN a_DT contractual_JJ obligation_NN of_IN the_DT Group_NNP see_VB Note_VB 34_CD ._.
The_DT market_NN value_NN of_IN other_JJ listed_VBN investments_NNS was_VBD $_$ 137m_CD 2001_CD $_$ 145m_CD at_IN the_DT year_NN end_NN ._.
17_CD Short_JJ term_NN borrowings_NNS 2002_CD 2001_CD $_$ m_CD $_$ m_CD Bank_NNP borrowings_NNS Fixed_VBN securities_NNS 11_CD 22_CD Secured_JJ by_IN floating_VBG charge_NN 8_CD Unsecured_NNP 191 183 202 213_CD Other_JJ borrowings_NNS unsecured_JJ 1_CD 202_CD 214_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 82_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 18_CD Other_JJ creditors_NNS 2002_CD 2001_CD $_$ m_CD $_$ m_CD Amounts_NNS due_JJ within_IN one_CD year_NN Trade_NNP creditors_NNS 3,171_CD 2,385_CD Corporate_JJ taxation_NN 1,191_CD 1,018_CD Value_NNP added_VBD and_CC payroll_NN taxes_NNS and_CC social_JJ security_NN 167_CD 173_CD Other_JJ creditors_NNS 1,507_CD 1,219_CD Accruals_NNP 855_CD 544_CD Dividends_NNS to_TO shareholders_NNS 808_CD 820_CD 7,699_CD 6,159_CD Amounts_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN Other_JJ creditors_NNS 34_CD 152_CD Included_VBN in_IN other_JJ creditors_NNS are_VBP amounts_NNS totalling_VBG $_$ 189m_CD 2001_CD $_$ 104m_CD to_TO meet_VB insurance_NN obligations_NNS of_IN the_DT Groups_NNS insurance_NN subsidiaries_NNS ._.
Also_RB included_VBN in_IN other_JJ creditors_NNS are_VBP amounts_NNS due_JJ within_IN one_CD year_NN in_IN connection_NN with_IN the_DT Groups_NNS exceptional_JJ charges_NNS as_IN detailed_VBN in_IN Note_NN 5_CD ._.
The_DT amounts_NNS comprise_VBP $_$ 350m_CD 2001_CD $_$ nil_CD in_IN respect_NN of_IN the_DT accrual_NN related_VBN to_TO the_DT Zoladex_NNP investigation_NN in_IN the_DT US_NNP ,_, $_$ 36m_CD 2001_CD $_$ 116m_CD in_IN respect_NN of_IN synergy_NN and_CC integration_NN costs_NNS ,_, $_$ 14m_CD 2001_CD $_$ 21m_CD in_IN respect_NN of_IN the_DT Agrochemicals_NNPS demerger_NN and_CC $_$ 48m_CD 2001_CD $_$ 64m_CD in_IN respect_NN of_IN the_DT Specialties_NNS disposal_NN and_CC other_JJ minor_JJ restructurings_NNS ._.
19_CD Loans_NNPS Repayment_NNP 2002_CD 2001_CD Dates_NNPS $_$ m_CD $_$ m_CD Secured_JJ loans_NNS Secured_JJ by_IN fixed_JJ charge_NN 2003_CD 2007_CD 19_CD 48_CD Total_JJ secured_VBN 19_CD 48_CD Unsecured_JJ loans_NNS US_NNP dollars_NNS 6.3_CD %_NN Guaranteed_VBN notes_NNS 2003 284 284_CD 7_CD %_NN Guaranteed_VBN debentures_NNS 2023 295 295_CD Others_NNS 2003_CD 2013_CD 44_CD 115_CD Total_JJ unsecured_JJ 623_CD 694_CD Total_JJ loans_NNS 642_CD 742_CD Less_RBR :_: current_JJ instalments_NNS of_IN loans_NNS 314_CD 107_CD Loans_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN 328_CD 635_CD In_IN the_DT above_JJ table_NN loans_NNS are_VBP shown_VBN after_IN taking_VBG account_NN of_IN associated_VBN cross-currency_NN swaps_NNS see_VBP Note_VB 20_CD ._.
Loans_NNS from_IN banks_NNS included_VBD in_IN the_DT table_NN above_IN amounted_VBD to_TO $_$ 61m_CD 2001_CD $_$ 156m_CD of_IN which_WDT $_$ 40m_CD 2001_CD $_$ 48m_CD was_VBD secured_VBN ._.
com_NN 83_CD 20_CD Financial_NNP instruments_NNS A_DT discussion_NN of_IN the_DT Groups_NNS objective_NN ,_, policy_NN and_CC strategy_NN in_IN respect_NN of_IN risk_NN management_NN and_CC the_DT use_NN of_IN financial_JJ instruments_NNS is_VBZ included_VBN in_IN the_DT Financial_NNP Review_NNP on_IN pages_NNS 30_CD to_TO 43_CD ._.
The_DT following_JJ disclosures_NNS exclude_VBP all_DT short_JJ term_NN trade_NN related_VBN debtors_NNS and_CC creditors_NNS ._.
Interest_NN rate_NN risks_NNS of_IN financial_JJ assets_NNS and_CC liabilities_NNS The_DT interest_NN rate_NN profile_NN ,_, after_IN taking_VBG account_NN of_IN interest_NN and_CC currency_NN swaps_NNS ,_, of_IN the_DT financial_JJ assets_NNS and_CC liabilities_NNS of_IN the_DT Group_NNP as_IN at_IN 31_CD December_NNP 2002_CD was_VBD :_: Financial_NNP Weighted_NNP Weighted_NNP assets_NNS liabilities_NNS average_JJ average_NN on_IN which_WDT fixed_JJ period_NN for_IN Floating_VBG Fixed_VBN no_DT interest_NN is_VBZ interest_NN which_WDT rate_NN rate_NN rate_NN paid_VBD received_VBN Total_JJ rate_NN is_VBZ fixed_VBN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD %_NN Years_NNS Financial_NNP liabilities_NNS US_NNP dollar_NN 782_CD 8_CD 126_CD 916_CD 12.8_CD 9.6_CD Sterling_NNP Euro_NNP Other_JJ 35_CD 19_CD 54_CD 6.3_CD 2.2_CD 817 27 126 970_CD Financial_NNP assets_NNS US_NNP dollar_NN 4,354_CD 4,354_CD Euro_NNP 71_CD 71_CD Sterling_NNP 114_CD 46_CD 160_CD SEK_NNP 33_CD 33_CD Other_JJ 70_CD 22_CD 92_CD 4,642_CD 68_CD 4,710_CD Financial_NNP liabilities_NNS on_IN which_WDT no_DT interest_NN is_VBZ paid_VBN comprise_VBP deferred_VBN payments_NNS due_JJ relating_VBG to_TO the_DT reacquisition_NN of_IN certain_JJ marketing_NN rights_NNS ._.
The_DT floating_VBG rate_NN financial_JJ liabilities_NNS comprise_VBP largely_RB of_IN fixed_JJ rate_NN debt_NN that_WDT has_VBZ been_VBN swapped_VBN into_IN floating_VBG rate_NN debt_NN ._.
One_CD long_JJ dated_JJ $_$ 300m_CD USD_NNP bond_NN reverts_VBZ back_RB to_TO a_DT fixed_JJ rate_NN in_IN 2009_CD ._.
The_DT financial_JJ liabilities_NNS also_RB include_VBP $_$ 202m_CD of_IN short_JJ term_NN bank_NN borrowings_NNS and_CC overdrafts_NNS ,_, bearing_VBG interest_NN at_IN rates_NNS fixed_VBN by_IN reference_NN to_TO local_JJ interbank_NN rates_NNS ._.
Financial_JJ assets_NNS on_IN which_WDT no_DT interest_NN is_VBZ received_VBN comprise_VBP equity_NN investments_NNS held_VBN by_IN the_DT Group_NNP ._.
The_DT financial_JJ assets_NNS principally_RB comprise_VBP cash_NN on_IN overnight_JJ deposit_NN and_CC short_JJ term_NN investments_NNS with_IN an_DT average_JJ maturity_NN of_IN 67_CD days_NNS ._.
These_DT include_VBP deposits_NNS where_WRB the_DT interest_NN rate_NN is_VBZ fixed_VBN until_IN maturity_NN but_CC ,_, as_IN the_DT original_JJ maturity_NN is_VBZ less_JJR than_IN one_CD year_NN ,_, they_PRP are_VBP classified_VBN as_IN floating_VBG rate_NN financial_JJ instruments_NNS ._.
The_DT benchmark_NN rates_NNS for_IN financial_JJ assets_NNS are_VBP the_DT LIBID_NNP rate_NN for_IN euro_NN and_CC US_NNP dollar_NN liquidity_NN balances_NNS and_CC the_DT average_JJ Federal_NNP Funds_NNPS effective_JJ rate_NN for_IN US_NNP dollar_NN overnight_JJ balances_NNS ._.
Financial_JJ assets_NNS include_VBP $_$ 46m_CD of_IN other_JJ fixed_JJ asset_NN investments_NNS on_IN which_WDT no_DT interest_NN is_VBZ received_VBN ._.
com_NN 84_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 20_CD Financial_NNP instruments_NNS continued_VBD Currency_NNP exposures_NNS 100_CD %_NN of_IN the_DT Groups_NNS transactional_JJ currency_NN exposures_NNS on_IN working_VBG capital_NN balances_NNS ,_, which_WDT typically_RB extend_VBP for_IN up_RB to_TO three_CD months_NNS ,_, are_VBP hedged_VBN using_VBG forward_RB foreign_JJ exchange_NN contracts_NNS ._.
As_IN a_DT result_NN ,_, as_RB at_IN 31_CD December_NNP 2002_CD ,_, there_EX were_VBD no_DT material_NN monetary_JJ assets_NNS or_CC liabilities_NNS in_IN currencies_NNS other_JJ than_IN the_DT functional_JJ currencies_NNS of_IN the_DT Group_NNP companies_NNS concerned_VBN ,_, having_VBG taken_VBN into_IN account_NN the_DT effect_NN of_IN forward_RB exchange_NN currency_NN contracts_NNS that_WDT have_VBP been_VBN utilised_VBN to_TO match_VB foreign_JJ currency_NN exposures_NNS ._.
Additionally_RB ,_, approximately_RB 50_CD %_NN of_IN forecast_NN future_JJ foreign_JJ currency_NN transaction_NN exposures_NNS extending_VBG for_IN 12_CD months_NNS are_VBP selectively_RB hedged_VBN ._.
The_DT principal_JJ currency_NN exposures_NNS sterling_NN ,_, Swedish_JJ kronor_NNS ,_, euro_NN ,_, Australian_JJ dollars_NNS ,_, Canadian_JJ dollars_NNS and_CC yen_NNS are_VBP hedged_VBN using_VBG a_DT mixture_NN of_IN purchased_JJ currency_NN options_NNS and_CC forward_RB foreign_JJ exchange_NN contracts_NNS ._.
As_IN at_IN 31_CD December_NNP 2002_CD the_DT Group_NNP held_VBD forward_RB and_CC option_NN contracts_NNS to_TO hedge_VB the_DT following_JJ forecast_NN foreign_JJ currency_NN transaction_NN exposures_NNS :_: 2002_CD 2001_CD Hedged_NNP Hedged_NNP amount_NN amount_NN $_$ m_CD $_$ m_CD Sterling_NN payables_NNS 1,316_CD 1,324_CD SEK_NNP payables_NNS 503_CD 401_CD Euro_NNP receivables_NN 713_CD 591_CD Yen_NNP receivables_NN 153_CD 89_CD AUD_NNP receivables_NN 81_CD 73_CD CAD_NNP receivables_NN 168_CD 128_CD Maturity_NN of_IN financial_JJ liabilities_NNS The_DT maturity_NN profile_NN of_IN the_DT Groups_NNS financial_JJ liabilities_NNS ,_, other_JJ than_IN short_JJ term_NN creditors_NNS such_JJ as_IN trade_NN creditors_NNS and_CC accruals_NNS ,_, at_IN 31_CD December_NNP 2002_CD was_VBD as_IN follows_VBZ :_: 2002_CD 2001_CD Analysis_NN by_IN year_NN of_IN repayment_NN Loans_NNP Other_JJ Total_NNP Loans_NNPS Other_JJ Total_JJ $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD After_IN five_CD years_NNS 308 308 314 314_CD From_IN five_CD to_TO four_CD years_NNS 13_CD 13_CD 14_CD 14_CD From_IN four_CD to_TO three_CD years_NNS 9_CD 9_CD From_IN three_CD to_TO two_CD years_NNS 7_CD 7_CD From_IN two_CD to_TO one_CD years_NNS 7_CD 7_CD 291 120 411_CD Due_JJ after_IN more_JJR than_IN one_CD year_NN 328 328 635 120_CD 755_CD Due_JJ within_IN one_CD year_NN 314 328 642 107_CD 356 463 642 328_CD 970 742 476_CD 1,218_CD Other_JJ financial_JJ liabilities_NNS comprise_VBP deferred_VBN payments_NNS to_TO re-acquire_JJ certain_JJ distribution_NN rights_NNS ,_, short_JJ term_NN borrowings_NNS and_CC finance_NN leases_NNS ._.
Borrowing_NN facilities_NNS The_DT Group_NNP has_VBZ various_JJ borrowing_NN facilities_NNS available_JJ to_TO it_PRP ,_, the_DT majority_NN of_IN which_WDT offer_VBP a_DT currency_NN option_NN of_IN US_NNP dollars_NNS ,_, euros_NNS or_CC sterling_NN ._.
Unused_JJ short_JJ term_NN credit_NN facilities_NNS both_DT committed_JJ and_CC uncommitted_JJ totalled_JJ approximately_RB $_$ 0.5_CD bn_NN at_IN 31_CD December_NNP 2002_CD ._.
Included_VBN in_IN this_DT were_VBD undrawn_JJ committed_JJ facilities_NNS in_IN respect_NN of_IN which_WDT all_DT conditions_NNS precedent_NN had_VBD been_VBN met_VBN at_IN that_DT date_NN as_IN follows_VBZ :_: 2002_CD 2001_CD $_$ m_CD $_$ m_CD Expiring_NN in_IN one_CD year_NN or_CC less_JJR 75_CD 375_CD Expiring_NN in_IN more_JJR than_IN one_CD year_NN but_CC not_RB more_JJR than_IN two_CD years_NNS Expiring_VBG in_IN more_JJR than_IN two_CD years_NNS 75_CD 375_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 85_CD 20_CD Financial_NNP instruments_NNS continued_VBD Fair_NNP values_NNS of_IN financial_JJ assets_NNS and_CC financial_JJ liabilities_NNS Set_VBP out_RP below_IN is_VBZ a_DT comparison_NN by_IN category_NN of_IN carrying_VBG values_NNS and_CC fair_JJ values_NNS of_IN all_PDT the_DT Groups_NNS financial_JJ assets_NNS and_CC financial_JJ liabilities_NNS as_IN at_IN 31_CD December_NNP 2002_CD and_CC 2001_CD ._.
2002 2002 2001 2001_CD Carrying_VBG Fair_NNP Carrying_VBG Fair_NNP value_NN value_NN value_NN value_NN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Primary_JJ financial_JJ instruments_NNS Short_JJ term_NN borrowings_NNS 202 202 214 214_CD Loans_NNPS 657 733 759 805_CD Cash_NN 726 726 705 705_CD Short_JJ term_NN investments_NNS 3,962_CD 4,067_CD 3,118_CD 3,192_CD Fixed_VBN asset_NN investments_NNS 46_CD 46_CD 23_CD 23_CD Derivative_JJ financial_JJ instruments_NNS held_VBN to_TO manage_VB the_DT interest_NN rate_NN and_CC currency_NN profile_NN Cross-currency_NN swaps_NNS and_CC interest_NN rate_NN swaps_NNS 15_CD 82_CD 17_CD 70_CD Derivative_JJ financial_JJ instruments_NNS held_VBN or_CC issued_VBN to_TO hedge_VB the_DT currency_NN exposure_NN on_IN existing_VBG transactions_NNS Forward_RB foreign_JJ exchange_NN contracts_NNS 9_CD 9_CD 11_CD 9_CD Foreign_JJ currency_NN option_NN contracts_NNS 1_CD Derivative_JJ financial_JJ instruments_NNS held_VBN or_CC issued_VBN to_TO hedge_VB the_DT currency_NN exposure_NN on_IN expected_JJ future_JJ transactions_NNS Forward_RB foreign_JJ exchange_NN contracts_NNS 1_CD Foreign_JJ currency_NN option_NN contracts_NNS 56_CD 97_CD 82_CD 81_CD In_IN addition_NN to_TO the_DT primary_JJ financial_JJ instruments_NNS above_IN ,_, the_DT Group_NNP has_VBZ financial_JJ liabilities_NNS of_IN $_$ 126m_CD comprising_VBG deferred_JJ payments_NNS due_JJ $_$ 129m_CD before_IN discounting_VBG ._.
The_DT Group_NNP has_VBZ a_DT standby_JJ letter_NN of_IN credit_NN covering_VBG these_DT financial_JJ liabilities_NNS which_WDT is_VBZ collateralised_VBN by_IN high_JJ grade_NN government_NN securities_NNS ._.
The_DT methods_NNS and_CC assumptions_NNS used_VBN to_TO estimate_VB the_DT fair_JJ values_NNS of_IN financial_JJ instruments_NNS are_VBP as_IN follows_VBZ :_: a._VB Short_JJ term_NN investments_NNS the_DT fair_JJ value_NN of_IN listed_VBN investments_NNS is_VBZ based_VBN on_IN year_NN end_NN quoted_VBN market_NN prices_NNS ._.
For_IN unlisted_JJ investments_NNS carrying_VBG values_NNS approximate_JJ fair_JJ value_NN ._.
Fixed_JJ asset_NN investments_NNS excluding_VBG equity_NN investments_NNS in_IN joint_JJ ventures_NNS and_CC associates_NNS the_DT fair_JJ value_NN of_IN listed_VBN investments_NNS is_VBZ based_VBN on_IN year_NN end_NN quoted_VBN market_NN prices_NNS ._.
c._FW Loans_NNPS the_DT fair_JJ value_NN of_IN publicly_RB traded_VBN debt_NN is_VBZ based_VBN on_IN year_NN end_NN quoted_VBN market_NN prices_NNS :_: the_DT fair_JJ value_NN of_IN floating_VBG rate_NN debt_NN is_VBZ nominal_JJ value_NN ,_, as_IN market_NN to_TO market_NN differences_NNS would_MD be_VB minimal_JJ given_VBN frequency_NN of_IN resets_NNS :_: the_DT fair_JJ value_NN of_IN remaining_VBG debt_NN is_VBZ estimated_VBN using_VBG appropriate_JJ zero_CD coupon_NN valuation_NN techniques_NNS based_VBN on_IN rates_NNS current_JJ at_IN year_NN end_NN ._.
d._FW Forward_RB foreign_JJ exchange_NN contracts_NNS the_DT Group_NNP has_VBZ forward_RB foreign_JJ exchange_NN contracts_NNS to_TO sell_VB currency_NN for_IN the_DT purpose_NN of_IN hedging_VBG nondollar_JJ commercial_JJ transaction_NN exposures_NNS which_WDT existed_VBD at_IN the_DT date_NN of_IN the_DT balance_NN sheet_NN and_CC to_TO hedge_VB anticipated_VBN ,_, but_CC not_RB firmly_RB committed_VBN ,_, non-dollar_JJ commercial_JJ transactions_NNS for_IN 2003_CD ._.
The_DT majority_NN of_IN the_DT contracts_NNS for_IN existing_VBG transactions_NNS had_VBD a_DT maturity_NN of_IN six_CD months_NNS or_CC less_JJR from_IN year_NN end_NN ._.
The_DT fair_JJ value_NN of_IN forward_RB foreign_JJ exchange_NN contracts_NNS is_VBZ based_VBN on_IN market_NN forward_RB foreign_JJ exchange_NN rates_NNS at_IN year_NN end_NN ._.
e._FW Foreign_JJ currency_NN option_NN contracts_NNS the_DT Group_NNP has_VBZ foreign_JJ currency_NN option_NN contracts_NNS to_TO hedge_VB anticipated_VBN ,_, but_CC not_RB firmly_RB committed_VBN ,_, nondollar_JJ commercial_JJ transactions_NNS for_IN 2003_CD ._.
The_DT fair_JJ value_NN of_IN option_NN contracts_NNS is_VBZ estimated_VBN using_VBG Black-Scholes_NNP valuation_NN techniques_NNS as_IN adapted_VBN by_IN Garman_NNP and_CC Kohlhagen_NNP ._.
f._FW Interest_NN rate_NN and_CC cross-currency_NN swaps_NNS AstraZeneca_NNP uses_VBZ interest_NN rate_NN and_CC cross-currency_NN swaps_NNS to_TO hedge_VB the_DT Groups_NNS exposure_NN to_TO fluctuations_NNS in_IN interest_NN rates_NNS and_CC foreign_JJ exchange_NN movements_NNS on_IN borrowings_NNS in_IN accordance_NN with_IN a_DT formal_JJ risk_NN management_NN strategy_NN ._.
The_DT fair_JJ value_NN is_VBZ estimated_VBN using_VBG appropriate_JJ zero_CD coupon_NN valuation_NN techniques_NNS based_VBN on_IN rates_NNS current_JJ at_IN year_NN end_NN ._.
com_NN 86_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 20_CD Financial_NNP instruments_NNS continued_VBD The_DT above_JJ financial_JJ instruments_NNS are_VBP subject_JJ to_TO credit_NN and_CC market_NN risk_NN ._.
AstraZeneca_NNP contains_VBZ credit_NN risk_NN through_IN the_DT use_NN of_IN counterparty_NN and_CC product_NN specific_JJ credit_NN limits_NNS and_CC by_IN ongoing_JJ review_NN procedures_NNS ._.
All_DT financial_JJ instruments_NNS except_IN the_DT letter_NN of_IN credit_NN are_VBP transacted_VBN with_IN commercial_JJ banks_NNS and_CC ,_, in_IN line_NN with_IN standard_JJ market_NN practice_NN ,_, are_VBP not_RB backed_VBN with_IN cash_NN collateral_NN ._.
The_DT notional_JJ principal_NN values_NNS of_IN off_JJ balance_NN sheet_NN financial_JJ instruments_NNS do_VBP not_RB represent_VB amounts_NNS exchanged_VBN by_IN the_DT parties_NNS and_CC are_VBP not_RB a_DT measure_NN of_IN the_DT credit_NN risk_NN to_TO the_DT Group_NNP of_IN these_DT instruments_NNS ._.
The_DT credit_NN risk_NN of_IN these_DT instruments_NNS is_VBZ limited_VBN to_TO the_DT positive_JJ fair_JJ values_NNS of_IN such_JJ contracts_NNS ._.
Market_NN risk_NN is_VBZ the_DT sensitivity_NN of_IN the_DT value_NN of_IN financial_JJ instruments_NNS to_TO changes_NNS in_IN related_JJ currency_NN and_CC interest_NN rates_NNS ._.
The_DT Group_NNP is_VBZ not_RB exposed_VBN to_TO material_NN market_NN risk_NN because_IN gains_NNS and_CC losses_NNS on_IN the_DT derivative_JJ financial_JJ instruments_NNS are_VBP largely_RB offset_VBN by_IN gains_NNS and_CC losses_NNS on_IN the_DT underlying_VBG assets_NNS ,_, liabilities_NNS and_CC transactions_NNS subject_JJ to_TO hedge_VB ._.
Hedges_NNP The_NNP Groups_NNS policy_NN is_VBZ to_TO hedge_VB 100_CD %_NN of_IN transactional_JJ currency_NN exposures_NNS and_CC 50_CD %_NN of_IN forecast_NN future_JJ transaction_NN exposures_NNS using_VBG forward_RB foreign_JJ exchange_NN contracts_NNS and_CC foreign_JJ currency_NN option_NN contracts_NNS ._.
It_PRP also_RB uses_VBZ cross-currency_NN and_CC interest_NN rate_NN swaps_NNS to_TO manage_VB its_PRP$ borrowings_NNS profile_VBP ._.
Gains_NNS and_CC losses_NNS on_IN instruments_NNS used_VBN for_IN hedging_VBG are_VBP not_RB recognized_VBN until_IN the_DT exposure_NN that_WDT is_VBZ being_VBG hedged_VBN is_VBZ itself_PRP recognized_VBN ._.
Unrecognised_JJ gains_NNS and_CC losses_NNS on_IN instruments_NNS used_VBN for_IN hedging_VBG are_VBP as_IN follows_VBZ :_: Total_JJ net_JJ Gains_NNS Losses_NNS gains_VBZ $_$ m_CD $_$ m_CD $_$ m_CD Unrecognised_JJ gains_NNS and_CC losses_NNS on_IN hedges_NNS at_IN 1_CD January_NNP 2002_CD 54_CD 4_CD 50_CD Gains_NNS and_CC losses_NNS arising_VBG in_IN previous_JJ years_NNS that_WDT were_VBD recognized_VBN in_IN 2002_CD 31_CD 4_CD 27_CD Gains_NNS and_CC losses_NNS arising_VBG in_IN previous_JJ years_NNS that_WDT were_VBD not_RB recognized_VBN in_IN 2002_CD 23_CD 23_CD Unrecognised_JJ gains_NNS and_CC losses_NNS on_IN hedges_NNS at_IN 31_CD December_NNP 2002 108 108_CD Gains_NNS and_CC losses_NNS expected_VBN to_TO be_VB recognized_VBN in_IN 2003_CD 56_CD 56_CD Gains_NNS and_CC losses_NNS expected_VBN to_TO be_VB recognized_VBN in_IN 2004_CD or_CC later_RB 52_CD 52_CD 21_CD Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS Environmental_NNP ,_, litigation_NN Integration_NNP Employee_NNP and_CC other_JJ Deferred_JJ and_CC synergies_NNS benefits_NNS provisions_NNS taxation_NN Total_JJ restated_VBN restated_VBN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD At_IN 1_CD January_NNP 2001_CD as_IN previously_RB reported_VBN 25 754 204_CD 85_CD 1,068_CD Prior_RB year_NN adjustment_NN page_NN 62 549 549_CD 25 754 204 634_CD 1,617_CD Profit_NN and_CC loss_NN account_NN 156_CD 103 14 329 602_CD Net_JJ amounts_NNS paid_VBN or_CC becoming_VBG current_JJ 148_CD 306_CD 55_CD 509_CD Acquisitions_NNS 1_CD 1_CD Other_JJ movements_NNS ,_, including_VBG exchange_NN 18_CD 23_CD 15_CD 55_CD 111_CD At_IN 31_CD December_NNP 2001_CD restated_VBN 15 529 148 908_CD 1,600_CD Profit_NN and_CC loss_NN account_NN 89 43 305 437_CD Net_JJ amounts_NNS paid_VBN or_CC becoming_VBG current_JJ 11_CD 279_CD 31_CD 321_CD Other_JJ movements_NNS ,_, including_VBG exchange_NN 10_CD 34_CD 16_CD 3_CD 57_CD At_IN 31_CD December_NNP 2002 14 373 176_CD 1,210_CD 1,773_CD Employee_NN benefit_NN provisions_NNS comprise_VBP pension_NN ,_, post-retirement_NN and_CC other_JJ employee_NN benefit_NN provisions_NNS ._.
These_DT will_MD crystallise_VB ,_, in_IN the_DT main_JJ ,_, over_IN the_DT estimated_VBN working_VBG lives_NNS of_IN the_DT employees_NNS concerned_VBN ._.
The_DT environmental_JJ provisions_NNS are_VBP principally_RB in_IN respect_NN of_IN sites_NNS in_IN the_DT US_NNP ,_, further_JJ details_NNS of_IN which_WDT are_VBP given_VBN in_IN Note_NN 34_CD ._.
No_DT provision_NN has_VBZ been_VBN released_VBN or_CC applied_VBN for_IN any_DT purpose_NN other_JJ than_IN that_DT for_IN which_WDT it_PRP was_VBD established_VBN ._.
com_NN 87_CD 22_CD Reconciliation_NNP of_IN movements_NNS in_IN shareholders_NNS funds_NNS 2002 2001 2000_CD restated_VBN restated_VBN $_$ m_CD $_$ m_CD $_$ m_CD Shareholders_NNS funds_NNS at_IN beginning_NN of_IN year_NN 9,586_CD 9,389_CD 10,302_CD Prior_RB year_NN adjustment_NN page_NN 62_CD 39_CD 9,586_CD 9,389_CD 10,263_CD Net_JJ profit_NN for_IN the_DT financial_JJ year_NN 2,836_CD 2,906_CD 2,277_CD Dividends_NNPS Cash_NNP 1,206_CD 1,225_CD 1,236_CD Dividend_NN in_IN specie_NN 1,669_CD 1,630_CD 1,681_CD 628_CD Issues_NNS of_IN AstraZeneca_NNP PLC_NNP Ordinary_NNP Shares_NNP 36_CD 86_CD 19_CD Re-purchase_NN of_IN AstraZeneca_NNP PLC_NNP Ordinary_NNP Shares_NNP 1,190_CD 1,080_CD 353_CD Astra_NNP AB_NNP minority_NN interest_NN buyout_NN 8_CD Goodwill_NNP written_VBN back_RB 862_CD Exchange_NNP adjustments_NNS on_IN net_JJ assets_NNS 1,106_CD 502_CD 870_CD Translation_NN differences_NNS on_IN foreign_JJ currency_NN borrowings_NNS 6_CD 18_CD 154_CD Tax_NNP on_IN translation_NN differences_NNS on_IN foreign_JJ currency_NN borrowings_NNS 2_CD 6_CD 42_CD Other_JJ movements_NNS 8_CD Net_JJ addition_NN to_TO reduction_NN in_IN shareholders_NNS funds_NNS 1,586_CD 197_CD 874_CD Shareholders_NNS funds_NNS at_IN end_NN of_IN year_NN 11,172_CD 9,586_CD 9,389_CD Shareholders_NNS funds_NNS at_IN the_DT beginning_NN of_IN the_DT year_NN were_VBD originally_RB $_$ 9,786_CD m_NN before_IN deducting_VBG the_DT prior_JJ year_NN adjustment_NN of_IN $_$ 200m_CD in_IN respect_NN of_IN deferred_JJ tax_NN under_IN FRS_NNP 19_CD 2001_CD $_$ 9,521_CD m_NN before_IN deduction_NN of_IN $_$ 132m_CD ._.
23_CD Reserves_NNS Share_NNP Capital_NNP Joint_NNP Profit_NNP premium_NN redemption_NN Merger_NNP Other_JJ ventures_NNS and_CC and_CC loss_NN account_NN reserve_NN reserve_NN reserves_NNS associates_NNS account_VBP Total_JJ restated_VBN restated_VBN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD At_IN 31_CD December_NNP 1999_CD as_IN previously_RB reported_VBN 202_CD 1_CD 441_CD 703_CD 27_CD 8,538_CD 9,858_CD Prior_RB year_NN adjustment_NN page_NN 62_CD 39_CD 39_CD 202_CD 1_CD 441_CD 703_CD 27_CD 8,499_CD 9,819_CD Loss_NN retained_VBN for_IN year_NN 157 471 628_CD Share_NN premiums_NNS 19_CD 19_CD Transfer_NN between_IN reserves_NNS 14_CD 14_CD Re-purchase_NN of_IN shares_NNS 2_CD 353_CD 351_CD Astra_NNP AB_NNP minority_NN interest_NN buyout_NN 8_CD 8_CD Goodwill_NNP written_VBN back_RB 862_CD 862_CD Exchange_NNP adjustments_NNS :_: Goodwill_NNP 67_CD 67_CD Net_JJ assets_NNS 1_CD 871_CD 870_CD On_IN foreign_JJ currency_NN borrowings_NNS 154_CD 154_CD Foreign_JJ currency_NN borrowings_NNS tax_NN effect_NN 42_CD 42_CD 67_CD 1_CD 826_CD 758_CD Other_JJ movements_NNS 2_CD 10_CD 8_CD Net_NN movements_NNS 33_CD 2_CD 8_CD 931_CD 156_CD 1,674_CD 872_CD At_IN 31_CD December_NNP 2000_CD restated_VBN 235_CD 3_CD 433_CD 1,634_CD 183_CD 6,825_CD 8,947_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 88_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 23_CD Reserves_NNS continued_VBN Share_NNP Capital_NNP Joint_NNP Profit_NNP premium_NN redemption_NN Merger_NNP Other_JJ ventures_NNS and_CC and_CC loss_NN account_NN reserve_NN reserve_NN reserves_NNS associates_NNS account_VBP Total_JJ restated_VBN restated_VBN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD At_IN 31_CD December_NNP 2000_CD restated_VBN 235_CD 3_CD 433_CD 1,634_CD 183_CD 6,825_CD 8,947_CD Profit_NN retained_VBN for_IN year_NN 1,681_CD 1,681_CD Share_NN premiums_NNS 86_CD 86_CD Transfer_NN between_IN reserves_NNS 13_CD 13_CD Re-purchase_NN of_IN shares_NNS 6_CD 1,080_CD 1,074_CD Exchange_NNP adjustments_NNS :_: Goodwill_NNP 19_CD 19_CD Net_JJ assets_NNS 502_CD 502_CD On_IN foreign_JJ currency_NN borrowings_NNS 18_CD 18_CD Foreign_JJ currency_NN borrowings_NNS tax_NN effect_NN 6_CD 6_CD 19 509 490_CD Net_JJ movements_NNS 99_CD 6_CD 19_CD 79_CD 203_CD At_IN 31_CD December_NNP 2001_CD restated_VBN 334_CD 9_CD 433_CD 1,653_CD 183_CD 6,904_CD 9,150_CD Profit_NN retained_VBN for_IN year_NN 1,630_CD 1,630_CD Share_NN premiums_NNS 36_CD 36_CD Transfer_NN between_IN reserves_NNS 33_CD 33_CD Re-purchase_NN of_IN shares_NNS 7_CD 1,190_CD 1,183_CD Exchange_NNP adjustments_NNS :_: Goodwill_NNP 30_CD 30_CD Net_JJ assets_NNS 1,106_CD 1,106_CD On_IN foreign_JJ currency_NN borrowings_NNS 66_CD Foreign_JJ currency_NN borrowings_NNS tax_NN effect_NN 2_CD 2_CD 30_CD 1,140_CD 1,110_CD Net_JJ movements_NNS 69_CD 7_CD 30_CD 1,547_CD 1,593_CD At_IN 31_CD December_NNP 2002_CD 403_CD 16_CD 433_CD 1,623_CD 183_CD 8,451_CD 10,743_CD The_DT prior_JJ year_NN adjustment_NN arises_VBZ as_IN a_DT result_NN of_IN the_DT adoption_NN of_IN FRS19_NNP Deferred_NNP Tax_NNP ,_, as_IN explained_VBN in_IN more_JJR detail_NN on_IN page_NN 62_CD ._.
The_DT movement_NN in_IN other_JJ reserves_NNS in_IN 2000_CD relates_VBZ to_TO the_DT realisation_NN of_IN goodwill_NN in_IN respect_NN of_IN the_DT demerger_NN of_IN Zeneca_NNP Agrochemicals_NNPS $_$ 813m_CD and_CC the_DT impairment_NN of_IN the_DT Advanta_NNP seeds_NNS business_NN goodwill_NN $_$ 49m_CD ._.
The_DT cumulative_JJ amount_NN of_IN goodwill_NN resulting_VBG from_IN acquisitions_NNS ,_, net_NN of_IN disposals_NNS ,_, prior_RB to_TO the_DT adoption_NN of_IN FRS_NNP 10_CD in_IN 1998_CD ,_, amounted_VBD to_TO $_$ 617m_CD 2001_CD $_$ 587m_CD ,_, 2000_CD $_$ 606m_CD using_VBG year_NN end_NN rates_NNS of_IN exchange_NN ._.
There_EX are_VBP no_DT significant_JJ statutory_JJ or_CC contractual_JJ restrictions_NNS on_IN the_DT distribution_NN of_IN current_JJ profits_NNS of_IN subsidiaries_NNS ,_, joint_JJ ventures_NNS or_CC associates_NNS :_: undistributed_JJ profits_NNS of_IN prior_JJ years_NNS are_VBP ,_, in_IN the_DT main_JJ ,_, permanently_RB employed_VBN in_IN the_DT businesses_NNS of_IN these_DT companies_NNS ._.
The_DT undistributed_JJ income_NN of_IN AstraZeneca_NNP companies_NNS overseas_RB may_MD be_VB liable_JJ to_TO overseas_JJ taxes_NNS and_CC or_CC UK_NNP taxation_NN after_IN allowing_VBG for_IN double_JJ taxation_NN relief_NN if_IN they_PRP were_VBD to_TO be_VB distributed_VBN as_IN dividends_NNS see_VBP Note_NN 7_CD ._.
com_NN 89_CD 24_CD Net_JJ cash_NN inflow_NN from_IN trading_NN operations_NNS 2002 2001 2000_CD $_$ m_CD $_$ m_CD $_$ m_CD Operating_NN profit_NN before_IN exceptional_JJ items_NNS 4,356_CD 4,156_CD 4,330_CD Depreciation_NN and_CC amortisation_NN 960 860 988_CD Stocks_NNS decrease_VBP increase_NN 101 417 670_CD Debtors_NNS increase_NN decrease_NN 198 138 987_CD Creditors_NNS increase_NN decrease_NN 402_CD 727_CD 1,317_CD Other_JJ non-cash_JJ movements_NNS 65_CD 120_CD 14_CD 5,686_CD 4,130_CD 4,992_CD 25_CD Cash_NN flows_VBZ related_VBN to_TO exceptional_JJ items_NNS Current_JJ period_NN cash_NN flow_NN related_VBN to_TO exceptional_JJ items_NNS and_CC merger_NN 2002 2001 2000_CD related_JJ payments_NNS ,_, before_IN associated_VBN tax_NN charge_NN relief_NN $_$ m_CD $_$ m_CD $_$ m_CD Merck_NNP trigger_NN event_NN payment_NN 93_CD Merger_NNP ,_, integration_NN and_CC synergy_NN costs_NNS 68 312 532_CD Salick_NNP Health_NNP Care_NNP rationalisation_NN 11_CD Agrochemicals_NNPS restructuring_VBG 46_CD Costs_NNS relating_VBG to_TO the_DT disposal_NN of_IN Specialties_NNS business_NN 21_CD 22_CD 62_CD Demerger_NN of_IN Zeneca_NNP Agrochemicals_NNPS and_CC formation_NN of_IN Syngenta_NNP AG_NNP 4_CD 34_CD 65_CD Outflow_NN related_VBN to_TO exceptional_JJ charges_NNS 93 368 809_CD Repayment_NN of_IN debt_NN by_IN Zeneca_NNP Agrochemicals_NNPS included_VBD in_IN Acquisitions_NNS and_CC disposals_NNS 909_CD Proceeds_NNS from_IN disposal_NN of_IN fixed_JJ assets_NNS accounted_VBD for_IN as_IN exceptional_JJ 10_CD Exceptional_JJ item_NN cash_NN flow_NN 93 358 100_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 90_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 26_CD Acquisitions_NNS of_IN subsidiaries_NNS and_CC purchases_NNS of_IN minority_NN interests_NNS There_EX were_VBD no_DT significant_JJ business_NN acquisitions_NNS in_IN any_DT of_IN the_DT years_NNS presented_VBN ._.
All_DT acquisitions_NNS have_VBP been_VBN accounted_VBN for_IN by_IN the_DT acquisition_NN method_NN of_IN accounting_NN ._.
2002 2001 2000_CD Total_JJ Total_JJ Total_JJ fair_JJ value_NN fair_JJ value_NN fair_JJ value_NN $_$ m_CD $_$ m_CD $_$ m_CD Fixed_VBN assets_NNS 4_CD Current_JJ assets_NNS 26_CD Creditors_NNS due_JJ within_IN one_CD year_NN 16_CD Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS 1_CD Fair_NNP value_NN of_IN net_JJ assets_NNS acquired_VBN 13_CD Goodwill_NNP acquired_VBD 41_CD 32_CD Consideration_NN for_IN subsidiaries_NNS and_CC operations_NNS acquired_VBD 54_CD 32_CD Purchases_NNS of_IN minority_NN interests_NNS 7_CD 135_CD 47_CD 167_CD Less_RBR :_: Cash_NN included_VBD in_IN undertaking_VBG acquired_VBN 3_CD Net_JJ cash_NN consideration_NN 44_CD 167_CD Assets_NNS and_CC liabilities_NNS were_VBD adjusted_VBN to_TO their_PRP$ fair_JJ values_NNS based_VBN on_IN external_JJ valuations_NNS and_CC internal_JJ assessments_NNS ._.
There_EX were_VBD no_DT significant_JJ differences_NNS between_IN book_NN and_CC fair_JJ values_NNS in_IN respect_NN of_IN the_DT acquisitions_NNS made_VBN in_IN any_DT of_IN the_DT years_NNS presented_VBN ._.
com_NN 91_CD 27_CD Zeneca_NNP Agrochemicals_NNPS demerger_NN On_IN 13_CD November_NNP 2000_CD Zeneca_NNP Agrochemicals_NNPS was_VBD demerged_VBN from_IN the_DT Group_NNP and_CC merged_VBD with_IN the_DT agribusiness_NN of_IN Novartis_NNP to_TO form_VB Syngenta_NNP AG_NNP ._.
The_DT Zeneca_NNP Agrochemicals_NNPS results_NNS for_IN the_DT period_NN to_TO 13_CD November_NNP 2000_CD have_VBP been_VBN reported_VBN as_IN discontinued_VBN in_IN the_DT AstraZeneca_NNP accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2000_CD ._.
The_DT demerger_NN of_IN Zeneca_NNP Agrochemicals_NNPS was_VBD accounted_VBN for_IN as_IN a_DT dividend_NN in_IN specie_NN ._.
The_DT impact_NN of_IN the_DT demerger_NN on_IN the_DT year_NN ended_VBD 31_CD December_NNP 2000_CD is_VBZ set_VBN out_RP below_IN ._.
$_$ m_CD Fixed_VBN assets_NNS 1,491_CD Current_JJ assets_NNS 2,130_CD Creditors_NNS due_JJ within_IN one_CD year_NN 1,306_CD Creditors_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN and_CC provisions_NNS 246_CD Book_NN value_NN of_IN Zeneca_NNP Agrochemicals_NNPS net_JJ assets_NNS disposed_VBD 2,069_CD Minority_NNP interest_NN share_NN of_IN net_JJ assets_NNS 10_CD Goodwill_NNP previously_RB charged_VBD to_TO reserves_NNS written_VBN back_RB 813_CD 2,872_CD Repayment_NN of_IN debt_NN by_IN Zeneca_NNP Agrochemicals_NNPS Net_JJ repayment_NN of_IN debt_NN per_IN Cash_NNP Flow_NNP Statement_NNP 909_CD Net_JJ financial_JJ liabilities_NNS demerged_VBD 294_CD 1,203_CD Dividend_NN in_IN specie_NN 1,669_CD In_IN the_DT year_NN ended_VBD 31_CD December_NNP 2000_CD ,_, prior_RB to_TO its_PRP$ demerger_NN ,_, the_DT Agrochemicals_NNPS business_NN contributed_VBD $_$ 173m_CD to_TO operating_VBG cash_NN flows_NNS before_IN exceptional_JJ items_NNS ,_, and_CC absorbed_VBD $_$ 78m_CD in_IN respect_NN of_IN exceptional_JJ items_NNS and_CC $_$ 149m_CD in_IN respect_NN of_IN capital_NN expenditure_NN ._.
28_CD Disposals_NNPS There_EX were_VBD no_DT significant_JJ disposals_NNS in_IN any_DT of_IN the_DT years_NNS presented_VBN ._.
29_CD Reconciliation_NNP of_IN net_JJ cash_NN flow_NN to_TO movement_NN in_IN net_JJ funds_NNS 2002 2001 2000_CD $_$ m_CD $_$ m_CD $_$ m_CD Decrease_NN increase_NN in_IN cash_NN 22 396 640_CD Cash_NN outflow_NN inflow_NN from_IN decrease_NN increase_NN in_IN loans_NNS and_CC short_JJ term_NN borrowings_NNS 118_CD 35_CD 66_CD Cash_NN outflow_NN inflow_NN from_IN increase_NN decrease_NN in_IN short_JJ term_NN investments_NNS 806 260 608_CD Change_NNP in_IN net_JJ funds_NNS resulting_VBG from_IN cash_NN flows_NNS 902_CD 691_CD 1,314_CD Debt_NN released_VBN on_IN disposals_NNS 127_CD Other_JJ non-cash_JJ changes_NNS 48_CD Exchange_NNP movements_NNS 75_CD 47_CD 53_CD Movement_NNP in_IN net_JJ funds_NNS 977_CD 738_CD 1,436_CD Net_JJ funds_NNS at_IN 1_CD January_NNP 2,867_CD 3,605_CD 2,169_CD Net_JJ funds_NNS at_IN 31_CD December_NNP 3,844_CD 2,867_CD 3,605_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 92_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 30_CD Analysis_NN of_IN net_JJ funds_NNS At_IN 1_CD Jan_NNP Cash_NNP Other_NNP Exchange_NNP At_IN 31_CD Dec_NNP 2002_CD flow_NN non-cash_JJ movements_NNS 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Loans_NNS due_JJ after_IN one_CD year_NN 635 28 279 328_CD Current_JJ instalments_NNS of_IN loans_NNS 107_CD 77_CD 279_CD 5_CD 314_CD Total_JJ loans_NNS 742_CD 105_CD 5_CD 642_CD Short_JJ term_NN investments_NNS 3,118_CD 806_CD 38_CD 3,962_CD Cash_NN 705_CD 18_CD 39_CD 726_CD Overdrafts_NNPS 195_CD 4_CD 3_CD 202_CD Short_JJ term_NN borrowings_NNS ,_, excluding_VBG overdrafts_NNS 19_CD 13_CD 6_CD 3,609_CD 797_CD 80_CD 4,486_CD Net_JJ funds_NNS 2,867_CD 902_CD 75_CD 3,844_CD Financing_NN items_NNS included_VBD in_IN cash_NN movements_NNS above_IN :_: Issue_NN of_IN shares_NNS 36_CD Re-purchase_NN of_IN shares_NNS 1,190_CD Net_JJ cash_NN inflow_NN before_IN management_NN of_IN liquid_JJ resources_NNS and_CC financing_NN 2,056_CD 31_CD Financing_NN 2002 2001 2000_CD Notes_NNP $_$ m_CD $_$ m_CD $_$ m_CD Issues_NNS of_IN AstraZeneca_NNP PLC_NNP Ordinary_NNP Shares_NNP 30_CD 36_CD 86_CD 19_CD Re-purchase_NN of_IN AstraZeneca_NNP PLC_NNP Ordinary_NNP Shares_NNP 30_CD 1,190_CD 1,080_CD 353_CD 1,154_CD 994_CD 334_CD Repayment_NN of_IN lease_NN finance_NN 2_CD New_NNP loans_NNS 220_CD 39_CD Loans_NNS repaid_VBN 105_CD 192_CD 36_CD Net_JJ decrease_NN increase_NN in_IN short_JJ term_NN borrowings_NNS 30_CD 13_CD 7_CD 67_CD 118_CD 35_CD 64_CD Net_JJ cash_NN outflow_NN from_IN financing_VBG 1,272_CD 959_CD 400_CD There_EX were_VBD no_DT major_JJ non-cash_JJ financing_NN transactions_NNS in_IN any_DT year_NN ._.
com_NN 93_CD 32_CD Post-retirement_NN benefits_NNS Pensions_NNP Background_NNP The_NNP Group_NNP continues_VBZ to_TO account_VB for_IN pension_NN costs_NNS in_IN its_PRP$ primary_JJ Financial_NNP Statements_NNP in_IN accordance_NN with_IN the_DT UK_NNP Statement_NNP of_IN Standard_NNP Accounting_NNP Practice_NNP No._NN ._.
In_IN addition_NN ,_, disclosures_NNS have_VBP been_VBN presented_VBN below_IN in_IN accordance_NN with_IN Financial_NNP Reporting_NNP Standard_NNP No._NN ._.
The_DT Company_NN and_CC most_JJS of_IN its_PRP$ subsidiaries_NNS offer_VBP retirement_NN plans_NNS which_WDT cover_VBP the_DT majority_NN of_IN employees_NNS in_IN the_DT Group_NNP ._.
Many_JJ of_IN these_DT plans_NNS are_VBP defined_VBN contribution_NN where_WRB the_DT company_NN contribution_NN and_CC resulting_VBG profit_NN and_CC loss_NN account_NN charge_NN is_VBZ fixed_VBN at_IN a_DT set_VBN level_NN or_CC is_VBZ a_DT set_NN percentage_NN of_IN employees_NNS pay_VBP ._.
However_RB ,_, several_JJ plans_NNS ,_, mainly_RB in_IN the_DT UK_NNP ,_, US_NNP and_CC Sweden_NNP ,_, are_VBP defined_VBN benefit_NN ,_, where_WRB benefits_NNS are_VBP based_VBN on_IN employees_NNS length_NN of_IN service_NN and_CC final_JJ pensionable_JJ pay_NN ._.
All_DT of_IN the_DT major_JJ plans_NNS are_VBP funded_VBN through_IN legally_RB separate_JJ trustee_NN administered_VBN funds_NNS ._.
The_DT major_JJ defined_VBN benefit_NN plans_NNS ,_, apart_RB from_IN the_DT Swedish_NNP plan_NN ,_, have_VBP been_VBN closed_VBN to_TO new_JJ entrants_NNS since_IN 2000_CD ._.
The_DT cash_NN funding_NN of_IN the_DT plans_NNS ,_, which_WDT may_MD from_IN time_NN to_TO time_NN involve_VB special_JJ payments_NNS ,_, is_VBZ designed_VBN ,_, in_IN consultation_NN with_IN independent_JJ qualified_JJ actuaries_NNS ,_, to_TO ensure_VB that_IN present_JJ and_CC future_JJ contributions_NNS should_MD be_VB sufficient_JJ to_TO meet_VB future_JJ liabilities_NNS ._.
SSAP_NNP 24_CD The_DT cost_NN of_IN defined_VBN benefit_NN plan_NN pensions_NNS in_IN a_DT year_NN can_MD notionally_RB be_VB divided_VBN into_IN the_DT regular_JJ cost_NN and_CC variations_NNS from_IN the_DT regular_JJ cost_NN ._.
Under_IN SSAP_NNP 24_CD the_DT regular_JJ cost_NN is_VBZ based_VBN on_IN actuarial_JJ assumptions_NNS and_CC charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN the_DT year_NN it_PRP is_VBZ paid_VBN whilst_IN any_DT variations_NNS ,_, which_WDT arise_VBP where_WRB the_DT experience_NN of_IN the_DT scheme_NN varies_VBZ from_IN the_DT assumptions_NNS made_VBN by_IN the_DT actuary_NN ,_, are_VBP charged_VBN or_CC credited_VBN over_IN the_DT estimated_VBN remaining_VBG service_NN lives_NNS of_IN the_DT employees_NNS ._.
Costs_NNS of_IN defined_VBN contribution_NN plan_NN pensions_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN immediately_RB ._.
On_IN these_DT bases_NNS ,_, the_DT total_JJ pension_NN cost_NN for_IN the_DT Group_NNP under_IN SSAP_NNP 24_CD for_IN 2002_CD was_VBD $_$ 220m_CD 2001_CD $_$ 194m_CD ,_, 2000_CD $_$ 184m_CD ._.
In_IN the_DT Group_NNP balance_NN sheet_NN at_IN 31_CD December_NNP 2002_CD ,_, accrued_VBN pension_NN costs_NNS included_VBD in_IN other_JJ creditors_NNS amounted_VBD to_TO $_$ 53m_CD 2001_CD $_$ 76m_CD :_: prepaid_JJ pension_NN costs_NNS of_IN $_$ 114m_CD 2001_CD $_$ 47m_CD are_VBP included_VBN in_IN debtors_NNS ._.
Provisions_NNS for_IN unfunded_JJ pension_NN obligations_NNS ,_, included_VBD in_IN provisions_NNS ,_, amounted_VBD to_TO $_$ 235m_CD 2001_CD $_$ 357m_CD ._.
With_IN regard_NN to_TO the_DT Groups_NNS main_JJ UK_NNP defined_VBD benefit_NN fund_NN ,_, the_DT latest_JJS actuarial_JJ valuation_NN was_VBD carried_VBN out_RP at_IN 31_CD March_NNP 2002_CD and_CC the_DT pension_NN cost_NN assessed_VBN using_VBG the_DT projected_VBN unit_NN credit_NN method_NN ._.
The_DT key_JJ accounting_NN assumptions_NNS for_IN the_DT purposes_NNS of_IN SSAP_NNP 24_CD were_VBD that_IN ,_, against_IN a_DT background_NN long_JJ term_NN UK_NNP price_NN inflation_NN averaging_VBG 2.5_CD %_NN pa_NN ,_, investment_NN returns_NNS would_MD average_VB 6.5_CD %_NN pa_NN ,_, salary_NN increases_NNS 4.3_CD %_NN pa_NN and_CC pension_NN increases_NNS 2.5_CD %_NN pa._NN ._.
The_DT market_NN value_NN of_IN the_DT funds_NNS assets_NNS at_IN the_DT valuation_NN date_NN was_VBD 2,161_CD m_NN $_$ 3,477_CD m_NN equivalent_NN ,_, representing_VBG 94.6_CD %_NN of_IN the_DT liabilities_NNS using_VBG these_DT assumptions_NNS ._.
The_DT regular_JJ cost_NN for_IN accounting_NN purposes_NNS equates_VBZ to_TO 18.8_CD %_NN of_IN pensionable_JJ salaries_NNS ._.
At_IN the_DT same_JJ time_NN ,_, the_DT valuation_NN was_VBD carried_VBN out_RP for_IN ongoing_JJ funding_NN purposes_NNS ,_, with_IN assumptions_NNS slightly_RB more_RBR conservative_JJ than_IN those_DT used_VBN for_IN SSAP_NNP 24_CD purposes_NNS ._.
The_DT market_NN value_NN of_IN the_DT funds_NNS assets_NNS at_IN the_DT valuation_NN date_NN represent_VBP 90.1_CD %_NN of_IN the_DT liabilities_NNS on_IN a_DT funding_NN basis_NN ._.
The_DT Company_NN has_VBZ indicated_VBN to_TO the_DT trustee_NN of_IN the_DT UK_NNP fund_NN its_PRP$ intention_NN to_TO target_VB a_DT solvency_NN ratio_NN of_IN 91_CD %_NN following_VBG the_DT 2003_CD actuarial_JJ valuation_NN ,_, with_IN a_DT longer_JJR term_NN aim_NN of_IN restoring_VBG solvency_NN over_IN a_DT period_NN of_IN around_IN 15_CD years_NNS ._.
Any_DT cash_NN contributions_NNS made_VBD to_TO the_DT fund_NN would_MD be_VB treated_VBN as_IN a_DT prepayment_NN and_CC taken_VBN into_IN account_NN in_IN the_DT actuarially_RB assessed_VBN contributions_NNS to_TO the_DT fund_NN charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
The_DT US_NNP defined_VBD benefits_NNS program_NN was_VBD actuarially_RB revalued_VBN at_IN 31_CD December_NNP 2002_CD when_WRB plan_NN obligations_NNS were_VBD estimated_VBN to_TO amount_VB to_TO $_$ 812m_CD and_CC plan_NN assets_NNS were_VBD $_$ 665m_CD ._.
The_DT US_NNP typically_RB makes_VBZ contributions_NNS to_TO provide_VB for_IN plan_NN benefit_VBP deficits_NNS on_IN a_DT regular_JJ basis_NN ._.
PRI_NNP Pensionstjnst_NNP AB_NNP ,_, a_DT joint_JJ company_NN for_IN Swedish_JJ industry_NN ,_, administers_VBZ the_DT Swedish_JJ plan_NN for_IN salaried_JJ employees_NNS and_CC Alecta_NNP establishes_VBZ benefit_NN levels_NNS and_CC actuarial_JJ assumptions_NNS ._.
During_IN 2002_CD AstraZeneca_NNP AB_NNP has_VBZ established_VBN separate_JJ trustee_NN administered_VBN funds_NNS to_TO support_VB its_PRP$ pension_NN liabilities_NNS :_: prior_RB to_TO 2002_CD the_DT plan_NN was_VBD unfunded_JJ ._.
Post-retirement_NN benefits_NNS other_JJ than_IN pensions_NNS In_IN the_DT US_NNP ,_, and_CC to_TO a_DT lesser_JJR extent_NN in_IN some_DT other_JJ countries_NNS ,_, AstraZenecas_NNP employment_NN practices_NNS include_VBP the_DT provision_NN of_IN healthcare_NN and_CC life_NN insurance_NN benefits_NNS for_IN retired_VBN employees_NNS ._.
Some_DT 6,920_CD retired_VBN employees_NNS and_CC covered_VBD dependants_NNS currently_RB benefit_VBP from_IN these_DT provisions_NNS and_CC some_DT 13,383_CD current_JJ employees_NNS will_MD be_VB eligible_JJ on_IN retirement_NN ._.
AstraZeneca_NNP accrues_VBZ for_IN the_DT present_JJ value_NN of_IN such_JJ retiree_NN obligations_NNS over_IN the_DT working_VBG life_NN of_IN the_DT employee_NN ._.
The_DT cost_NN of_IN post-retirement_JJ benefits_NNS other_JJ than_IN pensions_NNS for_IN the_DT Group_NNP in_IN 2002_CD was_VBD $_$ 22m_CD 2001_CD $_$ 16m_CD ,_, 2000_CD $_$ 25m_CD ._.
Provisions_NNS and_CC creditors_NNS set_VBN aside_RB for_IN the_DT benefit_NN obligations_NNS at_IN 31_CD December_NNP 2002_CD amounted_VBD to_TO $_$ 32m_CD 2001_CD $_$ 248m_CD ,_, 2000_CD $_$ 233m_CD ._.
Other_JJ than_IN this_DT provision_NN there_EX were_VBD plan_NN assets_NNS amounting_VBG to_TO $_$ 133m_CD in_IN the_DT US_NNP at_IN 31_CD December_NNP 2002_CD ._.
These_DT benefit_NN plans_NNS have_VBP been_VBN included_VBN in_IN the_DT disclosure_NN of_IN post-retirement_JJ benefits_NNS under_IN FRS17_NNP ._.
com_NN 94_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 32_CD Post-retirement_NN benefits_NNS continued_VBD FRS_NNP 17_CD Full_NNP implementation_NN of_IN FRS_NNP 17_CD had_VBD originally_RB been_VBN intended_VBN for_IN accounting_NN periods_NNS ending_VBG on_IN or_CC after_IN 22_CD June_NNP 2003_CD but_CC has_VBZ been_VBN deferred_VBN by_IN the_DT Accounting_NNP Standards_NNP Board_NNP until_IN accounting_NN periods_NNS commencing_VBG on_IN or_CC after_IN 1_CD January_NNP 2005_CD ._.
However_RB ,_, the_DT requirements_NNS for_IN disclosure_NN under_IN FRS_NNP 17_CD between_IN its_PRP$ issue_NN and_CC full_JJ implementation_NN dates_NNS remain_VBP and_CC this_DT information_NN is_VBZ set_VBN out_RP below_IN ._.
When_WRB fully_RB adopted_VBN ,_, the_DT objective_NN of_IN FRS_NNP 17_CD is_VBZ to_TO reflect_VB the_DT fair_JJ value_NN of_IN post-retirement_JJ plan_NN assets_NNS and_CC liabilities_NNS and_CC associated_VBN charges_NNS in_IN the_DT Financial_NNP Statements_NNP ._.
FRS_NNP 17_CD specifies_VBZ how_WRB key_JJ assumptions_NNS should_MD be_VB formulated_VBN and_CC applied_VBN :_: these_DT assumptions_NNS are_VBP often_RB different_JJ to_TO the_DT funding_NN bases_NNS established_VBN by_IN the_DT pension_NN funds_NNS trustees_NNS or_CC actuaries_NNS ._.
The_DT accounting_NN requirements_NNS of_IN FRS_NNP 17_CD are_VBP broadly_RB as_IN follows_VBZ :_: Post-retirement_NN scheme_NN assets_NNS are_VBP valued_VBN at_IN market_NN values_NNS at_IN the_DT balance_NN sheet_NN date_NN :_: Post-retirement_NN scheme_NN liabilities_NNS are_VBP measured_VBN using_VBG a_DT projected_VBN unit_NN method_NN and_CC discounted_VBN at_IN the_DT current_JJ rate_NN of_IN return_NN on_IN high_JJ quality_NN corporate_JJ bonds_NNS of_IN equivalent_JJ term_NN and_CC currency_NN to_TO the_DT liability_NN :_: and_CC The_DT movement_NN in_IN the_DT scheme_NN surplus_NN deficit_NN will_MD be_VB split_VBN between_IN operating_NN charges_NNS and_CC financing_NN items_NNS in_IN the_DT profit_NN and_CC loss_NN account_NN and_CC ,_, in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ,_, actuarial_JJ gains_NNS and_CC losses_NNS ._.
Financial_NNP assumptions_NNS Qualified_VBN independent_JJ actuaries_NNS have_VBP updated_VBN the_DT actuarial_JJ valuations_NNS of_IN the_DT major_JJ defined_VBN benefit_NN schemes_NNS operated_VBN by_IN the_DT Group_NNP to_TO 31_CD December_NNP 2002_CD ._.
The_DT assumptions_NNS used_VBN by_IN the_DT actuaries_NNS are_VBP the_DT best_JJS estimates_NNS chosen_VBN from_IN a_DT range_NN of_IN possible_JJ actuarial_JJ assumptions_NNS which_WDT ,_, due_JJ to_TO the_DT long_JJ term_NN nature_NN of_IN the_DT scheme_NN ,_, may_MD not_RB necessarily_RB be_VB borne_VBN out_RP in_IN practice_NN ._.
These_DT assumptions_NNS were_VBD as_IN follows_VBZ :_: 2002_CD 2001_CD Rest_VB of_IN Rest_VB of_IN UK_NNP Group_NNP UK_NNP Group_NNP Inflation_NN assumption_NN 2.2_CD %_NN 2.1_CD %_NN 2.5_CD %_NN 2.7_CD %_NN Rate_NN of_IN increase_NN in_IN salaries_NNS 4.0_CD %_NN 4.0_CD %_NN 4.3_CD %_NN 4.6_CD %_NN Rate_NN of_IN increase_NN in_IN pensions_NNS in_IN payment_NN 2.2_CD %_NN 0.5_CD %_NN 2.5_CD %_NN 0.5_CD %_NN Discount_NNP rate_NN 5.6_CD %_NN 5.8_CD %_NN 5.8_CD %_NN 6.2_CD %_NN Long_JJ term_NN rate_NN of_IN return_NN expected_VBN at_IN 31_CD December_NNP Equities_NNPS 8.3_CD %_NN 8.4_CD %_NN 7.6_CD %_NN 9.7_CD %_NN Bonds_NNS 4.9_CD %_NN 6.1_CD %_NN 5.3_CD %_NN 6.1_CD %_NN Others_NNS 3.7_CD %_NN 3.6_CD %_NN 4.0_CD %_NN 8.7_CD %_NN AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 95_CD 32_CD Post-retirement_NN benefits_NNS continued_VBD Post-retirement_JJ scheme_NN deficit_NN The_DT post-retirement_JJ scheme_NN deficit_NN set_VBN out_RP below_IN under_IN FRS_NNP 17_CD is_VBZ as_IN if_IN this_DT standard_NN were_VBD fully_RB applied_VBN ._.
However_RB ,_, under_IN the_DT current_JJ accounting_NN methodology_NN SSAP_NNP 24_CD there_EX are_VBP prepayments_NNS and_CC provisions_NNS including_VBG deferred_JJ tax_NN within_IN the_DT balance_NN sheet_NN at_IN 31_CD December_NNP 2002_CD that_WDT would_MD offset_VB the_DT effect_NN on_IN net_JJ assets_NNS of_IN this_DT deficit_NN in_IN the_DT event_NN of_IN a_DT restatement_NN under_IN FRS_NNP 17_CD ._.
The_DT assets_NNS and_CC liabilities_NNS of_IN the_DT major_JJ defined_VBN benefit_NN schemes_NNS operated_VBN by_IN the_DT Group_NNP at_IN 31_CD December_NNP 2002_CD as_IN calculated_VBN in_IN accordance_NN with_IN FRS_NNP 17_CD are_VBP shown_VBN below_IN ._.
The_DT fair_JJ values_NNS of_IN the_DT schemes_NNS assets_NNS are_VBP not_RB intended_VBN to_TO be_VB realized_VBN in_IN the_DT short_JJ term_NN and_CC may_MD be_VB subject_JJ to_TO significant_JJ change_NN before_IN they_PRP are_VBP realized_VBN ._.
The_DT present_JJ value_NN of_IN the_DT schemes_NNS liabilities_NNS is_VBZ derived_VBN from_IN cash_NN flow_NN projections_NNS over_IN long_JJ periods_NNS and_CC are_VBP thus_RB inherently_RB uncertain_JJ ._.
If_IN FRS_NNP 17_CD had_VBD been_VBN adopted_VBN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD the_DT Groups_NNS reported_VBD net_JJ assets_NNS see_VBP page_NN 60_CD would_MD be_VB reduced_VBN by_IN $_$ 637m_CD 5.7_CD %_NN to_TO $_$ 10,589_CD m._NN Further_JJ explanation_NN of_IN this_DT adjustment_NN is_VBZ included_VBN below_IN :_: Value_NN at_IN 31_CD December_NNP 2002_CD Value_NN at_IN 31_CD December_NNP 2001_CD Rest_VB of_IN Rest_VB of_IN UK_NNP Group_NNP Total_NNP UK_NNP Group_NNP Total_NNP $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Scheme_NN assets_NNS Equities_NNS 1,186_CD 708_CD 1,894_CD 1,255_CD 409_CD 1,664_CD Bonds_NNS 2,097_CD 464_CD 2,561_CD 1,831_CD 214_CD 2,045_CD Others_NNS 75 102 177_CD 59 131 190_CD Total_JJ fair_JJ value_NN of_IN assets_NNS 3,358_CD 1,274_CD 4,632_CD 3,145_CD 754_CD 3,899_CD Present_JJ value_NN of_IN scheme_NN liabilities_NNS 4,200_CD 1,665_CD 5,865_CD 3,569_CD 1,472_CD 5,041_CD Deficit_NN in_IN the_DT scheme_NN 842_CD 391_CD 1,233_CD 424_CD 718_CD 1,142_CD Related_VBN deferred_VBN tax_NN asset_NN 253 151 404 127_CD 248_CD 375_CD Net_JJ post-retirement_JJ deficit_NN under_IN FRS_NNP 17 589 240 829_CD 297 470 767_CD Adjustments_NNS for_IN assets_NNS and_CC provisions_NNS under_IN SSAP_NNP 24_CD Prepayment_NN ,_, net_NN of_IN related_JJ deferred_JJ tax_NN 177_CD 56_CD Accrual_NNP ,_, net_NN of_IN deferred_JJ tax_NN 36_CD 143_CD Provision_NNP ,_, net_NN of_IN deferred_JJ tax_NN 333_CD 296_CD Adjusted_VBN post-retirement_JJ deficit_NN ,_, net_NN of_IN related_JJ deferred_JJ tax_NN 637_CD 384_CD Net_JJ assets_NNS as_IN currently_RB disclosed_VBN restated_VBN see_VBP page_NN 60_CD 11,226_CD 9,629_CD Net_JJ assets_NNS as_IN adjusted_VBN if_IN FRS_NNP 17_CD were_VBD fully_RB adopted_VBN 10,589_CD 9,245_CD Profit_NN and_CC loss_NN account_NN disclosures_NNS On_IN full_JJ compliance_NN with_IN FRS_NNP 17_CD ,_, on_IN the_DT basis_NN of_IN the_DT above_JJ assumptions_NNS ,_, the_DT amounts_NNS that_WDT would_MD have_VB been_VBN charged_VBN to_TO the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN and_CC statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS in_IN respect_NN of_IN defined_VBN benefit_NN schemes_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD are_VBP set_VBN out_RP below_IN :_: Rest_VB of_IN UK_NNP Group_NNP Total_NNP $_$ m_CD $_$ m_CD $_$ m_CD Operating_NN profit_NN Current_JJ service_NN cost_NN 100_CD 69_CD 169_CD Past_JJ service_NN costs_NNS 2_CD 8_CD 6_CD Settlement_NNP and_CC curtailment_NN 24_CD 24_CD Total_JJ operating_VBG charge_NN 102_CD 37_CD 139_CD Finance_NNP expense_NN Expected_VBN return_NN on_IN post-retirement_JJ scheme_NN assets_NNS 197_CD 52_CD 249_CD Interest_NN on_IN post-retirement_JJ scheme_NN liabilities_NNS 210_CD 98_CD 308_CD Net_JJ return_NN 13_CD 46_CD 59_CD Loss_NN before_IN taxation_NN 115_CD 83_CD 198_CD Consolidated_NNP statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS Actual_JJ return_NN less_RBR expected_JJ return_NN on_IN the_DT post-retirement_JJ schemes_NNS assets_NNS 301_CD 91_CD 392_CD Experience_NN losses_NNS gains_VBZ arising_VBG on_IN the_DT post-retirement_JJ schemes_NNS liabilities_NNS 108_CD 8_CD 100_CD Changes_NNS in_IN assumptions_NNS underlying_VBG the_DT present_JJ value_NN of_IN the_DT post-retirement_JJ schemes_NNS liabilities_NNS 58_CD 27_CD 31_CD Actuarial_JJ loss_NN recognized_VBN 351 110 461_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 96_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 32_CD Post-retirement_NN benefits_NNS continued_VBD Additional_JJ disclosures_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD Rest_VB of_IN UK_NNP Group_NNP Total_NNP $_$ m_CD $_$ m_CD $_$ m_CD Difference_NN between_IN the_DT expected_VBN and_CC actual_JJ return_NN on_IN scheme_NN assets_NNS :_: Amount_NNP 301_CD 91_CD 392_CD Percentage_NN of_IN scheme_NN assets_NNS 9.0_CD %_NN 7.1_CD %_NN 8.5_CD %_NN Experience_NN gains_NNS and_CC losses_NNS on_IN scheme_NN liabilities_NNS :_: Amount_NNP 108_CD 8_CD 100_CD Percentage_NN of_IN the_DT present_JJ value_NN of_IN scheme_NN liabilities_NNS 2.6_CD %_NN 0.5_CD %_NN 1.7_CD %_NN Total_JJ amount_NN recognized_VBN in_IN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS :_: Amount_NNP 351 110 461_CD Percentage_NN of_IN the_DT present_JJ value_NN of_IN scheme_NN liabilities_NNS 8.4_CD %_NN 6.6_CD %_NN 7.9_CD %_NN Movement_NNP in_IN post-retirement_JJ deficit_NN during_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD Rest_VB of_IN UK_NNP Group_NNP Total_NNP $_$ m_CD $_$ m_CD $_$ m_CD Deficits_NNS in_IN schemes_NNS at_IN beginning_NN of_IN the_DT year_NN 424_CD 718_CD 1,142_CD Current_JJ service_NN cost_NN 100_CD 69_CD 169_CD Contributions_NNS 125 567 692_CD Past_JJ service_NN costs_NNS 2_CD 8_CD 6_CD Settlement_NNP and_CC curtailment_NN 24_CD 24_CD Other_JJ finance_NN income_NN 13_CD 46_CD 59_CD Actuarial_JJ loss_NN 351 110 461_CD Exchange_NNP 77_CD 47_CD 124_CD Deficits_NNS in_IN schemes_NNS at_IN end_NN of_IN the_DT year_NN 842_CD 391_CD 1,233_CD Adjusted_VBN post-retirement_JJ deficit_NN ,_, net_NN of_IN deferred_JJ tax_NN 637_CD The_DT increase_NN in_IN the_DT deficit_NN during_IN 2002_CD is_VBZ due_JJ principally_RB to_TO shortfalls_NNS on_IN returns_NNS of_IN post-retirement_JJ scheme_NN assets_NNS and_CC exchange_NN ,_, offset_VBN by_IN funding_NN of_IN Swedens_NNP pension_NN scheme_NN and_CC the_DT USs_NNP non-pension_JJ post-retirement_NN schemes_NNS for_IN the_DT first_JJ time_NN in_IN 2002_CD ._.
Reserves_NNS note_VBP for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD Total_JJ $_$ m_CD Profit_NN and_CC loss_NN reserve_NN excluding_VBG post-retirement_JJ liability_NN 8,451_CD Post-retirement_NN reserve_NN 637_CD Profit_NN and_CC loss_NN reserve_NN under_IN FRS17_NNP 7,814_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 97_CD 33_CD Employee_NN costs_NNS and_CC share_NN option_NN plans_NNS for_IN employees_NNS Employee_NN costs_VBZ The_DT average_JJ number_NN of_IN people_NNS employed_VBN by_IN the_DT Group_NNP in_IN 2002_CD was_VBD 57,500_CD 2001_CD 52,600_CD ,_, 2000_CD 57,000_CD and_CC the_DT costs_NNS incurred_VBN during_IN the_DT year_NN in_IN respect_NN of_IN these_DT employees_NNS were_VBD :_: 2002 2001 2000_CD $_$ m_CD $_$ m_CD $_$ m_CD Salaries_NNS 3,049_CD 2,701_CD 2,862_CD Social_NNP security_NN costs_NNS 505 465 464_CD Pension_NN costs_NNS 193 194 184_CD Other_JJ employment_NN costs_NNS 246 182 170_CD 3,993_CD 3,542_CD 3,680_CD Employee_NN costs_NNS above_IN do_VBP not_RB include_VB severance_NN costs_NNS ._.
The_DT Directors_NNS believe_VBP that_IN ,_, together_RB with_IN the_DT basic_JJ salary_NN system_NN ,_, the_DT Groups_NNS employee_NN incentive_NN schemes_NNS provide_VBP competitive_JJ and_CC marketrelated_JJ packages_NNS to_TO motivate_VB employees_NNS ._.
They_PRP should_MD also_RB align_VB the_DT interests_NNS of_IN employees_NNS with_IN those_DT of_IN shareholders_NNS ,_, as_IN a_DT whole_JJ ,_, through_IN long_JJ term_NN share_NN ownership_NN in_IN the_DT Company_NN ._.
The_DT Groups_NNS current_JJ UK_NNP ,_, Swedish_NNP and_CC US_NNP schemes_NNS are_VBP described_VBN below_IN :_: other_JJ arrangements_NNS apply_VBP elsewhere_RB ._.
The_DT AstraZeneca_NNP UK_NNP Performance_NNP Bonus_NNP Plan_NNP Employees_NNS of_IN participating_VBG AstraZeneca_NNP UK_NNP companies_NNS are_VBP invited_VBN to_TO participate_VB in_IN this_DT bonus_NN plan_NN which_WDT rewards_VBZ good_JJ performance_NN at_IN corporate_JJ ,_, function_NN business_NN and_CC individual_JJ team_NN levels_NNS ._.
Depending_VBG upon_IN performance_NN and_CC upon_IN which_WDT level_NN it_PRP is_VBZ measured_VBN ,_, bonuses_NNS may_MD be_VB paid_VBN partly_RB in_IN the_DT form_NN of_IN free_JJ Ordinary_NNP Shares_NNP in_IN the_DT Company_NN under_IN the_DT Inland_NNP Revenue_NN approved_VBD AstraZeneca_NNP All-Employee_NNP Share_NNP Plan_NNP and_CC up_RB to_TO a_DT maximum_JJ annual_JJ value_NN of_IN 3,000_CD and_CC partly_RB in_IN cash_NN ._.
A_DT tax_NN efficient_JJ share_NN retention_NN scheme_NN ,_, under_IN which_WDT employees_NNS leave_VBP their_PRP$ bonus_NN shares_NNS in_IN trust_NN for_IN three_CD to_TO five_CD years_NNS ,_, forms_NNS part_NN of_IN the_DT All-Employee_NNP Share_NN Plan_NN ._.
In_IN 2002_CD ,_, for_IN the_DT first_JJ time_NN the_DT Company_NN offered_VBD UK_NNP employees_NNS the_DT opportunity_NN to_TO buy_VB Partnership_NNP Shares_NNP Ordinary_NNP Shares_NNP under_IN the_DT All-Employee_NNP Share_NN Plan_NN ._.
Employees_NNS may_MD invest_VB up_RP to_TO 125_CD per_IN month_NN over_IN a_DT 12_CD month_NN accumulation_NN period_NN and_CC purchase_NN Partnership_NNP Shares_NNP in_IN the_DT Company_NN with_IN the_DT total_JJ proceeds_NNS at_IN the_DT end_NN of_IN the_DT period_NN ._.
The_DT purchase_NN price_NN for_IN the_DT shares_NNS is_VBZ the_DT lower_JJR of_IN the_DT price_NN at_IN the_DT beginning_NN or_CC the_DT end_NN of_IN the_DT 12_CD month_NN period_NN ._.
A_DT tax_NN efficient_JJ share_NN retention_NN scheme_NN is_VBZ also_RB available_JJ in_IN respect_NN of_IN Partnership_NNP Shares_NNP ._.
At_IN the_DT Companys_NNPS AGM_NNP in_IN 2002_CD ,_, shareholders_NNS approved_VBD the_DT issue_NN of_IN new_JJ shares_NNS for_IN the_DT purposes_NNS of_IN the_DT All-Employee_NNP Share_NN Plan_NN ._.
The_DT AstraZeneca_NNP Executive_NNP Annual_JJ Bonus_NNP Scheme_NNP This_DT scheme_NN is_VBZ a_DT performance_NN bonus_NN scheme_NN for_IN Directors_NNS and_CC senior_JJ employees_NNS who_WP do_VBP not_RB participate_VB in_IN the_DT AstraZeneca_NNP UK_NNP Performance_NNP Bonus_NNP Plan_NNP ._.
Annual_JJ bonuses_NNS are_VBP paid_VBN in_IN cash_NN and_CC reflect_VB both_DT corporate_JJ and_CC individual_JJ performance_NN measures_NNS ._.
The_DT Remuneration_NNP Committee_NNP has_VBZ discretion_NN to_TO reduce_VB or_CC withhold_VB bonuses_NNS if_IN business_NN performance_NN falls_VBZ sufficiently_RB short_JJ of_IN expectations_NNS in_IN any_DT year_NN such_JJ as_IN to_TO make_VB the_DT payment_NN of_IN bonuses_NNS inappropriate_JJ ._.
The_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Scheme_NN UK_NNP employees_NNS may_MD make_VB regular_JJ monthly_JJ savings_NNS contributions_NNS over_IN a_DT three_CD or_CC five_CD year_NN period_NN and_CC may_MD apply_VB for_IN options_NNS to_TO acquire_VB AstraZeneca_NNP shares_NNS ._.
Further_JJ details_NNS are_VBP set_VBN out_RP below_IN ._.
The_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN This_DT is_VBZ a_DT share_NN option_NN plan_NN for_IN employees_NNS of_IN participating_VBG AstraZeneca_NNP Group_NNP companies_NNS which_WDT was_VBD approved_VBN by_IN shareholders_NNS at_IN the_DT Companys_NNPS AGM_NNP in_IN 2000_CD ._.
The_DT first_JJ grant_NN of_IN options_NNS occurred_VBD in_IN August_NNP 2000_CD ._.
The_DT main_JJ grant_NN of_IN options_NNS in_IN 2002_CD under_IN the_DT plan_NN was_VBD in_IN March_NNP ,_, with_IN a_DT further_RBR ,_, smaller_JJR grant_NN in_IN August_NNP ._.
The_DT Remuneration_NNP Committee_NNP sets_VBZ the_DT policy_NN for_IN the_DT Companys_NNP operation_NN of_IN the_DT plan_NN ._.
Sweden_NNP In_IN Sweden_NNP an_DT all_DT employee_NN performance_NN bonus_NN plan_NN is_VBZ in_IN operation_NN ._.
The_DT plan_NN rewards_VBZ good_JJ performance_NN at_IN corporate_JJ ,_, function_NN and_CC individual_JJ team_NN level_NN ._.
Bonuses_NNS for_IN corporate_JJ and_CC function_NN performance_NN are_VBP always_RB paid_VBN in_IN the_DT form_NN of_IN AstraZeneca_NNP Ordinary_NNP Shares_NNP ._.
Bonuses_NNS for_IN individual_JJ team_NN performance_NN may_MD be_VB paid_VBN in_IN Ordinary_NNP Shares_NNP or_CC in_IN cash_NN ,_, at_IN the_DT employees_NNS discretion_NN ._.
Existing_VBG Ordinary_NNP Shares_NNP are_VBP used_VBN to_TO pay_VB bonuses_NNS awarded_VBN under_IN the_DT plan_NN ._.
These_DT are_VBP purchased_VBN in_IN the_DT market_NN ._.
They_PRP must_MD be_VB left_VBN in_IN trust_NN for_IN three_CD years_NNS ._.
The_DT AstraZeneca_NNP Executive_NNP Annual_JJ Bonus_NNP Scheme_NNP and_CC the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN both_DT operate_VBP in_IN respect_NN of_IN relevant_JJ AstraZeneca_NNP employees_NNS in_IN Sweden_NNP ._.
US_NNP In_IN the_DT US_NNP ,_, there_EX are_VBP four_CD senior_JJ staff_NN incentive_NN schemes_NNS ,_, under_IN which_WDT either_CC AstraZeneca_NNP ADSs_NNPS or_CC stock_NN appreciation_NN rights_NNS related_VBN to_TO AstraZeneca_NNP ADSs_NNS are_VBP awarded_VBN to_TO participants_NNS ._.
There_EX are_VBP currently_RB approximately_RB 146_CD participants_NNS in_IN these_DT schemes_NNS ._.
AstraZeneca_NNP ADSs_NNP necessary_JJ to_TO satisfy_VB the_DT awards_NNS under_IN these_DT schemes_NNS are_VBP purchased_VBN in_IN the_DT market_NN and_CC no_DT subscriptions_NNS for_IN new_JJ Ordinary_NNP Shares_NNP have_VBP been_VBN involved_VBN ._.
The_DT AstraZeneca_NNP Share_NN Option_NN Plan_NNP operates_VBZ in_IN respect_NN of_IN relevant_JJ AstraZeneca_NNP employees_NNS in_IN the_DT US_NNP ._.
com_NN 98_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 33_CD Employee_NN costs_NNS and_CC share_NN option_NN plans_NNS for_IN employees_NNS continued_VBD Share_NN Option_NN Plans_NNS At_IN 31_CD December_NNP 2002_CD ,_, there_EX were_VBD options_NNS outstanding_JJ under_IN the_DT Zeneca_NNP 1993_CD Senior_JJ Staff_NN Share_NN Option_NN Scheme_NN ,_, the_DT Zeneca_NNP 1994_CD Executive_NNP Share_NNP Option_NN Scheme_NN ,_, the_DT Astra_NNP Shareholder_NN Value_NNP Incentive_NNP Plan_NNP ,_, the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Scheme_NN and_CC the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN ._.
1_CD Summary_NNP of_IN the_DT Zeneca_NNP 1993_CD Senior_JJ Staff_NN Share_NN Option_NN Scheme_NNP The_NNP Zeneca_NNP 1993_CD Senior_JJ Staff_NN Share_NN Option_NN Scheme_NN was_VBD introduced_VBN at_IN the_DT time_NN of_IN the_DT demerger_NN of_IN Zeneca_NNP from_IN ICI_NNP in_IN 1993_CD ._.
The_DT last_JJ date_NN for_IN the_DT grant_NN of_IN options_NNS was_VBD 19_CD May_NNP 1994_CD and_CC the_DT scheme_NN was_VBD replaced_VBN by_IN the_DT Zeneca_NNP 1994_CD Executive_NNP Share_NNP Option_NN Scheme_NN ._.
2_CD Summary_NNP of_IN the_DT Zeneca_NNP 1994_CD Executive_NNP Share_NNP Option_NN Scheme_NNP The_NNP Zeneca_NNP 1994_CD Executive_NNP Share_NNP Option_NN Scheme_NN was_VBD introduced_VBN in_IN 1994_CD ._.
The_DT last_JJ date_NN for_IN the_DT grant_NN of_IN options_NNS was_VBD 16_CD March_NNP 2000_CD and_CC the_DT scheme_NN has_VBZ been_VBN replaced_VBN by_IN the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN ._.
Options_NNS granted_VBN under_IN the_DT 1994_CD scheme_NN will_MD normally_RB be_VB exercisable_JJ between_IN three_CD and_CC 10_CD years_NNS following_VBG grant_NN ,_, provided_VBD the_DT relevant_JJ performance_NN condition_NN has_VBZ been_VBN satisfied_VBN ._.
Options_NNS may_MD be_VB satisfied_VBN by_IN the_DT issue_NN of_IN new_JJ shares_NNS or_CC by_IN existing_VBG shares_NNS purchased_VBN in_IN the_DT market_NN ._.
Options_NNS will_MD not_RB normally_RB be_VB exercisable_JJ unless_IN a_DT performance_NN condition_NN set_VBN by_IN the_DT Remuneration_NNP Committee_NNP has_VBZ been_VBN satisfied_VBN ._.
The_DT performance_NN condition_NN is_VBZ that_IN earnings_NNS per_IN share_NN must_MD grow_VB by_IN at_IN least_JJS the_DT increase_NN in_IN the_DT UK_NNP Retail_NNP Price_NNP Index_NNP over_IN three_CD years_NNS plus_CC 3_CD %_NN per_IN annum_NN ._.
Satisfaction_NN of_IN this_DT condition_NN is_VBZ tested_VBN annually_RB by_IN reference_NN to_TO the_DT audited_JJ financial_JJ statements_NNS ._.
Once_RB the_DT condition_NN is_VBZ satisfied_VBN in_IN respect_NN of_IN any_DT rolling_VBG three_CD year_NN period_NN beginning_VBG no_DT earlier_JJR than_IN the_DT end_NN of_IN the_DT financial_JJ year_NN prior_RB to_TO the_DT grant_NN of_IN the_DT option_NN ,_, then_RB it_PRP need_MD not_RB be_VB satisfied_VBN again_RB in_IN respect_NN of_IN that_DT option_NN ._.
The_DT Remuneration_NNP Committee_NNP reviews_VBZ the_DT performance_NN conditions_NNS at_IN intervals_NNS to_TO ensure_VB that_IN they_PRP continue_VBP to_TO be_VB appropriate_JJ ._.
3_CD Summary_NNP of_IN the_DT Astra_NNP Shareholder_NN Value_NNP Incentive_NNP Plan_NNP In_IN 1996_CD ,_, Astra_NNP established_VBD a_DT stock_NN option_NN plan_NN for_IN some_DT 100_CD Astra_NNP employees_NNS in_IN key_JJ senior_JJ positions_NNS ._.
The_DT plan_NN is_VBZ no_RB longer_RB used_VBN for_IN the_DT grant_NN of_IN options_NNS and_CC has_VBZ been_VBN superseded_VBN by_IN the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN ._.
On_IN completion_NN of_IN the_DT merger_NN with_IN Zeneca_NNP ,_, options_NNS in_IN Astra_NNP shares_NNS granted_VBN under_IN the_DT plan_NN were_VBD replaced_VBN by_IN options_NNS to_TO acquire_VB a_DT number_NN of_IN AstraZeneca_NNP shares_NNS based_VBN on_IN the_DT exchange_NN ratio_NN used_VBN in_IN the_DT exchange_NN offers_VBZ used_VBN to_TO effect_VB the_DT AstraZeneca_NNP merger_NN ._.
The_DT ratio_NN of_IN AstraZeneca_NNP options_NNS granted_VBN in_IN respect_NN of_IN former_JJ Astra_NNP options_NNS was_VBD 0.5045_CD AstraZeneca_NNP options_NNS for_IN each_DT Astra_NNP option_NN held_VBD and_CC the_DT table_NN shown_VBN on_IN page_NN 100_CD has_VBZ been_VBN restated_VBN throughout_IN accordingly_RB ._.
4_CD Summary_NNP of_IN the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Scheme_NNP Eligibility_NNP UK_NNP resident_NN employees_NNS of_IN participating_VBG AstraZeneca_NNP companies_NNS are_VBP automatically_RB eligible_JJ to_TO participate_VB ._.
Grant_NNP of_IN options_NNS Invitations_NNS to_TO apply_VB for_IN options_NNS may_MD be_VB issued_VBN within_IN six_CD weeks_NNS after_IN the_DT announcement_NN by_IN the_DT Company_NN of_IN its_PRP$ results_NNS for_IN any_DT period_NN and_CC at_IN other_JJ times_NNS in_IN circumstances_NNS considered_VBN to_TO be_VB exceptional_JJ by_IN the_DT Directors_NNS ._.
No_DT invitations_NNS may_MD be_VB issued_VBN later_RB than_IN 10_CD years_NNS after_IN the_DT approval_NN of_IN the_DT scheme_NN by_IN shareholders_NNS ._.
Options_NNS may_MD only_RB be_VB granted_VBN to_TO employees_NNS who_WP enter_VBP into_IN UK_NNP Inland_NNP Revenue_NN approved_VBD savings_NNS contracts_NNS with_IN the_DT savings_NNS body_NN nominated_VBN by_IN the_DT Company_NN ,_, under_IN which_WDT monthly_JJ savings_NNS of_IN a_DT fixed_VBN amount_NN currently_RB not_RB less_JJR than_IN 5_CD nor_CC more_JJR than_IN 250_CD are_VBP made_VBN over_RP a_DT period_NN of_IN three_CD or_CC five_CD years_NNS ._.
The_DT number_NN of_IN shares_NNS over_IN which_WDT an_DT option_NN is_VBZ granted_VBN will_MD be_VB such_JJ that_IN the_DT total_JJ amount_NN payable_JJ on_IN its_PRP$ exercise_NN will_MD be_VB the_DT proceeds_NNS on_IN maturity_NN of_IN the_DT related_JJ savings_NNS contract_NN ._.
No_DT payment_NN will_MD be_VB required_VBN for_IN the_DT grant_NN of_IN an_DT option_NN ._.
Individual_JJ participation_NN Monthly_JJ savings_NNS by_IN an_DT employee_NN under_IN all_DT savings_NNS contracts_NNS linked_VBN to_TO options_NNS granted_VBN under_IN any_DT SAYE_NNP scheme_NN may_MD not_RB exceed_VB 250_CD or_CC such_JJ lower_JJR amounts_NNS as_IN may_MD be_VB determined_VBN by_IN the_DT Directors_NNS ._.
com_NN 99_CD 33_CD Employee_NN costs_NNS and_CC share_NN option_NN plans_NNS for_IN employees_NNS continued_VBD Acquisition_NNP price_NN The_DT price_NN per_IN Ordinary_NNP Share_NNP payable_JJ upon_IN the_DT exercise_NN of_IN an_DT option_NN will_MD not_RB normally_RB be_VB less_JJR than_IN the_DT higher_JJR of_IN :_: a_DT 90_CD %_NN of_IN the_DT arithmetical_JJ average_NN of_IN the_DT middle-market_JJ quotations_NNS for_IN an_DT Ordinary_NNP Share_NN on_IN the_DT London_NNP Stock_NNP Exchange_NNP on_IN three_CD consecutive_JJ dealing_VBG days_NNS shortly_RB before_IN the_DT date_NN on_IN which_WDT invitations_NNS to_TO apply_VB for_IN options_NNS are_VBP issued_VBN provided_VBN that_IN no_DT such_JJ day_NN may_MD fall_VB before_IN the_DT Company_NN last_JJ announced_VBD its_PRP$ results_NNS for_IN any_DT period_NN or_CC such_JJ other_JJ dealing_VBG day_NN or_CC days_NNS falling_VBG within_IN the_DT six_CD week_NN period_NN for_IN the_DT issue_NN of_IN invitations_NNS as_IN the_DT Directors_NNS may_MD decide_VB :_: and_CC b_NN the_DT nominal_JJ value_NN of_IN an_DT Ordinary_NNP Share_NN unless_IN the_DT option_NN is_VBZ expressed_VBN to_TO relate_VB only_RB to_TO existing_VBG shares_NNS ._.
Exercise_NN of_IN options_NNS An_DT option_NN will_MD normally_RB be_VB exercisable_JJ only_RB for_IN six_CD months_NNS commencing_VBG on_IN the_DT third_JJ or_CC fifth_JJ anniversary_NN of_IN the_DT commencement_NN of_IN the_DT related_JJ savings_NNS contract_NN ._.
Options_NNS normally_RB lapse_NN on_IN cessation_NN of_IN employment_NN ._.
Exercise_NN is_VBZ ,_, however_RB ,_, permitted_VBD for_IN a_DT limited_JJ period_NN irrespective_RB of_IN the_DT period_NN during_IN which_WDT the_DT option_NN has_VBZ been_VBN held_VBN following_VBG cessation_NN of_IN employment_NN in_IN certain_JJ compassionate_JJ circumstances_NNS or_CC where_WRB an_DT option_NN has_VBZ been_VBN held_VBN for_IN more_JJR than_IN three_CD years_NNS except_IN on_IN dismissal_NN for_IN misconduct_NN and_CC on_IN an_DT amalgamation_NN ,_, take-over_NN or_CC winding-up_NN of_IN the_DT Company_NN ._.
AstraZeneca_NNP has_VBZ chosen_VBN to_TO avail_NN itself_PRP of_IN the_DT exemption_NN to_TO application_NN of_IN UITF17_NNP revised_VBD to_TO its_PRP$ SAYE_NNP scheme_NN ._.
5_CD Summary_NNP of_IN the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NNP Eligibility_NNP Any_DT AstraZeneca_NNP employee_NN may_MD be_VB recommended_VBN from_IN time_NN to_TO time_NN for_IN the_DT grant_NN of_IN an_DT option_NN ._.
The_DT Remuneration_NNP Committee_NNP sets_VBZ the_DT policy_NN for_IN the_DT Companys_NNP operation_NN of_IN the_DT plan_NN including_VBG as_IN regards_VBZ which_WDT employees_NNS will_MD be_VB eligible_JJ to_TO participate_VB ._.
Grant_NNP of_IN options_NNS Options_NNS may_MD be_VB granted_VBN at_IN any_DT time_NN other_JJ than_IN during_IN a_DT close_JJ period_NN ._.
No_DT options_NNS may_MD be_VB granted_VBN after_IN the_DT fifth_JJ anniversary_NN of_IN the_DT approval_NN of_IN the_DT plan_NN by_IN shareholders_NNS until_IN the_DT Remuneration_NNP Committee_NNP has_VBZ reviewed_VBN the_DT plan_NN ._.
The_DT grant_NN of_IN options_NNS is_VBZ supervised_VBN by_IN the_DT Remuneration_NNP Committee_NNP which_WDT is_VBZ comprised_VBN wholly_RB of_IN Non-Executive_JJ Directors_NNS ._.
No_DT payment_NN is_VBZ required_VBN for_IN the_DT grant_NN of_IN an_DT option_NN ._.
Options_NNS may_MD be_VB granted_VBN over_IN Ordinary_NNP Shares_NNP in_IN AstraZeneca_NNP PLC_NNP or_CC over_IN the_DT Companys_NNPS ADSs_NNPS ._.
Acquisition_NNP price_NN The_DT price_NN per_IN Ordinary_NNP Share_NNP payable_JJ upon_IN the_DT exercise_NN of_IN an_DT option_NN will_MD not_RB be_VB less_JJR than_IN an_DT amount_NN equal_JJ to_TO the_DT average_NN of_IN the_DT middle-market_JJ closing_NN price_NN on_IN the_DT date_NN of_IN grant_NN for_IN an_DT Ordinary_NNP Share_NN of_IN the_DT Company_NN on_IN the_DT London_NNP Stock_NNP Exchange_NNP on_IN the_DT three_CD consecutive_JJ dealing_VBG days_NNS immediately_RB before_IN the_DT date_NN of_IN grant_NN or_CC as_IN otherwise_RB agreed_VBN with_IN the_DT Inland_NNP Revenue_NN ._.
Where_WRB the_DT option_NN is_VBZ an_DT option_NN to_TO subscribe_VB ,_, the_DT price_NN payable_JJ upon_IN exercise_NN can_MD not_RB be_VB less_JJR than_IN the_DT nominal_JJ value_NN of_IN an_DT Ordinary_NNP Share_NN of_IN the_DT Company_NN ._.
Exercise_NN of_IN options_NNS An_DT option_NN will_MD normally_RB be_VB exercisable_JJ between_IN three_CD and_CC 10_CD years_NNS following_VBG its_PRP$ grant_NN provided_VBD any_DT relevant_JJ performance_NN condition_NN has_VBZ been_VBN satisfied_VBN ._.
The_DT Remuneration_NNP Committee_NNP sets_VBZ the_DT policy_NN for_IN the_DT Companys_NNP operation_NN of_IN the_DT plan_NN including_VBG as_IN regards_VBZ whether_IN any_DT performance_NN target_NN s_PRP will_MD apply_VB to_TO the_DT grant_NN and_CC or_CC exercise_NN of_IN each_DT eligible_JJ employees_NNS option_NN ._.
Exercise_NN is_VBZ ,_, however_RB ,_, permitted_VBD for_IN a_DT limited_JJ period_NN following_VBG cessation_NN of_IN employment_NN either_CC for_IN reasons_NNS of_IN injury_NN or_CC disability_NN ,_, redundancy_NN or_CC retirement_NN ,_, or_CC at_IN the_DT discretion_NN of_IN the_DT Remuneration_NNP Committee_NNP ,_, and_CC on_IN an_DT amalgamation_NN ,_, take-over_NN or_CC winding-up_NN of_IN the_DT Company_NN ._.
com_NN 100_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 33_CD Employee_NN costs_NNS and_CC share_NN option_NN plans_NNS for_IN employees_NNS continued_VBD AstraZeneca_NNP Share_NNP Option_NN Plan_NN 1994_CD Scheme_NNP SAYE_NNP Scheme_NNP ASVIP_NNP Shares_NNP under_IN Options_NNPS WAEP_NNP Options_NNPS WAEP_NNP Options_NNPS WAEP_NNP option_NN WAEP_NNP 000_CD pence_NN 000_CD pence_NN 000_CD pence_NN 000_CD SEK_NNP At_IN 1_CD January_NNP 2000_CD Options_NNPS outstanding_JJ Nil_NNP Nil_NNP 3,001_CD 1934_CD 4,388_CD 1708_CD 1,249_CD 361_CD Movements_NNS during_IN 2000_CD Options_NNS granted_VBN 712_CD 3093_CD 8,885_CD 2714 723 2806_CD Nil_NNP Options_NNPS exercised_VBD Nil_NNP Nil_NNP 800_CD 1525_CD 1,078_CD 1117 159 303_CD Options_NNS forfeited_VBD Nil_NNP Nil_NNP 99 2675 207 1843_CD Nil_NNP Options_NNPS lapsed_VBD Nil_NNP Nil_NNP Nil_NNP Nil_NNP Nil_NNP Weighted_NNP average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN during_IN the_DT year_NN 809 712 396_CD At_IN 31_CD December_NNP 2000_CD Options_NNPS outstanding_JJ 712_CD 3093_CD 10,987_CD 2588_CD 3,826_CD 2074_CD 1,090_CD 370_CD Movements_NNS during_IN 2001_CD Options_NNS granted_VBN 10,984_CD 3245 649 2971_CD Options_NNS exercised_VBN 1_CD 3093 592 1687_CD 1,125_CD 1583 117 328_CD Options_NNS forfeited_VBD 296 3231 457 2709_CD 551_CD 2181_CD 8_CD 306_CD Options_NNS lapsed_VBD Weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN during_IN the_DT year_NN 653_CD 495_CD At_IN 31_CD December_NNP 2001_CD Options_NNPS outstanding_JJ 11,399_CD 3236_CD 9,938_CD 2636_CD 2,799_CD 2459 965 375_CD Movements_NNS during_IN 2002_CD Options_NNS granted_VBN 10,658_CD 3462_CD 2,721_CD 1756_CD Options_NNS exercised_VBN 22 3214 243 2175_CD 469 1888 206 317_CD Options_NNS forfeited_VBD 637 3298 406 2654_CD 986_CD 2735_CD Options_NNS lapsed_VBD Weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN during_IN the_DT year_NN 1186_CD 559_CD At_IN 31_CD December_NNP 2002_CD Options_NNPS outstanding_JJ 21,398_CD 3347_CD 9,289_CD 2647_CD 4,065_CD 1987 759 391_CD Range_NNP of_IN exercise_NN prices_NNS 1913p_VBP to_TO 826p_VB to_TO 1756p_VB to_TO 298SEK_CD to_TO 3487p_CD 2749p_CD 2971p_JJ 442SEK_NNP Weighted_NNP average_JJ remaining_VBG contractual_JJ life_NN 3,183_CD days_NNS 2,542_CD days_NNS 1,439_CD days_NNS 746_CD days_NNS Options_NNPS exercisable_JJ 351 3303 1786 2367_CD 130 2070 759 391_CD Weighted_NNP Average_NNP Exercise_NNP Price_NNP In_IN addition_NN to_TO the_DT schemes_NNS disclosed_VBN above_IN at_IN 31_CD December_NNP 2002_CD there_EX were_VBD 5,000_CD options_NNS outstanding_JJ issued_VBN under_IN the_DT Zeneca_NNP 1993_CD Senior_JJ Staff_NN Share_NN Option_NN Scheme_NN with_IN a_DT weighted_JJ average_JJ exercise_NN price_NN of_IN 717p_CD ._.
com_NN 101_CD 34_CD Assets_NNS pledged_VBN ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS 2002 2001 2000_CD $_$ m_CD $_$ m_CD $_$ m_CD Assets_NNPS pledged_VBD Mortgages_NNS and_CC other_JJ assets_NNS pledged_VBD 90_CD 118_CD 51_CD Commitments_NNS Contracts_NNS placed_VBN for_IN future_JJ capital_NN expenditure_NN not_RB provided_VBN for_IN in_IN these_DT accounts_NNS 500 515 604_CD Included_VBN in_IN the_DT above_JJ total_NN are_VBP contracts_NNS related_VBN to_TO certain_JJ product_NN purchase_NN and_CC licence_NN agreements_NNS with_IN deferred_JJ consideration_NN obligations_NNS ,_, the_DT amounts_NNS of_IN which_WDT are_VBP variable_JJ depending_VBG upon_IN particular_JJ milestone_NN achievements_NNS ._.
Sales_NNS of_IN the_DT products_NNS to_TO which_WDT these_DT milestones_NNS relate_VBP could_MD give_VB rise_VB to_TO additional_JJ payments_NNS ,_, contingent_NN upon_IN the_DT sales_NNS levels_NNS achieved_VBN ._.
Guarantees_NNS and_CC contingencies_NNS arising_VBG in_IN the_DT ordinary_JJ course_NN of_IN business_NN ,_, for_IN which_WDT no_DT security_NN has_VBZ been_VBN given_VBN ,_, are_VBP not_RB expected_VBN to_TO result_VB in_IN any_DT material_NN financial_JJ loss_NN ._.
Commitments_NNS AstraZeneca_NNP is_VBZ required_VBN to_TO pay_VB approximately_RB $_$ 800m_CD over_IN at_IN least_JJS a_DT five-year_JJ period_NN which_WDT commenced_VBD in_IN 1999_CD ,_, under_IN the_DT terms_NNS of_IN an_DT agreement_NN with_IN Schering-Plough_NNP ._.
With_IN effect_NN from_IN 1_CD January_NNP 1999_CD ,_, in_IN connection_NN with_IN this_DT agreement_NN ,_, AstraZeneca_NNP obtained_VBD a_DT stand-by_JJ letter_NN of_IN credit_NN in_IN the_DT amount_NN of_IN $_$ 608m_CD ._.
This_DT letter_NN of_IN credit_NN is_VBZ collateralised_VBN by_IN high-grade_JJ government_NN securities_NNS which_WDT are_VBP not_RB available_JJ to_TO AstraZeneca_NNP to_TO the_DT extent_NN of_IN the_DT outstanding_JJ balance_NN of_IN the_DT letter_NN of_IN credit_NN ._.
The_DT amount_NN outstanding_JJ under_IN the_DT letter_NN of_IN credit_NN is_VBZ automatically_RB reduced_VBN with_IN each_DT payment_NN made_VBN by_IN AstraZeneca_NNP to_TO Schering-Plough_NNP ._.
Under_IN the_DT terms_NNS of_IN this_DT agreement_NN AstraZeneca_NNP reacquired_VBD the_DT rights_NNS to_TO market_NN omeprazole_NN under_IN the_DT Losec_NNP trade_NN mark_NN and_CC felodipine_NN under_IN the_DT Prevex_NNP and_CC Perfudal_NNP trade_NN marks_NNS in_IN Italy_NNP and_CC Spain_NNP ._.
The_DT total_JJ discounted_JJ liability_NN and_CC associated_VBN asset_NN were_VBD recognized_VBN in_IN 1999_CD ._.
Payments_NNS under_IN this_DT agreement_NN in_IN 2002_CD totalled_VBD approximately_RB $_$ 146m_CD ._.
The_DT final_JJ payment_NN will_MD be_VB made_VBN in_IN 2003_CD ._.
In_IN 1998_CD ,_, Astra_NNP and_CC Merck_NNP &_CC Co._NNP ._.
Inc_NNP restructured_VBD their_PRP$ joint_JJ venture_NN the_DT restructuring_NN which_WDT had_VBD been_VBN established_VBN some_DT years_NNS earlier_RBR for_IN the_DT purpose_NN of_IN selling_NN and_CC marketing_NN certain_JJ Astra_NNP products_NNS in_IN the_DT US_NNP ._.
Under_IN the_DT terms_NNS of_IN the_DT 1998_CD restructuring_NN ,_, the_DT merger_NN between_IN Astra_NNP and_CC Zeneca_NNP in_IN 1999_CD triggered_VBD two_CD one-time_JJ payments_NNS from_IN AstraZeneca_NNP to_TO Merck_NNP :_: a_DT Lump_NNP Sum_NNP Payment_NN of_IN $_$ 809m_CD ,_, which_WDT was_VBD charged_VBN to_TO profit_VB and_CC loss_NN account_NN ,_, as_IN a_DT result_NN of_IN which_WDT Merck_NNP relinquished_VBD any_DT rights_NNS to_TO Zeneca_NNP products_NNS :_: and_CC an_DT Advance_NNP Payment_NN of_IN $_$ 967m_CD ._.
This_DT Advance_NNP Payment_NN was_VBD calculated_VBN as_IN the_DT then_RB net_JJ present_JJ value_NN of_IN $_$ 2.8_CD bn_NN discounted_VBN from_IN 2008_CD to_TO the_DT date_NN of_IN payment_NN at_IN a_DT rate_NN of_IN 13_CD %_NN per_IN annum_NN and_CC led_VBD Merck_NNP to_TO relinquish_VB any_DT rights_NNS to_TO future_JJ Astra_NNP products_NNS with_IN no_DT existing_VBG or_CC pending_VBG US_NNP patents_NNS at_IN the_DT time_NN of_IN the_DT merger_NN ._.
AstraZeneca_NNP makes_VBZ ongoing_JJ payments_NNS to_TO Merck_NNP based_VBN on_IN sales_NNS of_IN certain_JJ AstraZeneca_NNP products_NNS in_IN the_DT US_NNP the_DT contingent_JJ payments_NNS on_IN the_DT agreement_NN products_NNS as_RB well_RB as_IN certain_JJ other_JJ partnership_NN distributions_NNS ,_, the_DT latter_NN of_IN which_WDT are_VBP not_RB material_JJ to_TO the_DT Group_NNP ._.
As_IN a_DT result_NN of_IN the_DT 1999_CD merger_NN ,_, these_DT contingent_JJ payments_NNS excluding_VBG those_DT in_IN respect_NN of_IN Prilosec_NNP and_CC Nexium_NNP are_VBP subject_JJ to_TO defined_VBN minimum_JJ amounts_NNS ranging_VBG from_IN $_$ 125m_CD to_TO $_$ 225m_CD between_IN 2002_CD and_CC 2007_CD ._.
Payments_NNS under_IN these_DT arrangements_NNS have_VBP exceeded_VBN the_DT minimum_JJ level_NN in_IN 2002_CD ._.
The_DT terms_NNS of_IN the_DT 1998_CD restructuring_NN also_RB provide_VB for_IN the_DT following_VBG events_NNS :_: Partial_NNP Redemption_NNP First_NNP Option_NN Second_JJ Option_NN Partial_NNP Redemption_NNP In_IN 2008_CD ,_, there_EX will_MD be_VB a_DT partial_JJ redemption_NN of_IN Mercks_NNP limited_JJ partnership_NN interest_NN which_WDT will_MD end_VB Mercks_NNP rights_NNS to_TO contingent_JJ payments_NNS in_IN respect_NN of_IN certain_JJ of_IN the_DT agreement_NN products_NNS by_IN distribution_NN to_TO Merck_NNP of_IN an_DT amount_NN calculated_VBN as_IN a_DT multiple_NN of_IN the_DT previous_JJ three_CD years_NNS contingent_JJ payments_NNS on_IN the_DT relevant_JJ products_NNS ,_, plus_CC $_$ 750m_CD ._.
First_NNP Option_NN In_IN 2008_CD a_DT calculation_NN will_MD be_VB made_VBN of_IN the_DT Appraised_NNP Value_NNP ,_, being_VBG the_DT net_JJ present_JJ value_NN of_IN the_DT future_JJ contingent_JJ payments_NNS in_IN respect_NN of_IN all_DT other_JJ agreement_NN products_NNS not_RB covered_VBN by_IN the_DT Partial_NNP Redemption_NNP other_JJ than_IN Prilosec_NNP and_CC Nexium_NNP ._.
Payment_NN of_IN this_DT amount_NN to_TO Merck_NNP in_IN 2008_CD is_VBZ ,_, however_RB ,_, contingent_NN on_IN Mercks_NNP exercise_NN of_IN the_DT First_NNP Option_NN ._.
Exercise_NN of_IN the_DT First_NNP Option_NN will_MD require_VB AstraZeneca_NNP to_TO re-purchase_VB Mercks_NNPS interest_NN in_IN these_DT products_NNS ._.
Should_MD Merck_NNP not_RB exercise_VB this_DT option_NN in_IN 2008_CD ,_, AstraZeneca_NNP may_MD exercise_VB it_PRP in_IN 2010_CD for_IN a_DT sum_NN equal_JJ to_TO the_DT 2008_CD Appraised_NNP Value_NNP ._.
If_IN neither_DT Merck_NNP nor_CC AstraZeneca_NNP exercise_VBP the_DT option_NN ,_, the_DT contingent_JJ payment_NN arrangements_NNS in_IN respect_NN of_IN these_DT agreement_NN products_NNS will_MD continue_VB and_CC the_DT Appraised_NNP Value_NNP will_MD not_RB be_VB paid_VBN ._.
com_NN 102_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 34_CD Assets_NNS pledged_VBN ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS continued_VBD In_IN addition_NN ,_, in_IN 2008_CD there_EX will_MD be_VB a_DT true_JJ up_RB of_IN the_DT Advance_NNP Payment_NN ._.
The_DT calculation_NN of_IN this_DT will_MD be_VB based_VBN on_IN a_DT multiple_NN of_IN the_DT previous_JJ three_CD years_NNS contingent_JJ payments_NNS in_IN respect_NN of_IN all_PDT the_DT agreement_NN products_NNS with_IN the_DT exception_NN of_IN Prilosec_NNP and_CC Nexium_NNP ,_, plus_CC other_JJ defined_VBN amounts_NNS ,_, which_WDT are_VBP then_RB reduced_VBN by_IN the_DT Appraised_NNP Value_NNP whether_IN paid_VBN or_CC not_RB ,_, the_DT Partial_NNP Redemption_NNP and_CC the_DT Advance_NNP Payment_NN ._.
This_DT could_MD result_VB in_IN a_DT further_JJ payment_NN by_IN AstraZeneca_NNP to_TO Merck_NNP or_CC a_DT payment_NN by_IN Merck_NNP to_TO AstraZeneca_NNP ._.
The_DT precise_JJ amount_NN of_IN settlements_NNS with_IN Merck_NNP under_IN the_DT Partial_NNP Redemption_NNP and_CC the_DT First_NNP Option_NN can_MD not_RB be_VB determined_VBN at_IN this_DT time_NN ,_, as_IN some_DT of_IN the_DT payments_NNS are_VBP based_VBN on_IN calculations_NNS based_VBN on_IN sales_NNS between_IN 2005_CD and_CC 2007_CD ,_, and_CC another_DT is_VBZ contingent_JJ upon_IN Merck_NNP exercising_VBG the_DT First_NNP Option_NN ._.
However_RB ,_, if_IN Merck_NNP does_VBZ exercise_VB this_DT option_NN ,_, the_DT combined_VBN effect_NN will_MD involve_VB a_DT minimum_NN amount_NN payable_JJ to_TO Merck_NNP in_IN 2008_CD of_IN approximately_RB $_$ 4.7_CD bn_NN ._.
If_IN AstraZeneca_NNP exercises_VBZ this_DT option_NN in_IN 2010_CD ,_, the_DT combined_VBN effect_NN will_MD involve_VB a_DT minimum_JJ aggregate_JJ payable_JJ to_TO Merck_NNP in_IN 2008_CD and_CC 2010_CD of_IN approximately_RB $_$ 4.7_CD bn_NN ._.
Finally_RB ,_, in_IN 2008_CD Merck_NNP will_MD repay_VB to_TO AstraZeneca_NNP a_DT loan_NN in_IN the_DT amount_NN of_IN $_$ 1.4_CD bn_NN made_VBN at_IN the_DT time_NN of_IN the_DT restructuring_NN ._.
Second_JJ Option_NN A_DT Second_JJ Option_NN exists_VBZ whereby_WRB AstraZeneca_NNP has_VBZ the_DT option_NN to_TO re-purchase_VB Mercks_NNP interests_NNS in_IN Prilosec_NNP and_CC Nexium_NNP in_IN the_DT US_NNP ._.
This_DT option_NN is_VBZ exercisable_JJ by_IN AstraZeneca_NNP two_CD years_NNS after_IN the_DT exercise_NN of_IN the_DT First_NNP Option_NN in_IN either_CC 2008_CD or_CC 2010_CD ._.
Exercise_NN of_IN the_DT Second_JJ Option_NN by_IN AstraZeneca_NNP at_IN a_DT later_JJ date_NN is_VBZ also_RB provided_VBN for_IN in_IN 2017_CD or_CC if_IN combined_VBN annual_JJ sales_NNS of_IN the_DT two_CD products_NNS fall_VBP below_IN a_DT minimum_JJ amount_NN provided_VBN ,_, in_IN each_DT case_NN only_RB so_RB long_RB as_IN the_DT First_NNP Option_NN has_VBZ been_VBN exercised_VBN ._.
The_DT exercise_NN price_NN for_IN the_DT Second_JJ Option_NN is_VBZ the_DT fair_JJ value_NN of_IN these_DT product_NN rights_NNS as_IN determined_VBN at_IN the_DT time_NN of_IN exercise_NN ._.
If_IN the_DT Second_JJ Option_NN is_VBZ exercised_VBN ,_, Merck_NNP will_MD have_VB no_DT further_JJ rights_NNS to_TO contingent_JJ payments_NNS from_IN AstraZeneca_NNP ._.
Environmental_JJ costs_NNS and_CC liabilities_NNS The_DT Groups_NNS expenditure_NN on_IN environmental_JJ protection_NN ,_, including_VBG both_DT capital_NN and_CC revenue_NN items_NNS ,_, relates_VBZ to_TO costs_NNS which_WDT are_VBP necessary_JJ for_IN meeting_VBG current_JJ good_JJ practice_NN standards_NNS and_CC regulatory_JJ requirements_NNS for_IN processes_NNS and_CC products_NNS ._.
They_PRP are_VBP an_DT integral_JJ part_NN of_IN normal_JJ ongoing_JJ expenditure_NN for_IN maintaining_VBG the_DT Groups_NNS manufacturing_VBG capacity_NN and_CC product_NN ranges_NNS and_CC are_VBP not_RB separated_VBN from_IN overall_JJ operating_NN and_CC development_NN costs_NNS ._.
There_EX are_VBP no_DT known_VBN changes_NNS in_IN environmental_JJ ,_, regulatory_JJ or_CC other_JJ requirements_NNS resulting_VBG in_IN material_NN changes_NNS to_TO the_DT levels_NNS of_IN expenditure_NN for_IN 2000_CD ,_, 2001_CD or_CC 2002_CD ._.
In_IN addition_NN to_TO expenditure_NN for_IN meeting_NN current_JJ and_CC foreseen_VBN environmental_JJ protection_NN requirements_NNS ,_, the_DT Group_NNP incurs_VBZ substantial_JJ costs_NNS in_IN investigating_VBG and_CC cleaning_VBG up_RP land_NN and_CC groundwater_NN contamination_NN ._.
In_IN particular_JJ ,_, AstraZeneca_NNP has_VBZ environmental_JJ liabilities_NNS at_IN some_DT currently_RB or_CC formerly_RB owned_VBN ,_, leased_VBN and_CC third_JJ party_NN sites_NNS in_IN the_DT US_NNP and_CC Europe_NNP ._.
AstraZeneca_NNP ,_, or_CC its_PRP$ indemnitees_NNS ,_, have_VBP been_VBN named_VBN under_IN US_NNP legislation_NN the_DT Comprehensive_NNP Environmental_NNP Response_NNP ,_, Compensation_NNP and_CC Liability_NNP Act_NNP of_IN 1980_CD ,_, as_IN amended_VBN as_IN potentially_RB responsible_JJ parties_NNS PRP_NNP in_IN respect_NN of_IN 32_CD sites_NNS although_IN AstraZeneca_NNP expects_VBZ to_TO be_VB indemnified_VBN against_IN liabilities_NNS associated_VBN with_IN nine_CD of_IN these_DT sites_NNS by_IN the_DT seller_NN or_CC owner_NN of_IN the_DT businesses_NNS associated_VBN with_IN such_JJ sites_NNS and_CC ,_, where_WRB appropriate_JJ ,_, actively_RB participates_VBZ in_IN or_CC monitors_VBZ the_DT clean-up_JJ activities_NNS at_IN sites_NNS in_IN respect_NN of_IN which_WDT it_PRP is_VBZ a_DT PRP_NNP ._.
Stauffer_NNP Management_NNP Company_NNP ,_, a_DT subsidiary_NN of_IN AstraZeneca_NNP established_VBN in_IN 1987_CD to_TO own_VB and_CC manage_VB certain_JJ assets_NNS of_IN Stauffer_NNP Chemical_NNP Company_NNP which_WDT was_VBD acquired_VBN that_DT year_NN ,_, has_VBZ identified_VBN 28_CD sites_NNS including_VBG 18_CD for_IN which_WDT an_DT AstraZeneca_NNP indemnitee_NN has_VBZ been_VBN named_VBN a_DT PRP_NNP for_IN which_WDT it_PRP may_MD have_VB responsibility_NN that_WDT will_MD ,_, in_IN aggregate_NN ,_, require_VBP significant_JJ expenditure_NN on_IN clean-up_JJ and_CC monitoring_NN ._.
Liabilities_NNS are_VBP generally_RB more_RBR likely_JJ to_TO crystallise_VB where_WRB a_DT contaminated_VBN site_NN is_VBZ to_TO be_VB sold_VBN ,_, its_PRP$ use_NN changed_VBD or_CC where_WRB a_DT regulatory_JJ authority_NN imposes_VBZ a_DT particular_JJ remedial_JJ measure_NN ._.
Costs_NNS of_IN these_DT liabilities_NNS may_MD be_VB offset_VBN by_IN amounts_NNS recovered_VBD from_IN third_JJ parties_NNS ,_, such_JJ as_IN previous_JJ owners_NNS of_IN the_DT sites_NNS in_IN question_NN or_CC through_IN insurance_NN ._.
The_DT future_JJ level_NN of_IN investigation_NN and_CC clean_VB up_RP costs_NNS will_MD depend_VB on_IN a_DT number_NN of_IN factors_NNS ,_, including_VBG the_DT nature_NN and_CC extent_NN of_IN any_DT contamination_NN that_WDT may_MD ultimately_RB be_VB found_VBN to_TO exist_VB ,_, the_DT need_NN for_IN and_CC type_NN of_IN any_DT remedial_JJ work_NN to_TO be_VB undertaken_VBN and_CC the_DT standards_NNS required_VBN by_IN applicable_JJ current_JJ and_CC future_JJ environmental_JJ laws_NNS and_CC regulations_NNS and_CC the_DT number_NN and_CC financial_JJ viability_NN of_IN other_JJ PRPs_NNS ._.
The_DT relative_JJ importance_NN of_IN these_DT factors_NNS varies_VBZ significantly_RB from_IN site_NN to_TO site_NN ._.
Many_JJ sites_NNS are_VBP at_IN different_JJ stages_NNS in_IN the_DT regulatory_JJ process_NN or_CC at_IN different_JJ stages_NNS in_IN the_DT process_NN of_IN evaluating_VBG environmental_JJ damage_NN or_CC alternative_NN remediation_NN methods_NNS ._.
It_PRP is_VBZ therefore_RB difficult_JJ to_TO form_VB meaningful_JJ ranges_NNS of_IN estimates_NNS for_IN such_JJ costs_NNS ._.
AstraZeneca_NNP had_VBD provisions_NNS at_IN 31_CD December_NNP 2002_CD in_IN respect_NN of_IN such_JJ costs_NNS in_IN accordance_NN with_IN the_DT accounting_NN policies_NNS on_IN page_NN 64_CD ._.
Although_IN there_EX can_MD be_VB no_DT assurance_NN ,_, management_NN believes_VBZ that_IN ,_, taking_VBG account_NN of_IN these_DT provisions_NNS ,_, the_DT costs_NNS of_IN addressing_VBG currently_RB identified_VBN environmental_JJ obligations_NNS ,_, as_IN AstraZeneca_NNP currently_RB views_VBZ those_DT obligations_NNS ,_, is_VBZ unlikely_JJ to_TO impair_VB materially_RB AstraZenecas_NNP financial_JJ position_NN ._.
Such_JJ contingent_NN costs_NNS ,_, to_TO the_DT extent_NN that_IN they_PRP exceed_VBP applicable_JJ provisions_NNS ,_, could_MD have_VB a_DT material_NN adverse_JJ effect_NN on_IN AstraZenecas_NNP results_NNS of_IN operations_NNS for_IN the_DT relevant_JJ period_NN ._.
com_NN 103_CD Legal_NNP proceedings_NNS Losec_NNP Prilosec_NNP omeprazole_NN In_IN June_NNP 1997_CD ,_, the_DT German_NNP Federal_NNP Patent_NNP Court_NNP declared_VBD invalid_JJ a_DT previously_RB granted_VBN supplementary_JJ protection_NN certificate_NN which_WDT extended_VBD protection_NN for_IN omeprazole_NN ,_, the_DT active_JJ ingredient_NN contained_VBN in_IN Losec_NNP ,_, from_IN 1999_CD to_TO 2003_CD ._.
The_DT decision_NN was_VBD appealed_VBN and_CC on_IN 1_CD February_NNP 2000_CD ,_, at_IN AstraZenecas_NNP request_NN ,_, the_DT German_NNP Supreme_NNP Court_NNP decided_VBD to_TO refer_VB the_DT case_NN to_TO the_DT European_NNP Court_NNP of_IN Justice_NNP for_IN a_DT preliminary_JJ ruling_NN ._.
The_DT court_NN heard_VBD the_DT case_NN on_IN 8_CD November_NNP 2001_CD and_CC its_PRP$ decision_NN is_VBZ pending_VBG ._.
The_DT case_NN does_VBZ not_RB involve_VB any_DT financial_JJ claims_NNS ._.
In_IN March_NNP 2000_CD ,_, the_DT German_NNP Federal_NNP Patent_NNP Court_NNP declared_VBD that_IN AstraZenecas_NNP formulation_NN patent_NN for_IN omeprazole_NN was_VBD invalid_JJ ._.
The_DT decision_NN has_VBZ been_VBN appealed_VBN to_TO the_DT German_JJ Supreme_NNP Court_NNP ._.
As_IN a_DT consequence_NN ,_, all_DT pending_VBG infringement_NN actions_NNS in_IN Germany_NNP have_VBP been_VBN stayed_VBN awaiting_VBG the_DT outcome_NN of_IN the_DT appeal_NN ._.
There_EX is_VBZ one_CD interlocutory_NN injunction_NN in_IN force_NN against_IN ratiopharm_JJ GmbH_NNP based_VBN on_IN the_DT formulation_NN patent_NN ._.
If_IN the_DT final_JJ decision_NN on_IN the_DT validity_NN of_IN the_DT formulation_NN patent_NN goes_VBZ against_IN AstraZeneca_NNP ,_, ratiopharm_NN may_MD claim_VB damages_NNS for_IN lost_VBN sales_NNS due_JJ to_TO the_DT interlocutory_JJ injunction_NN ._.
In_IN 1998_CD ,_, Astra_NNP filed_VBD suits_NNS in_IN the_DT US_NNP against_IN Andrx_NNP Pharmaceuticals_NNP ,_, Inc._NNP and_CC Genpharm_NNP ,_, Inc._NNP ._.
This_DT followed_VBD the_DT filing_NN of_IN abbreviated_JJ new_JJ drug_NN applications_NNS by_IN Andrx_NNP and_CC Genpharm_NNP with_IN the_DT US_NNP Food_NNP and_CC Drug_NNP Administration_NNP FDA_NNP concerning_VBG the_DT two_CD companies_NNS intention_NN to_TO market_NN generic_JJ omeprazole_NN products_NNS in_IN the_DT US_NNP ._.
During_IN 1999_CD ,_, Astra_NNP also_RB filed_VBD suits_NNS against_IN Kremers_NNP Urban_NNP Development_NNP Company_NNP and_CC Schwarz_NNP Pharma_NNP ,_, Inc._NNP and_CC against_IN Cheminor_NNP Drugs_NNPS Ltd._NNP ._.
Reddy-Cheminor_NNP Inc._NNP and_CC Schein_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
During_IN 2000_CD ,_, AstraZeneca_NNP filed_VBD further_JJ suits_NNS against_IN Lek_NNP Pharmaceutical_NNP and_CC Chemical_NNP Company_NNP d._FW d_LS ,_, Impax_NNP Laboratories_NNPS Inc._NNP ._.
Eon_NNP Labs_NNPS Manufacturing_NNP Inc._NNP and_CC Mylan_NNP Pharmaceuticals_NNP Inc._NNP ._.
During_IN 2001_CD ,_, AstraZeneca_NNP filed_VBD further_JJ suits_NNS against_IN Torpharm_NNP ,_, Inc._NNP and_CC Zenith_NNP Goldline_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
Ivax_NNP ._.
The_DT basis_NN for_IN the_DT proceedings_NNS is_VBZ that_IN the_DT actions_NNS of_IN all_PDT the_DT companies_NNS infringe_VBP several_JJ patents_NNS relating_VBG to_TO omeprazole_VB Prilosec_NNP in_IN the_DT US_NNP ._.
The_DT cases_NNS are_VBP proceeding_VBG under_IN the_DT US_NNP Hatch-Waxman_NNP legislation_NN ._.
AstraZeneca_NNP filed_VBD additional_JJ patent_NN infringement_NN suits_NNS during_IN 2001_CD against_IN Andrx_NNP and_CC Genpharm_NNP in_IN respect_NN of_IN one_CD other_JJ omeprazole_JJ patent_NN outside_IN the_DT Hatch-Waxman_NNP legislation_NN ._.
The_DT trial_NN against_IN Andrx_NNP ,_, Genpharm_NNP ,_, Kremers_NNP Urban_NNP Development_NNP Company_NNP and_CC Cheminor_NNP started_VBD in_IN December_NNP 2001_CD and_CC ended_VBN in_IN July_NNP 2002_CD ._.
In_IN October_NNP 2002_CD ,_, the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP ruled_VBD that_IN two_CD AstraZeneca_NNP patents_NNS 230_CD and_CC 505_CD relating_VBG to_TO the_DT formulation_NN of_IN omeprazole_NN are_VBP valid_JJ until_IN 2007_CD ,_, that_IN Andrx_NNP ,_, Genpharm_NNP and_CC Cheminor_NNP all_DT infringed_VBN both_DT patents_NNS but_CC that_IN Kremers_NNP Urban_NNP Development_NNP Company_NNP did_VBD not_RB infringe_VB either_DT patent_NN ._.
The_DT court_NN did_VBD not_RB rule_NN on_IN the_DT 281_CD patent_NN relating_VBG to_TO a_DT manufacturing_NN process_NN for_IN omeprazole_JJ formulations_NNS in_IN respect_NN of_IN which_WDT AstraZeneca_NNP has_VBZ sued_VBN Andrx_NNP only_RB ._.
AstraZeneca_NNP has_VBZ appealed_VBN the_DT judgement_NN with_IN regard_NN to_TO non-infringement_JJ and_CC Kremers_NNP Urban_NNP Development_NNP Company_NNP ._.
Andrx_NNP ,_, Genpharm_NNP and_CC Cheminor_NNP have_VBP appealed_VBN the_DT decision_NN with_IN regard_NN to_TO infringement_NN and_CC validity_NN of_IN the_DT patents_NNS ._.
In_IN April_NNP 2001_CD ,_, Andrx_NNP filed_VBD a_DT case_NN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP against_IN AstraZeneca_NNP ,_, Merck_NNP &_CC Co._NNP ._.
Inc._NNP and_CC the_DT FDA_NNP alleging_VBG that_IN the_DT listing_NN of_IN certain_JJ patents_NNS in_IN the_DT FDAs_NNP Orange_NNP Book_NNP was_VBD improper_JJ and_CC constituted_VBD violations_NNS of_IN certain_JJ provisions_NNS of_IN the_DT Sherman_NNP Act_NNP ,_, the_DT US_NNP federal_JJ anti-trust_JJ legislation_NN ,_, and_CC a_DT state_NN statute_NN analogous_JJ to_TO the_DT federal_JJ anti-trust_JJ laws_NNS ._.
Andrx_NNP seeks_VBZ injunctive_JJ relief_NN compelling_JJ the_DT parties_NNS to_TO delist_VB omeprazole-related_JJ patents_NNS it_PRP claims_VBZ were_VBN improperly_RB listed_VBN in_IN the_DT Orange_NNP Book_NNP and_CC prohibiting_VBG the_DT defendants_NNS from_IN using_VBG patents_NNS to_TO delay_VB the_DT effective_JJ date_NN of_IN the_DT FDAs_NNS approval_NN of_IN Andrxs_NNP ANDA_NNP for_IN omeprazole_NN ._.
AstraZeneca_NNP and_CC Merck_NNP have_VBP filed_VBN motions_NNS to_TO dismiss_VB the_DT case_NN ,_, which_WDT are_VBP pending_VBG ._.
AstraZeneca_NNP and_CC Merck_NNP &_CC Co._NNP ._.
Inc._NNP were_VBD named_VBN as_IN defendants_NNS in_IN three_CD class_NN actions_NNS :_: two_CD in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP and_CC one_CD in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP ._.
The_DT plaintiffs_NNS are_VBP consumers_NNS and_CC third_JJ party_NN payers_NNS who_WP have_VBP alleged_VBN that_IN they_PRP and_CC others_NNS who_WP are_VBP similarly_RB situated_VBN have_VBP been_VBN forced_VBN to_TO pay_VB higher_JJR prices_NNS for_IN omeprazole_NN as_IN a_DT result_NN of_IN agreements_NNS that_WDT AstraZeneca_NNP and_CC Merck_NNP entered_VBD into_IN that_DT resulted_VBD in_IN unreasonable_JJ restraints_NNS of_IN trade_NN and_CC competition_NN ._.
Furthermore_RB ,_, the_DT plaintiffs_NNS have_VBP alleged_VBN that_IN AstraZeneca_NNP and_CC Merck_NNP engaged_VBD in_IN conduct_NN designed_VBN to_TO extend_VB their_PRP$ monopoly_NN power_NN beyond_IN the_DT lawful_JJ boundaries_NNS of_IN their_PRP$ patents_NNS ._.
The_DT plaintiffs_NNS are_VBP seeking_VBG declarative_NN ,_, equitable_JJ and_CC injunctive_JJ relief_NN enjoining_VBG AstraZeneca_NNP and_CC Merck_NNP from_IN continuing_VBG their_PRP$ alleged_VBN illegal_JJ activities_NNS ,_, costs_NNS of_IN suit_NN ,_, reasonable_JJ attorneys_NNS fees_NNS and_CC expenses_NNS and_CC any_DT other_JJ relief_NN determined_VBN by_IN the_DT court_NN ._.
AstraZeneca_NNP filed_VBD a_DT motion_NN in_IN March_NNP 2002_CD to_TO dismiss_VB the_DT two_CD class_NN actions_NNS before_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP ,_, which_WDT was_VBD granted_VBN in_IN June_NNP 2002_CD ._.
The_DT plaintiffs_NNS did_VBD not_RB appeal_NN ._.
The_DT plaintiffs_NNS voluntarily_RB dismissed_VBD the_DT New_NNP Jersey_NNP case_NN also_RB in_IN June_NNP 2002_CD ._.
In_IN October_NNP 2000_CD ,_, the_DT Federal_NNP Court_NNP of_IN Australia_NNP Full_NNP Court_NNP handed_VBD down_RP a_DT patent_NN ruling_NN pertaining_VBG to_TO omeprazole_VB in_IN connection_NN with_IN a_DT dispute_NN between_IN AstraZeneca_NNP and_CC the_DT generic_JJ company_NN ,_, Alphapharm_NNP Pty_NNP Ltd._NNP ._.
The_DT court_NN declared_VBD that_IN AstraZenecas_NNP formulation_NN patent_NN was_VBD invalid_JJ ._.
In_IN November_NNP 2001_CD ,_, AstraZeneca_NNP applied_VBD for_IN special_JJ leave_NN to_TO appeal_VB the_DT decision_NN to_TO the_DT High_NNP Court_NNP of_IN Australia_NNP and_CC this_DT application_NN was_VBD granted_VBN in_IN December_NNP 2001_CD ._.
The_DT appeal_NN was_VBD heard_VBN by_IN the_DT High_NNP Court_NNP in_IN May_NNP 2002_CD and_CC in_IN December_NNP 2002_CD the_DT High_NNP Court_NNP reversed_VBD the_DT judgement_NN of_IN the_DT lower_JJR court_NN ._.
The_DT High_NNP Court_NNP ruled_VBD that_IN AstraZenecas_NNP formulation_NN patent_NN is_VBZ valid_JJ and_CC that_IN the_DT case_NN should_MD be_VB returned_VBN to_TO the_DT lower_JJR court_NN for_IN determination_NN of_IN the_DT remaining_VBG issues_NNS ._.
During_IN 2000_CD ,_, AstraZeneca_NNP was_VBD granted_VBN interlocutory_JJ injunctions_NNS based_VBN on_IN certain_JJ of_IN AstraZenecas_NNP omeprazole_NN patents_NNS and_CC supplementary_JJ protection_NN certificates_NNS against_IN the_DT generic_JJ company_NN ,_, Scandinavian_NNP AB_NNP Scand_NNP Pharm_NNP ,_, in_IN Sweden_NNP ,_, Denmark_NNP and_CC Norway_NNP ._.
In_IN October_NNP 2000_CD ,_, the_DT District_NNP Court_NNP of_IN Stockholm_NNP ruled_VBD that_IN Scand_NNP Pharm_NNP had_VBD infringed_VBN one_CD of_IN AstraZenecas_NNP supplementary_JJ protection_NN certificates_NNS for_IN omeprazole_NN ._.
Scand_NNP Pharm_NNP has_VBZ appealed_VBN this_DT decision_NN ._.
In_IN October_NNP 2001_CD ,_, Oslo_NNP City_NNP Court_NNP in_IN Norway_NNP found_VBD that_IN Scand_NNP Pharm_NNP had_VBD infringed_VBN AstraZenecas_NNP formulation_NN patent_NN for_IN omeprazole_NN ._.
At_IN the_DT same_JJ time_NN ,_, the_DT court_NN declared_VBD AstraZenecas_NNP formulation_NN patent_NN valid_JJ ._.
As_IN a_DT result_NN of_IN the_DT Norwegian_JJ case_NN ,_, Scand_NNP Pharm_NNP can_MD not_RB sell_VB its_PRP$ omeprazole_JJ product_NN in_IN Norway_NNP ,_, nor_CC can_MD it_PRP do_VB so_RB in_IN Sweden_NNP or_CC Denmark_NNP pending_VBG the_DT outcome_NN of_IN the_DT main_JJ actions_NNS in_IN the_DT cases_NNS in_IN these_DT countries_NNS ._.
If_IN the_DT final_JJ decisions_NNS in_IN these_DT cases_NNS are_VBP against_IN AstraZeneca_NNP ,_, Scand_NNP Pharm_NNP may_MD claim_VB damages_NNS for_IN lost_VBN sales_NNS due_JJ to_TO the_DT interlocutory_JJ injunctions_NNS ._.
com_NN 104_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 34_CD Assets_NNS pledged_VBN ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS continued_VBD In_IN March_NNP 2002_CD ,_, the_DT Patents_NNP Court_NNP in_IN the_DT UK_NNP handed_VBD down_RP a_DT ruling_NN invalidating_VBG certain_JJ of_IN AstraZenecas_NNP formulation_NN patents_NNS for_IN omeprazole_NN ._.
AstraZeneca_NNP applied_VBD for_IN leave_NN to_TO appeal_VB the_DT decision_NN to_TO the_DT Court_NNP of_IN Appeal_NNP and_CC this_DT application_NN was_VBD granted_VBN ._.
The_DT appeal_NN was_VBD heard_VBN by_IN the_DT Court_NNP of_IN Appeal_NNP in_IN October_NNP 2002_CD and_CC the_DT court_NN affirmed_VBD the_DT original_JJ decision_NN of_IN the_DT Patents_NNP Court_NNP invalidating_VBG the_DT formulation_NN patents_NNS ._.
In_IN the_DT Netherlands_NNP ,_, Pharmachemie_NNP BV_NNP has_VBZ filed_VBN a_DT claim_NN against_IN two_CD AstraZeneca_NNP companies_NNS alleging_VBG that_IN AstraZeneca_NNP has_VBZ misused_VBN its_PRP$ exclusive_JJ rights_NNS in_IN the_DT Netherlands_NNP in_IN relation_NN to_TO the_DT expiration_NN date_NN for_IN AstraZenecas_NNP supplementary_JJ protection_NN certificate_NN for_IN omeprazole_NN ._.
AstraZeneca_NNP denies_VBZ the_DT allegations_NNS and_CC is_VBZ defending_VBG the_DT case_NN ._.
Other_JJ court_NN cases_NNS relating_VBG to_TO omeprazole_VB patents_NNS are_VBP pending_VBG worldwide_NN ._.
However_RB ,_, the_DT financial_JJ impact_NN if_IN AstraZeneca_NNP loses_VBZ is_VBZ not_RB considered_VBN to_TO be_VB material_NN ._.
In_IN February_NNP 2000_CD ,_, the_DT European_JJ Commission_NNP commenced_VBD an_DT investigation_NN relating_VBG to_TO certain_JJ omeprazole_NN intellectual_JJ property_NN rights_NNS ,_, and_CC associated_VBN regulatory_JJ and_CC patent_NN infringement_NN litigation_NN ._.
The_DT investigation_NN is_VBZ pursuant_JJ to_TO Article_NNP 82_CD of_IN the_DT EC_NNP Treaty_NNP ,_, which_WDT prohibits_VBZ an_DT abuse_NN of_IN a_DT dominant_JJ position_NN ._.
The_DT investigation_NN was_VBD precipitated_VBN by_IN a_DT complaint_NN by_IN a_DT party_NN to_TO a_DT number_NN of_IN patent_NN and_CC other_JJ proceedings_NNS involving_VBG AstraZeneca_NNP and_CC relates_VBZ to_TO a_DT limited_JJ number_NN of_IN European_JJ countries_NNS ._.
AstraZeneca_NNP has_VBZ ,_, in_IN accordance_NN with_IN its_PRP$ corporate_JJ policy_NN ,_, co-operated_JJ with_IN the_DT Commission_NNP ._.
AstraZeneca_NNP remains_VBZ of_IN the_DT view_NN that_IN the_DT complaint_NN is_VBZ unfounded_JJ and_CC that_IN it_PRP has_VBZ complied_VBN with_IN all_DT relevant_JJ competition_NN laws_NNS ._.
In_IN particular_JJ ,_, it_PRP considers_VBZ that_IN the_DT matters_NNS raised_VBN by_IN the_DT complaint_NN are_VBP more_RBR properly_RB dealt_VBN with_IN by_IN the_DT courts_NNS in_IN the_DT context_NN of_IN the_DT litigation_NN in_IN which_WDT the_DT complainant_NN is_VBZ involved_VBN ._.
The_DT Commission_NNP has_VBZ recently_RB requested_VBN certain_JJ factual_JJ patent_NN and_CC regulatory_JJ information_NN from_IN AstraZeneca_NNP and_CC AstraZeneca_NNP will_MD continue_VB to_TO co-operate_VB with_IN the_DT Commission_NNP ._.
Zoladex_NNP goserelin_NN acetate_NN implant_VBP investigation_NN The_DT US_NNP Department_NNP of_IN Justice_NNP has_VBZ been_VBN conducting_VBG a_DT civil_JJ and_CC criminal_JJ investigation_NN into_IN the_DT sale_NN and_CC marketing_NN of_IN Zoladex_NNP goserelin_NN acetate_NN implant_VBP ._.
The_DT investigation_NN was_VBD prompted_VBN by_IN the_DT filing_NN of_IN a_DT qui_FW tam_FW complaint_NN by_IN a_DT private_JJ party_NN in_IN 1997_CD and_CC involves_VBZ allegations_NNS of_IN improper_JJ submissions_NNS of_IN claims_NNS to_TO the_DT Medicare_NNP and_CC Medicaid_NNP programs_NNS ._.
Plendil_NNP felodipine_NN In_IN August_NNP 2000_CD ,_, AstraZeneca_NNP LP_NNP received_VBD a_DT letter_NN from_IN Mutual_JJ Pharmaceutical_NNP Co._NNP ._.
Inc._NNP informing_VBG AstraZeneca_NNP of_IN Mutuals_NNP intention_NN to_TO market_VB a_DT generic_JJ version_NN of_IN AstraZenecas_NNP felodipine_NN extended_VBD release_NN tablets_NNS Plendil_NNP prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP patent_NN covering_VBG the_DT extended_JJ release_NN formulation_NN ._.
AstraZeneca_NNP filed_VBD a_DT patent_NN infringement_NN action_NN against_IN Mutual_JJ in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Pennsylvania_NNP ._.
Mutual_JJ responded_VBD and_CC filed_VBD counterclaims_NNS alleging_VBG non-infringement_JJ and_CC invalidity_NN ._.
Expert_NN discovery_NN is_VBZ due_JJ to_TO close_VB in_IN March_NNP 2003_CD ._.
A_DT trial_NN date_NN has_VBZ not_RB yet_RB been_VBN set_VBN ._.
In_IN May_NNP 2001_CD ,_, AstraZeneca_NNP Pharmaceuticals_NNP LP_NNP received_VBD a_DT similar_JJ letter_NN from_IN Zenith_NNP Goldline_NNP Pharmaceuticals_NNP ,_, Inc._NNP and_CC in_IN July_NNP 2001_CD ,_, AstraZeneca_NNP filed_VBD a_DT patent_NN infringement_NN action_NN against_IN Zenith_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP ._.
Zenith_NNP responded_VBD and_CC filed_VBD counterclaims_NNS alleging_VBG non-infringement_JJ ._.
Fact_NN discovery_NN is_VBZ due_JJ to_TO close_VB in_IN May_NNP 2003_CD ._.
Nolvadex_NNP tamoxifen_NN AstraZeneca_NNP is_VBZ a_DT co-defendant_NN with_IN Barr_NNP Laboratories_NNPS ,_, Inc._NNP in_IN numerous_JJ purported_JJ class_NN actions_NNS filed_VBN in_IN federal_JJ and_CC state_NN courts_NNS throughout_IN the_DT US_NNP ._.
All_DT of_IN the_DT state_NN court_NN actions_NNS were_VBD removed_VBN to_TO federal_JJ court_NN and_CC have_VBP been_VBN consolidated_JJ ,_, along_IN with_IN all_DT of_IN the_DT cases_NNS originally_RB filed_VBN in_IN federal_JJ court_NN ,_, in_IN a_DT federal_JJ multi-district_JJ litigation_NN proceeding_VBG pending_VBG in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN New_NNP York_NNP ._.
Some_DT of_IN the_DT cases_NNS were_VBD filed_VBN by_IN plaintiffs_NNS representing_VBG a_DT putative_JJ class_NN of_IN consumers_NNS who_WP purchased_VBD tamoxifen_NN ._.
The_DT other_JJ cases_NNS were_VBD filed_VBN on_IN behalf_NN of_IN a_DT putative_JJ class_NN of_IN third_JJ party_NN payers_NNS including_VBG health_NN maintenance_NN organizations_NNS ,_, insurers_NNS and_CC other_JJ managed_VBN care_NN providers_NNS and_CC health_NN plans_NNS that_WDT have_VBP reimbursed_VBN or_CC otherwise_RB paid_VBN for_IN prescriptions_NNS of_IN tamoxifen_NN ._.
The_DT plaintiffs_NNS allege_VBP that_IN they_PRP paid_VBD supra-competitive_JJ and_CC monopolistic_JJ prices_NNS for_IN tamoxifen_NN as_IN a_DT result_NN of_IN the_DT settlement_NN of_IN patent_NN litigation_NN between_IN Zeneca_NNP and_CC Barr_NNP in_IN 1993_CD ._.
The_DT plaintiffs_NNS seek_VBP injunctive_JJ relief_NN ,_, treble_JJ damages_NNS under_IN the_DT anti-trust_JJ laws_NNS ,_, disgorgement_NN and_CC restitution_NN ._.
In_IN April_NNP 2002_CD ,_, AstraZeneca_NNP filed_VBD a_DT motion_NN to_TO dismiss_VB the_DT cases_NNS for_IN failure_NN to_TO state_VB a_DT cause_NN of_IN action_NN ._.
The_DT courts_NNS decision_NN is_VBZ awaited_VBN ._.
In_IN August_NNP 2002_CD ,_, AstraZenecas_NNP US_NNP distribution_NN agreement_NN with_IN Barr_NNP Laboratories_NNPS ,_, Inc._NNP for_IN non-branded_JJ tamoxifen_NN expired_VBD ,_, as_IN did_VBD AstraZenecas_NNP patent_NN for_IN Nolvadex_NNP tamoxifen_NN ._.
At_IN the_DT same_JJ time_NN ,_, a_DT six_CD month_NN period_NN of_IN market_NN exclusivity_NN ,_, awarded_VBN by_IN the_DT US_NNP Food_NNP and_CC Drug_NNP Administration_NNP in_IN connection_NN with_IN the_DT successful_JJ completion_NN of_IN certain_JJ paediatric_JJ testing_NN with_IN the_DT product_NN ,_, commenced_VBN ._.
Barr_NNP thereafter_RB commenced_VBD litigation_NN against_IN the_DT FDA_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Columbia_NNP ,_, challenging_VBG the_DT FDAs_NNS refusal_NN to_TO grant_VB Barr_NNP final_JJ approval_NN for_IN its_PRP$ own_JJ generic_JJ tamoxifen_NN prior_RB to_TO expiration_NN of_IN AstraZenecas_NNP exclusivity_NN period_NN ._.
Barr_NNP also_RB declined_VBD AstraZenecas_NNP offer_NN to_TO extend_VB the_DT distribution_NN agreement_NN through_IN the_DT end_NN of_IN the_DT exclusivity_NN period_NN ._.
Therefore_RB ,_, in_IN October_NNP 2002_CD ,_, AstraZeneca_NNP began_VBD shipping_VBG its_PRP$ own_JJ non-branded_JJ tamoxifen_NN to_TO customers_NNS to_TO ensure_VB an_DT uninterrupted_JJ supply_NN to_TO patients_NNS ._.
In_IN December_NNP 2002_CD ,_, the_DT Court_NNP held_VBD that_IN Barr_NNP could_MD not_RB obtain_VB final_JJ FDA_NNP approval_NN for_IN its_PRP$ own_JJ generic_JJ tamoxifen_NN prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP paediatric_JJ exclusivity_NN for_IN Nolvadex_NNP ._.
In_IN January_NNP 2003_CD ,_, Barr_NNP made_VBD a_DT claim_NN that_IN AstraZeneca_NNP improperly_RB thwarted_VBD Barrs_NNP entry_NN into_IN the_DT tamoxifen_JJ market_NN and_CC caused_VBD Barr_NNP monetary_JJ damages_NNS ._.
com_NN 105_CD Zestril_NNP lisinopril_NN In_IN 1986_CD ,_, AstraZenecas_NNP predecessor_NN company_NN and_CC Merck_NNP &_CC Co._NNP ._.
Inc._NNP entered_VBD into_IN licence_NN agreements_NNS under_IN which_WDT AstraZeneca_NNP was_VBD granted_VBN the_DT right_NN to_TO make_VB ,_, use_VB and_CC sell_VB lisinopril_NN Zestril_NNP ,_, in_IN return_NN for_IN which_WDT AstraZeneca_NNP agreed_VBD to_TO pay_VB royalties_NNS to_TO Merck_NNP ._.
In_IN April_NNP 2002_CD ,_, AstraZeneca_NNP commenced_VBD arbitration_NN proceedings_NNS against_IN Merck_NNP under_IN one_CD of_IN the_DT licence_NN agreements_NNS ._.
In_IN the_DT arbitration_NN ,_, AstraZeneca_NNP is_VBZ seeking_VBG repayment_NN of_IN approximately_RB $_$ 38m_CD of_IN prior_JJ royalty_NN amounts_NNS and_CC a_DT prospective_JJ reduction_NN in_IN the_DT royalty_NN rate_NN going_VBG forward_RB ,_, based_VBN on_IN a_DT provision_NN of_IN the_DT licence_NN agreement_NN which_WDT reduces_VBZ the_DT royalty_NN rate_NN if_IN sales_NNS of_IN lisinopril_NN by_IN third_JJ parties_NNS exceed_VBP a_DT certain_JJ level_NN ._.
The_DT case_NN is_VBZ currently_RB progressing_VBG under_IN the_DT arbitration_NN rules_NNS of_IN the_DT International_NNP Chamber_NNP of_IN Commerce_NNP ._.
Retail_JJ pharmacies_NNS drug_NN purchasers_NNS actions_NNS Since_IN October_NNP 1993_CD ,_, several_JJ thousand_CD retail_JJ pharmacies_NNS and_CC certain_JJ retail_JJ drug_NN purchasers_NNS have_VBP commenced_VBN purported_JJ class_NN actions_NNS and_CC individual_JJ actions_NNS in_IN various_JJ federal_JJ and_CC state_NN courts_NNS throughout_IN the_DT US_NNP alleging_VBG that_IN ,_, with_IN respect_NN to_TO brand_NN name_NN prescription_NN drugs_NNS ,_, manufacturers_NNS and_CC wholesalers_NNS engaged_VBN in_IN discriminatory_JJ pricing_NN practices_NNS ,_, discriminatory_JJ discounting_NN and_CC rebate_NN practices_NNS ,_, and_CC or_CC conspired_VBN with_IN one_CD another_DT to_TO fix_VB prices_NNS and_CC artificially_RB maintain_VBP high_JJ prices_NNS to_TO the_DT plaintiffs_NNS in_IN restraint_NN of_IN trade_NN and_CC commerce_NN ._.
More_JJR than_IN 20_CD brand_NN name_NN prescription_NN drug_NN manufacturers_NNS and_CC eight_CD wholesalers_NNS have_VBP been_VBN named_VBN defendants_NNS in_IN some_DT or_CC all_DT of_IN these_DT suits_NNS ._.
AstraZeneca_NNP entered_VBD into_IN a_DT settlement_NN agreement_NN with_IN the_DT retail_JJ class_NN plaintiffs_NNS whose_WP$ anti-trust_JJ claims_NNS were_VBD consolidated_VBN in_IN a_DT federal_JJ multidistrict_JJ litigation_NN proceeding_VBG pending_VBG in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Northern_NNP District_NNP of_IN Illinois_NNP ._.
AstraZeneca_NNP also_RB reached_VBD settlements_NNS with_IN numerous_JJ independent_JJ and_CC chain_NN pharmacies_NNS that_WDT opted_VBD out_IN of_IN the_DT federal_JJ class_NN action_NN ,_, although_IN there_EX are_VBP still_RB actions_NNS brought_VBN by_IN certain_JJ chain_NN and_CC independent_JJ pharmacies_NNS pending_VBG in_IN federal_JJ court_NN ._.
AstraZeneca_NNP has_VBZ settled_VBN or_CC been_VBN dismissed_VBN from_IN all_DT of_IN the_DT state_NN cases_NNS except_IN for_IN a_DT consumer_NN case_NN pending_VBG in_IN state_NN court_NN in_IN Alabama_NNP ._.
AstraZeneca_NNP has_VBZ consistently_RB denied_VBN liability_NN and_CC continues_VBZ to_TO believe_VB it_PRP has_VBZ meritorious_JJ defences_NNS to_TO all_DT of_IN these_DT claims_NNS ._.
However_RB ,_, it_PRP believes_VBZ that_IN entering_VBG into_IN these_DT settlements_NNS is_VBZ the_DT prudent_JJ course_NN of_IN action_NN given_VBN the_DT inherent_JJ risks_NNS and_CC costs_NNS of_IN litigation_NN and_CC to_TO avoid_VB further_JJ business_NN disruption_NN ._.
Average_JJ wholesale_JJ price_NN class_NN action_NN litigation_NN In_IN January_NNP 2002_CD ,_, AstraZeneca_NNP was_VBD named_VBN as_IN a_DT defendant_NN along_IN with_IN 24_CD other_JJ pharmaceutical_JJ manufacturers_NNS in_IN a_DT class_NN action_NN suit_NN ,_, in_IN Massachusetts_NNP ,_, brought_VBD on_RP behalf_NN of_IN a_DT putative_JJ class_NN of_IN plaintiffs_NNS alleged_VBN to_TO have_VB overpaid_VBN for_IN prescription_NN drugs_NNS as_IN a_DT result_NN of_IN inflated_JJ wholesale_JJ list_NN prices_NNS ._.
The_DT suit_NN seeks_VBZ to_TO recover_VB unspecified_JJ damages_NNS ._.
AstraZeneca_NNP has_VBZ also_RB been_VBN named_VBN as_IN a_DT co-defendant_NN with_IN various_JJ other_JJ pharmaceutical_JJ manufacturers_NNS in_IN similar_JJ class_NN action_NN suits_NNS filed_VBN in_IN five_CD other_JJ states_NNS ._.
Most_JJS of_IN these_DT suits_NNS have_VBP been_VBN consolidated_VBN with_IN the_DT Massachusetts_NNP action_NN for_IN pre-trial_JJ purposes_NNS pursuant_JJ to_TO federal_JJ multi-district_JJ litigation_NN procedures_NNS ._.
AstraZeneca_NNP believes_VBZ that_IN it_PRP has_VBZ meritorious_JJ defences_NNS to_TO all_DT of_IN these_DT claims_NNS ._.
Additional_JJ government_NN investigations_NNS into_IN drug_NN marketing_NN practices_NNS As_IN is_VBZ true_JJ for_IN most_JJS ,_, if_IN not_RB all_DT ,_, major_JJ prescription_NN pharmaceutical_JJ companies_NNS operating_VBG in_IN the_DT US_NNP ,_, AstraZeneca_NNP is_VBZ currently_RB involved_VBN in_IN multiple_JJ additional_JJ US_NNP federal_JJ and_CC state_NN criminal_JJ and_CC civil_JJ investigations_NNS into_IN drug_NN marketing_NN and_CC pricing_NN practices_NNS ._.
AstraZeneca_NNP has_VBZ received_VBN subpoenas_NNS from_IN the_DT US_NNP Attorneys_NNP Office_NNP in_IN Boston_NNP requesting_VBG production_NN of_IN documents_NNS relating_VBG to_TO the_DT sale_NN and_CC promotion_NN of_IN Prilosec_NNP to_TO the_DT New_NNP England_NNP Medical_NNP Center_NNP in_IN Boston_NNP ._.
A_DT separate_JJ subpoena_NN from_IN the_DT same_JJ office_NN requests_NNS documents_NNS relating_VBG to_TO Prilosec_NNP purchasing_NN and_CC services_NNS agreements_NNS with_IN AdvancePCS_NNP ,_, the_DT pharmacy_NN benefits_NNS management_NN company_NN ._.
AstraZeneca_NNP has_VBZ also_RB received_VBN a_DT subpoena_NN from_IN the_DT Massachusetts_NNP Attorney_NNP Generals_NNP Office_NNP seeking_VBG documents_NNS relating_VBG to_TO the_DT sale_NN and_CC promotion_NN of_IN five_CD products_NNS Prilosec_NNP ,_, Seroquel_NNP ,_, Rhinocort_NNP Aqua_NNP ,_, Toprol-XL_NNP and_CC Zestril_NNP within_IN Massachusetts_NNP ._.
AstraZeneca_NNP has_VBZ received_VBN an_DT investigative_JJ demand_NN from_IN the_DT Missouri_NNP Attorney_NNP Generals_NNP Office_NNP seeking_VBG documents_NNS and_CC information_NN relating_VBG to_TO agreements_NNS with_IN drug_NN retailers_NNS doing_VBG business_NN within_IN Missouri_NNP ._.
Most_RBS recently_RB ,_, AstraZeneca_NNP has_VBZ received_VBN a_DT Civil_JJ Investigative_NNP Demand_NN from_IN the_DT US_NNP Federal_NNP Trade_NNP Commission_NNP for_IN certain_JJ information_NN concerning_VBG AstraZenecas_NNP advertising_NN and_CC marketing_NN of_IN Nexium_NNP ._.
AstraZeneca_NNP is_VBZ cooperating_VBG with_IN these_DT investigations_NNS ._.
It_PRP is_VBZ not_RB possible_JJ to_TO predict_VB the_DT outcome_NN of_IN any_DT of_IN these_DT investigations_NNS ,_, which_WDT could_MD include_VB the_DT payment_NN of_IN damages_NNS and_CC the_DT imposition_NN of_IN fines_NNS ,_, penalties_NNS and_CC administrative_JJ remedies_NNS ._.
General_NNP AstraZeneca_NNP is_VBZ also_RB involved_VBN in_IN various_JJ other_JJ legal_JJ proceedings_NNS considered_VBN typical_JJ to_TO its_PRP$ businesses_NNS ,_, including_VBG some_DT remaining_VBG US_NNP retail_JJ pharmacy_NN anti-trust_JJ class_NN and_CC individual_JJ actions_NNS outside_IN the_DT scope_NN of_IN the_DT settlements_NNS described_VBN above_IN and_CC litigation_NN relating_VBG to_TO employment_NN ,_, product_NN liability_NN ,_, commercial_JJ disputes_NNS ,_, infringement_NN of_IN intellectual_JJ property_NN rights_NNS and_CC the_DT validity_NN of_IN certain_JJ patents_NNS ._.
Although_IN there_EX can_MD be_VB no_DT assurance_NN regarding_VBG the_DT outcome_NN of_IN any_DT of_IN the_DT legal_JJ proceedings_NNS or_CC investigations_NNS referred_VBD to_TO in_IN this_DT Note_NN 34_CD to_TO the_DT Financial_NNP Statements_NNP ,_, AstraZeneca_NNP does_VBZ not_RB expect_VB them_PRP to_TO have_VB a_DT materially_RB adverse_JJ effect_NN on_IN AstraZenecas_NNP financial_JJ position_NN or_CC profitability_NN ._.
com_NN 106_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 35_CD Leases_NNP Total_NNP rentals_NNS under_IN operating_VBG leases_NNS charged_VBN to_TO profit_VB and_CC loss_NN account_NN were_VBD as_IN follows_VBZ :_: 2002 2001 2000_CD $_$ m_CD $_$ m_CD $_$ m_CD Hire_NNP of_IN plant_NN and_CC machinery_NN 23_CD 25_CD 15_CD Other_JJ 96_CD 76 74 119 101_CD 89_CD Commitments_NNS under_IN operating_VBG leases_NNS to_TO pay_VB rentals_NNS during_IN the_DT year_NN following_VBG the_DT year_NN of_IN these_DT Financial_NNP Statements_NNP analyzed_VBD according_VBG to_TO the_DT period_NN in_IN which_WDT each_DT lease_NN expires_VBZ were_VBD as_IN follows_VBZ :_: Land_NNP and_CC buildings_NNS Other_JJ assets_NNS 2002 2001 2002 2001_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Expiring_NN within_IN one_CD year_NN 5_CD 5_CD 11_CD 12_CD Expiring_NN in_IN years_NNS two_CD to_TO five_CD 25_CD 37_CD 15_CD 13_CD Expiring_VBG thereafter_RB 32_CD 25_CD 2_CD 2_CD 62_CD 67_CD 28_CD 27_CD The_DT future_NN minimum_NN lease_NN payments_NNS under_IN operating_VBG leases_NNS that_WDT have_VBP initial_JJ or_CC remaining_VBG terms_NNS in_IN excess_NN of_IN one_CD year_NN at_IN 31_CD December_NNP 2002_CD were_VBD as_IN follows_VBZ :_: Operating_VBG leases_NNS 2002_CD 2001_CD $_$ m_CD $_$ m_CD Obligations_NNS under_IN leases_NNS comprise_VBP Rentals_NNS due_JJ within_IN one_CD year_NN 90_CD 94_CD Rentals_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN After_IN five_CD years_NNS from_IN balance_NN sheet_NN date_NN 94_CD 97_CD From_IN four_CD to_TO five_CD years_NNS 21_CD 20_CD From_IN three_CD to_TO four_CD years_NNS 27_CD 21_CD From_IN two_CD to_TO three_CD years_NNS 38_CD 25_CD From_IN one_CD to_TO two_CD years_NNS 47 35 227 198_CD 317_CD 292_CD The_DT Group_NNP had_VBD no_DT commitments_NNS 2001_CD $_$ nil_JJ under_IN finance_NN leases_NNS at_IN the_DT balance_NN sheet_NN date_NN which_WDT were_VBD due_JJ to_TO commence_VB thereafter_RB ._.
com_NN 107_CD 36_CD Statutory_NNP and_CC other_JJ information_NN 2002 2001 2000_CD $_$ m_CD $_$ m_CD $_$ m_CD Statutory_JJ audit_NN fees_NNS KPMG_NNP Audit_NNP Plc_NNP 3.5_CD 2.5_CD 3.2_CD Others_NNS 0.1_CD 0.1_CD 3.6_CD 2.6_CD 3.2_CD Fees_NNS for_IN other_JJ services_NNS KPMG_NNP Audit_NNP Plc_NNP and_CC associates_NNS UK_NNP 0.4_CD 3.2_CD 8.9_CD Worldwide_NNP 3.1_CD 2.0_CD 5.0_CD 3.5_CD 5.2_CD 13.9_CD Non_NNP statutory_JJ audit_NN fees_NNS paid_VBN to_TO KPMG_NNP Audit_NNP Plc_NNP and_CC its_PRP$ associates_NNS were_VBD in_IN relation_NN to_TO other_JJ assurance_NN services_NNS $_$ 1.5_CD m_NN 2001_CD $_$ 1.8_CD m_NN :_: taxation_NN $_$ 1.8_CD m_NN 2001_CD $_$ 2.1_CD m_NN :_: and_CC other_JJ non_NN audit_NN services_NNS $_$ 0.2_CD m_NN 2001_CD $_$ 1.3_CD m._NN In_IN addition_NN to_TO the_DT above_JJ ,_, in_IN 2000_CD KPMG_NNP Audit_NNP Plc_NNP and_CC its_PRP$ associates_NNS charged_VBN fees_NNS for_IN other_JJ services_NNS of_IN $_$ 8.0_CD m_NN that_WDT were_VBD borne_VBN by_IN Syngenta_NNP AG_NNP in_IN relation_NN to_TO its_PRP$ demerger_NN from_IN AstraZeneca_NNP ._.
The_DT charge_NN for_IN the_DT statutory_JJ audit_NN of_IN the_DT Company_NN ,_, AstraZeneca_NNP PLC_NNP ,_, was_VBD $_$ 1,600_CD 2001_CD $_$ 1,600_CD ,_, 2000_CD $_$ 1,600_CD ._.
KPMG_NNP Audit_NNP Plc_NNP were_VBD sole_JJ auditors_NNS to_TO AstraZeneca_NNP in_IN 2002_CD and_CC 2001_CD ._.
The_DT bulk_NN of_IN fees_NNS for_IN other_JJ services_NNS charged_VBN by_IN KPMG_NNP Audit_NNP Plc_NNP and_CC its_PRP$ associates_NNS aside_RB from_IN the_DT Zeneca_NNP Agrochemicals_NNPS demerger_NN and_CC associated_VBN restructuring_NN work_NN were_VBD incurred_VBN in_IN the_DT early_JJ months_NNS of_IN 2000_CD ,_, completing_VBG 1999_CD integration_NN projects_NNS ._.
Related_VBN party_NN transactions_NNS The_DT Group_NNP had_VBD no_DT material_NN related_VBN party_NN transactions_NNS which_WDT might_MD reasonably_RB be_VB expected_VBN to_TO influence_VB decisions_NNS made_VBN by_IN the_DT users_NNS of_IN these_DT Financial_NNP Statements_NNP ._.
Subsequent_JJ events_NNS No_DT significant_JJ change_NN has_VBZ occurred_VBN since_IN the_DT date_NN of_IN the_DT annual_JJ Financial_NNP Statements_NNP ._.
com_NN 108_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 37_CD Company_NN information_NN Company_NN Balance_NNP Sheet_NNP At_IN 31_CD December_NNP 2002_CD 2001_CD Notes_NNS $_$ m_CD $_$ m_CD Fixed_VBN assets_NNS Fixed_VBN asset_NN investments_NNS 37_CD 7,236_CD 6,736_CD 7,236_CD 6,736_CD Current_JJ assets_NNS Debtors_NNS amounts_NNS owed_VBN by_IN subsidiaries_NNS 27,104_CD 27,998_CD Total_JJ assets_NNS 34,340_CD 34,734_CD Creditors_NNS due_JJ within_IN one_CD year_NN Non-trade_JJ creditors_NNS 37_CD 2,961_CD 835_CD 2,961_CD 835_CD Net_JJ current_JJ assets_NNS 24,143_CD 27,163_CD Total_JJ assets_NNS less_RBR current_JJ liabilities_NNS 31,379_CD 33,899_CD Creditors_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN Loans_NNPS owed_VBD to_TO subsidiaries_NNS 37 295 590_CD Net_JJ assets_NNS 31,084_CD 33,309_CD Capital_NN and_CC reserves_NNS Called-up_JJ share_NN capital_NN 38 429 436_CD Share_NN premium_NN account_NN 37 403 334_CD Capital_NNP redemption_NN reserve_NN 37_CD 16_CD 9_CD Other_JJ reserves_NNS 37_CD 1,841_CD 2,239_CD Profit_NN and_CC loss_NN account_NN 37_CD 28,395_CD 30,291_CD Shareholders_NNS funds_NNS equity_NN interests_NNS 31,084_CD 33,309_CD The_DT financial_JJ statements_NNS on_IN pages_NNS 58_CD to_TO 122_CD were_VBD approved_VBN by_IN the_DT Board_NNP of_IN Directors_NNS on_IN 30_CD January_NNP 2003_CD and_CC were_VBD signed_VBN on_IN its_PRP$ behalf_NN by_IN :_: Sir_NNP Tom_NNP McKillop_NNP Jonathan_NNP Symonds_NNP Director_NNP Director_NNP AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 109_CD 37_CD Company_NN information_NN continued_VBD Deferred_JJ taxation_NN The_DT parent_NN company_NN had_VBD no_DT deferred_JJ tax_NN assets_NNS or_CC liabilities_NNS actual_JJ or_CC potential_JJ at_IN 31_CD December_NNP 2002_CD ._.
Investments_NNP in_IN subsidiaries_NNS Fixed_VBN asset_NN investments_NNS Shares_NNP Loans_NNP Total_NNP $_$ m_CD $_$ m_CD $_$ m_CD Cost_NN at_IN beginning_NN of_IN year_NN 6,145_CD 591_CD 6,736_CD Additions_NNS 500_CD 500_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2002_CD 6,645_CD 591_CD 7,236_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2001_CD 6,145_CD 591_CD 6,736_CD Non-trade_JJ creditors_NNS 2002_CD 2001_CD $_$ m_CD $_$ m_CD Amounts_NNS due_JJ within_IN one_CD year_NN Short_JJ term_NN borrowings_NNS unsecured_JJ 3_CD 3_CD Other_JJ creditors_NNS 50_CD 4_CD Amounts_NNS owed_VBN to_TO subsidiaries_NNS 2,100_CD 8_CD Dividends_NNS to_TO Shareholders_NNS 808_CD 820_CD 2,961_CD 835_CD Loans_NNPS owed_VBD to_TO subsidiaries_NNS Repayment_NN 2002_CD 2001_CD Dates_NNPS $_$ m_CD $_$ m_CD Loans_JJ unsecured_JJ US_NNP dollars_NNS 6.58_CD %_NN loan_NN 2003 295 295_CD 7.2_CD %_NN loan_NN 2023 295 295_CD Total_JJ loans_NNS 590_CD 590_CD Loans_NNPS or_CC instalments_NNS thereof_RB are_VBP repayable_JJ After_IN five_CD years_NNS from_IN balance_NN sheet_NN date_NN 295_CD 295_CD From_IN two_CD to_TO five_CD years_NNS From_IN one_CD to_TO two_CD years_NNS 295_CD Total_JJ unsecured_JJ 295_CD 590_CD Total_JJ due_JJ within_IN one_CD year_NN 295_CD Total_JJ loans_NNS 590_CD 590_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 110_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 37_CD Company_NN information_NN continued_VBD Share_NNP Capital_NNP Profit_NNP premium_NN redemption_NN Other_JJ and_CC loss_NN 2002_CD 2001_CD Reserves_NNS account_VBP reserve_NN reserves_NNS account_VBP Total_JJ Total_JJ $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD At_IN beginning_NN of_IN year_NN 334_CD 9_CD 2,239_CD 30,291_CD 32,873_CD 32,759_CD Net_JJ profit_NN for_IN the_DT year_NN 102_CD 102_CD 2,314_CD Dividends_NNS 398_CD 808_CD 1,206_CD 1,225_CD Share_NN re-purchase_NN 7_CD 1,190_CD 1,183_CD 1,074_CD Share_NN premiums_NNS 69_CD 69_CD 99_CD At_IN end_NN of_IN year_NN 403_CD 16_CD 1,841_CD 28,395_CD 30,655_CD 32,873_CD Distributable_JJ reserves_NNS at_IN end_NN of_IN year_NN 443_CD 1,614_CD 2,057_CD 1,623_CD As_IN permitted_VBN by_IN section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, the_DT Company_NN has_VBZ not_RB presented_VBN its_PRP$ profit_NN and_CC loss_NN account_NN ._.
At_IN 31_CD December_NNP 2002_CD $_$ 26,781_CD m_NN 31_CD December_NNP 2001_CD $_$ 29,440_CD m_NN of_IN the_DT profit_NN and_CC loss_NN account_NN reserve_NN was_VBD not_RB available_JJ for_IN distribution_NN ._.
The_DT majority_NN of_IN this_DT non-distributable_JJ amount_NN relates_VBZ to_TO profit_VB arising_VBG on_IN the_DT sale_NN of_IN Astra_NNP AB_NNP to_TO a_DT subsidiary_NN in_IN 1999_CD ,_, which_WDT becomes_VBZ distributable_JJ as_IN the_DT underlying_VBG receivable_NN is_VBZ settled_VBN in_IN cash_NN ._.
During_IN 2002_CD ,_, $_$ 2,659_CD m_NN of_IN the_DT profit_NN was_VBD realized_VBN by_IN repayment_NN ._.
Subsequent_JJ to_TO the_DT year_NN end_NN a_DT further_JJ $_$ 825m_CD was_VBD repaid_VBN on_IN 23_CD January_NNP 2003_CD resulting_VBG in_IN additional_JJ distributable_JJ reserves_NNS not_RB included_VBD in_IN the_DT figures_NNS above_IN ._.
Included_VBN in_IN other_JJ reserves_NNS is_VBZ a_DT special_JJ reserve_NN of_IN $_$ 157m_CD ,_, arising_VBG on_IN the_DT redenomination_NN of_IN share_NN capital_NN in_IN 1999_CD ._.
2002_CD 2001_CD Reconciliation_NNP of_IN movement_NN in_IN shareholders_NNS funds_NNS $_$ m_CD $_$ m_CD Shareholders_NNS funds_NNS at_IN beginning_NN of_IN year_NN 33,309_CD 33,201_CD Net_JJ profit_NN for_IN the_DT financial_JJ year_NN 102_CD 2,314_CD Dividends_NNS 1,206_CD 1,225_CD Issues_NNS of_IN AstraZeneca_NNP PLC_NNP Ordinary_NNP Shares_NNP 69_CD 99_CD Re-purchase_NN of_IN AstraZeneca_NNP PLC_NNP Ordinary_NNP Shares_NNP 1,190_CD 1,080_CD Net_JJ reduction_NN in_IN addition_NN to_TO shareholders_NNS funds_NNS 2,225_CD 108_CD Shareholders_NNS funds_NNS at_IN end_NN of_IN year_NN 31,084_CD 33,309_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 111_CD 38_CD Called-up_JJ share_NN capital_NN of_IN parent_NN company_NN Allotted_NNP ,_, called-up_JJ Authorised_NNP and_CC fully_RB paid_VBN 2002 2002 2001_CD $_$ m_CD $_$ m_CD $_$ m_CD Ordinary_NNP Shares_NNP $_$ 0.25_CD each_DT 429 429 436_CD Unissued_NNP Ordinary_NNP Shares_NNP $_$ 0.25_CD each_DT 171_CD Redeemable_JJ Preference_NNP Shares_NNP 50,000_CD 600 429 436_CD The_DT Redeemable_JJ Preference_NN Shares_NNS carry_VBP limited_JJ class_NN voting_NN rights_NNS and_CC no_DT dividend_NN rights_NNS ._.
This_DT class_NN of_IN shares_NNS is_VBZ capable_JJ of_IN redemption_NN at_IN par_NN at_IN the_DT option_NN of_IN the_DT Company_NN on_IN the_DT giving_VBG of_IN seven_CD days_NNS written_VBN notice_NN to_TO the_DT registered_VBN holder_NN of_IN the_DT shares_NNS ._.
The_DT movements_NNS in_IN share_NN capital_NN during_IN the_DT year_NN can_MD be_VB summarised_VBN as_IN follows_VBZ :_: No._NN ._.
of_IN shares_NNS million_CD $_$ m_CD At_IN beginning_NN of_IN year_NN 1,745_CD 436_CD Issues_NNS of_IN shares_NNS 2_CD Re-purchase_NN of_IN shares_NNS 28_CD 7_CD At_IN 31_CD December_NNP 2002_CD 1,719_CD 429_CD Share_NN buy-back_NN During_IN the_DT year_NN the_DT Company_NN purchased_VBD ,_, and_CC subsequently_RB canceled_VBN ,_, 28,386,560_CD Ordinary_NNP Shares_NNP at_IN an_DT average_JJ price_NN of_IN 2785_CD pence_NN per_IN share_NN for_IN a_DT consideration_NN ,_, including_VBG expenses_NNS ,_, of_IN $_$ 1,190_CD m._FW The_DT excess_NN of_IN the_DT consideration_NN over_IN the_DT nominal_JJ value_NN has_VBZ been_VBN charged_VBN against_IN the_DT profit_NN and_CC loss_NN account_NN reserve_NN ._.
Share_NN schemes_NNS A_DT total_NN of_IN 1,737,401_CD shares_NNS were_VBD issued_VBN during_IN the_DT year_NN in_IN respect_NN of_IN share_NN schemes_NNS ._.
Details_NNS of_IN movements_NNS in_IN the_DT number_NN of_IN shares_NNS under_IN option_NN are_VBP shown_VBN in_IN Note_NN 33_CD :_: details_NNS of_IN options_NNS granted_VBN to_TO Directors_NNS are_VBP shown_VBN in_IN the_DT Directors_NNS Remuneration_NNP Report_NNP ._.
